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Abstract 
 
Myxobacteria produce a broad range of anti-infectives that contain novel scaffolds and 
exhibit promising bioactivities. These features make myxobacterial secondary metabolites an 
interesting target for scientific research and clinical application. The present thesis deals with 
myxopyronins from Myxococcus fulvus Mx f50 which target a novel binding site at the 
bacterial RNA polymerase “switch region”. Due to their insufficient physicochemical and 
pharmacokinetic properties for direct clinical drug usage, this work aims to exploit and 
optimize this compound family through biotechnological approaches.  
Genetic tools for the myxopyronin producer were established to facilitate the 
identification and elucidation of the myxopyronin biosynthetic gene cluster through directed 
mutagenesis. Detailed biochemical and structural characterization of the key enzyme 
responsible for -pyrone ring formation provided valuable insights into the reaction 
mechanism and structural requirements of modified polyketide chain substrates. Furthermore, 
mutasynthesis approaches at different stages of the biosynthesis allowed the generation of 
novel myxopyronin analogues. In order to improve productivity, a heterologous expression 
system for myxopyronin production was achieved in Myxococcus xanthus DK1622 at 
promising yields. The obtained results provide various platforms for further pathway 
engineering to generate myxopyronin analogues with improved pharmaceutical properties. 
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Zusammenfassung 
 
Myxobakterien produzieren ein breites Spektrum an Anti-Infektiva mit neuen Grundgerüsten 
und vielversprechenden Bioaktivitäten. Diese Eigenschaften machen myxobakterielle 
Sekundärmetabolite zu interessanten Zielstrukturen für die Forschung und klinische 
Anwendungen. Die vorliegende Arbeit beschäftigt sich mit Myxopyroninen aus Myxococcus 
fulvus Mx f50, die an eine neue Stelle, die „switch region“, der RNA-Polymerase binden. Da 
ihre physikochemischen und pharmakokinetischen Eigenschaften keine direkte klinische 
Anwendung erlauben, zielt diese Arbeit darauf ab, über biotechnologische Ansätze die 
Naturstoff-Familie zu optimieren und weiter auszunutzen.  
Es wurden genetische Verfahren für den Myxopyronin-Produzenten etabliert, um den 
Myxopyronin-Biosynthesegencluster mittels gerichteter Mutagenese zu identifizieren und 
charakterisieren. Detaillierte Studien zur Biochemie und Struktur des an der -Pyronring-
Biosynthese beteiligten Schlüsselenzyms lieferten wertvolle Einblicke in den 
Reaktionsmechanismus und die Strukturanforderungen modifizierter Polyketidketten-
Substrate. Zudem gelang es über Mutasynthese-Experimente auf verschiedenen Stadien der 
Biosynthese neue Myxopyronin-Analoga zu generieren. Zur Produktionsverbesserung wurde 
ein heterologes Expressionssystem in Myxococcus xanthus DK1622 mit vielversprechenden 
Ausbeuten etabliert. Die erzielten Ergebnisse bieten verschiedene Plattformen zur 
Manipulation der Biosynthese, um Myxopyronin-Analoga mit verbesserten pharmazeutischen 
Eigenschaften herzustellen.   
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1 Introduction 
1.1 Natural Products the Source of Novel Anti-Infectives  
Infectious disease is one of the main leading cause of deaths worldwide.1 The widespread use 
of anti-infective drugs over several decades has improved human life expectancy. 
Unfortunately, antibiotics are also vastly misused in both humans and food-producing 
animals in a fashion that favours the selection and spread of resistant bacteria.2–4 
Antimicrobial resistance has made drugs, which were previously effective to treat infections 
caused by bacteria, fungi, viruses and parasites, are no longer competent to cure them. This 
rapid development and spreading of antimicrobial resistance has then made human beings 
vulnerable to re-occurring and new infectious diseases.5 Thus, one approach to address the 
resistance to these anti-infectives is to find new sources for drug discovery.  
Throughout history, Nature has been used as a source of medicines to treat a broad 
spectrum of diseases. Progress in scientific knowledge led to the discovery of biologically 
active compounds, commonly referred to as natural products (NPs). NPs produced by 
bacteria, fungi, and plants have been a prolific source for drug discovery and development.6 
Not only have NPs shown impressive structural diversity and complexity hardly possible to 
make by organic synthesis, but they also display complex mechanisms of action that are very 
difficult to achieve by human rational design.7  
The discovery of penicillins from fungi started the way for the ‘golden era’ of 
antibiotic discovery from microbes (1945-1960) during which most of the chemical classes of 
antibiotics now in clinical use were first characterized (Fig. 1). Nevertheless, there was a 
significant gap between the introduction of quinolones in 1962 and the next new structural 
classes of antibiotics such as the oxazolidinones (linezolid, 2000) and the lipopeptides 
(daptomycin, 2003). Resistant bacteria against linezolid and daptomycin are readily 
developed in only a few years after their first clinical use.8,9 Indeed, many years later, other 
new classes of antibiotics, fidaxomicin was approved in 2011 and synthetic bedaquiline in 
2012 (Fig. 1).10 Inevitably, the introduction of a new drug for clinical use is always followed 
by survival of the small fraction of a bacterial population that have acquired a resistance 
mechanism. Furthermore, all these new antibiotic classes are limited to the treatment of 
infections by Gram-positive bacteria while anti-infectives against Gram-negatives are 
urgently required. However, despite the need of novel, effective, and safe anti-infectives, the 
rate of discovery and development has lagged far behind the rate of resistance development. 
No other resource has returned as much lead generation value to drug discovery as have 
secondary metabolites derived from microbes and plants.11 
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Figure 1 Structures and discovery timeline of antibiotics in clinical use. A) Naturally and B) Synthetically derived 
antibiotics, in bracket is the compound class; C) timeline of antibiotics drug discovery, in bold are microbe-derived 
antibiotics.  
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Therefore, the urgent need to find new drugs has become a major driving force for the 
scientific community to keep exploring natural products, as the most promising source of the 
future antibiotics, to overcome the above mentioned situations regarding antibiotics. 
1.2 The Potential of Myxobacteria as Producers of Anti-Infectives 
Since the golden era of antibiotics, the majority of anti-infective compound classes in use 
today have been isolated from a limited number of taxonomic groups, mainly from soil 
actinobacteria and fungi. However, in the last decades, Gram-negative myxobacteria have 
been featured as prominent producers of structurally diverse microbial secondary 
metabolites.12–14 Secondary metabolites, including antibiotics, are regarded as natural 
products produced by living organisms and often used against competitors or predators.15  
 
 
 
Figure 2. Different stages of the myxobacterial life cycle. (a) vegetative cells of Cystobacter sp.; (b) fruiting bodies of 
Cystobacter sp.; (c) fruiting bodies and swarming colony of Sorangium cellulosum Soce 1875 on agar; (d) fruiting body 
of Chondromyces crocatus; (e) swarm colony edge of Myxococcus xanthus sp on agar showing ripples and flare-like 
pattern. (a), (b), pictured in phase-contrast and (c), (d), and (e) in stereophotomicrograph (pictures: Ronald O. Garcia) 
 
Myxobacteria belong to the group of -proteobacteria and are distinguished from 
other bacteria by unique features.16–18 They move by gliding or creeping, and under starvation 
conditions they produce fruiting bodies in which the vegetative cells convert into dormant, 
resistant myxospores (Fig. 2). Myxobacteria have a unique ability not only to degrade an 
array of biological macromolecules as food source, but also they possess predatory behavior 
against bacteria and fungi.19 
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In the last three decades, myxobacteria have been established as potent producers of 
novel compounds yielding more than 100 natural products and approximately 600 additional 
structural derivatives.14,20,21 In particular, many of these compounds exhibit rarely observed or 
wholly novel mode of actions, which makes myxobacteria a promising source of anti-
infective drugs.22,23 Traditionally, antibiotics have been classified for their ability to kill 
bacteria (bactericidal activity) or inhibit growth (bacteriostatic activity). They achieve this by 
interfering with the essential bacterial functions such as cell wall synthesis, DNA replication, 
RNA transcription and protein synthesis that are indispensable for the growth.24 Even though 
it is obvious that antibiotics directed at cellular viability have been highly effective, these 
modes of action inflict selective pressure that stimulates the growth of antibiotic-resistant 
strains. Therefore, in addition to the compounds that act by targeting in vitro cell growth, it is 
important to develop anti-infectives that have novel mode of actions. Several isolated 
myxobacterial compounds present novel structural scaffolds or unique modes of action,22 
such as the cystobactamids 15 (DNA topoisomerase II inhibitor),25 aetheramides 16 (HIV 
inhibitor),26 ambruticin 17 (anti-fungal),27 and argyrin 18 (inhibitor of elongation factor 
G),28,29 (Fig.3).  
Studies on the -pyrone antibiotics myxopyronin A 1930 or corallopyronin A 20,31 
and the macrolactone ripostatin 21,32 revealed their novel target site at the RNA polymerase 
(RNAP).33,34 RNAP catalyzes the DNA-dependent synthesis of RNA. This enzyme is 
essential for bacterial growth and survival. RNAP subunit sequences are highly conserved 
among Gram-negative and Gram-positive bacteria permitting broad-spectrum antibacterial 
therapy and exhibits major structural differences from eukaryotic RNAP allowing therapeutic 
selectivity.35,36  
Selective bacterial RNAP inhibition is the basis for antibiotic treatment of 
tuberculosis (TB), the most widespread and persistent bacterial infection.37 In 2013, there 
were approximately 9 million new TB cases and 1.5 million TB deaths reported.38 The 
rifamycins (rifampicin 22, rifapentine, and rifabutin) have been in use as the first-line anti-TB 
therapy in combination with other agents (e.g. isoniazid, pyrazinamide) since the 1960s.38,39 
However, their efficiency and versatility is becoming limited by the rapid emergence of 
multi-resistant variants of Mycobacterium tuberculosis (MDR-TB and XDR-TB). This high-
level resistance to rifampicin can be caused by a single mutation in rpoB, the gene that 
encodes for the RNAP -subunit.40 These mutations change amino acids in or surrounding the 
Rif-binding pocket, which cause a drastic decrease in the antibacterial activity.41 Therefore, 
antibiotics that have the same ability to inhibit bacterial RNAP as rifamycins do, but inhibit 
the bacterial RNAP through binding sites that are distinct from the rifamycins binding site, 
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are urgently needed not only for anti-TB development but also for developing broad spectrum 
anti-infectives.  
 
 
Figure 3. Myxobacterial anti-infectives. The structure, name, mode of action or target, and producer organism are 
given. 
   
In 2008, the structure determination of Thermus thermophilus RNA polymerase 
(RNAP) holoenzyme in complex with the myxobacterial -pyrones myxopyronin A 1930 and 
corallopyronin A 20,31 or the macrolactone ripostatin 21,32 have revealed a novel target site in 
RNAP, called the switch region (Fig. 4).33 The switch region is a hinge that mediates opening 
and closing of the RNAP active center cleft. The binding of those three compounds to the 
RNAP switch region will then prevent interaction of RNAP with promoter DNA, probably by 
preventing opening of the clamp to permit entry of promoter DNA during transcription 
initiation.33 The amino acid residues involved in the interaction of those three compounds in 
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the switch region of RNAP are remote from the binding site of rifampicin, which explains the 
absence of cross-resistance between the antibiotics (Fig. 4).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. Structural basis of RNA transcription inhibition by myxopyronin A 19, corallopyronin A 20, and ripostatin A 
21 at the switch region of RNAP (blue ribbon, black circle) from Thermus thermophilus (yellow ribbon, PDB: 3DXJ) 
and binding site of rifampicin 22 (red circle) to RNAP from Escherichia coli (golden ribbon, PDB: 4KMU). 
Superposition is performed using Pymol V 1.7.4 (crystal figure: Jesko Koehnke).  
Further structural studies using dMyx (a desmethyl derivative of myxopyronin B) 
complexed with T. thermophilus RNAP holoenzyme also showed that dMyx binds to a 
pocket deep inside the RNAP clamp head domain, which interacts with the DNA template in 
the transcription bubble.42 Although myxopyronin and corallopyronin have similar structures, 
they show differences in their inhibitory mechanisms. Myxopyronin is not able to completely 
block the RNA formation, which relates to the longer alkyl chain of corallopyronin.31 
Nonetheless, myxopyronin shows better minimal inhibitory concentration (MIC) values 
against several pathogens such as M. tuberculosis, Enterococcus faecalis, and Staphylococcus 
aureus.34 Altogether, these properties show that these three myxobacterial compounds are 
promising candidates for development of broad-spectrum antibacterial therapeutics agents 
and indicate that myxobacteria are indeed a rich source for novel anti-infectives discovery.  
In parallel with continuous isolation and characterization of myxobacterial 
compounds, the information on the biosynthetic potential of myxobacteria has also been 
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increasingly collected from genome sequence projects. This information regarding the genetic 
basis of natural product formation in myxobacteria revealed that their genetic potential for the 
production of novel anti-infectives is far from exhausted.20 Thus, there is definitely much 
more biosynthetic potential to be explored, and the prospects for imminent natural product 
research with myxobacteria are very promising. 
1.3 Microbial Natural Product Assembly Lines  
Microorganisms utilize complex biosynthetic machineries to produce structurally diverse 
natural products. Two major classes of natural products are constituted by multimodular 
megasynthase systems called polyketide synthases (PKS) or non-ribosomal peptide 
synthetases (NRPS), or hybrids of both systems.43,44 Understanding the mechanism involved 
in the biosynthesis of PKS, NRPS or hybrid systems is required for optimizing product yields 
and for manipulation of the biosynthetic pathways to achieve structural modification of 
secondary metabolites. 
Although PKS and NRPS employ different building blocks, both systems share 
similarities in their modular architecture of various catalytic domains and assembly-like 
mechanisms. Each module usually incorporates one building block into the growing ketide or 
peptide chain and passes the elongated product on to a downstream module, with that the 
growing chain is shuttled from the beginning of the enzyme-complex to the end. The process 
is linear and resembles an assembly line which led to the term called “molecular assembly 
line”.45 The order of catalytic modules in the biosynthetic complex is closely reflected in the 
chromosomal order of the underlying genes – a property known as the “collinearity rule” 
which then permits the prediction of the product based on the order of catalytic modules and 
vice versa.46,47 One module consists of several domains and every domain is responsible for a 
single reaction step.48 Essentially, a module catalyzes a full round of monomer selection, 
attachment, and coupling (C-C bond formation in PKS and C-N bond formation in NRPS).44 
In PKS assembly lines, the monomers are acyl-coenzyme A (acyl-CoA) precursors while the 
NRPs are assembled by proteinogenic amino acids, nonproteinogenic amino acids, and aryl 
acids.44 The compatible biosynthetic logic of PKS and NRPS allows growing polyketide 
chains to be transferred across a PKS-NRPS interface to switch from incorporating acyl-CoA 
monomers to amino acid monomers, and vice versa.44 
 The biosynthetic mechanism of polyketide biosynthesis is similar to fatty acid 
biosynthesis.43,49 In principal, they are constructed by repetitive decarboxylative Claisen 
thioester condensation which involves three essential domains: an acyltransferase (AT) 
domain for extender unit selection and loading, a carrier protein (CP) domain to covalently 
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bind the extender unit, and a -ketoacylsynthase (KS) domain, which performs a 
decarboxylative Claisen thioester condensation of the extender unit (generally malonyl-CoA 
or methylmalonyl-CoA) with the acyl thioester intermediate from the upstream module (Fig. 
5).  
 
 
 
 
The inactive CP protein (apo-CP) requires a posttranslational activation to allow 
covalent binding of precursors or intermediates. In this process, the 4’-phosphopantetheine 
(PPant) prosthetic group of CoA is transferred to the serine active site residue of the CP by a 
phosphopantetheinyl transferase (PPTase) resulting in the catalytically active CP form (holo-
CP).50 A free thiol group at the end of this PPant-arm serves as an anchor for the growing 
chain and is often described as a “swinging arm” in the CP.51 This “swinging arm” is able to 
channel the intermediates through all the various catalytic sites on the PKS/NRPS/Fatty acid 
synthase (FAS). At the terminus of the assembly lines, the module usually contains a 
thioesterase (TE) domain, which catalyzes the release of the growing chain from the enzyme 
either as linear polyketide by hydrolysis or as cyclized lactone ring.52 
The significant difference between PKS and FAS is that in fatty acid biosynthesis, 
after every chain elongation using malonyl-CoA as extender unit, the resulting -keto group 
is always fully reduced53 in a stepwise process catalyzed by three additional domain 
Figure 5. Polyketide chain extension and optional steps on -keto processing. The elimination of water can result either 
in E or Z configuration at the conjugated ester. 
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activities: A ketoreductase (KR) domain reduce the -keto function to a hydroxyl group, a 
dehydratase (DH) domain performs elimination of water (dehydration) to form a conjugated 
ester, which is then reduced by  an enoyl reductase (ER) domain to generate a fully saturated 
acyl chain intermediate. In PKS, not only there is a broader range of building blocks than 
acetyl-CoA or malonyl-CoA, but also the full reductive cycle by KR, DH, and ER is optional 
(Fig. 5). These three steps can be skipped (partially or altogether) before the next round of 
elongation, thus allowing the synthesis of a wide variety of complex polyketides.   
A typical PKS elongation domain comprises minimally AT, CP, and KS domains. 
Similarly, three domains are necessary as the basic machinery of an NRPS elongation 
module: an adenylation (A) domain responsible for amino acid recognition and activation, a 
CP or thiolation (T) domain to which the activated amino acid is covalently attached as 
thioester, and a condensation (C) domain that catalyzes the peptide bond formation. In 
summary, the core domains of PKS (KS, AT, CP) have similar counterparts in NRPS (C, A, 
CP) which catalyze three main steps as explained above.44 The specificity of A domains 
towards the amino acids play an important role in the peptide sequence of the final natural 
product and the biological activity as well. The crystallization and structural analysis of a 
prototype A domain with its amino acid substrate and ATP revealed the structural basis of 
substrate recognition and activation54 In combination with primary sequence alignment 
analyses to other A domains, 8-10 amino acids within the substrate binding pocket could be 
identified. These residues can be defined as specificity-conferring code for substrate 
prediction of NRPSs.55 The ability to produce a wide range of compounds with high 
structural diversity is further increased by the presence of additional optional catalytic and 
modifying enzymes catalyzing reactions such as epimerization, hydroxylation, methylation, 
isomerization, and halogenation.56 
The structural and catalytic similarities between PKSs and NRPSs allow a conception 
that these modular enzymatic systems, termed hybrid PKS/NRPS system, can closely 
cooperate to produce natural products. Indeed, the advances in cloning and characterization of 
biosynthetic gene clusters for naturally produced polyketides/peptides metabolites have 
provided clear evidence for the existence of hybrid PKS/NRPS systems.57–60 The secondary 
metabolites produced by myxobacteria are also often derived from PKS/NRPS 
megasynthetase hybrid systems61,62 such as ambruticin 1763, myxopyronin 1964, 
corallopyronin 2065 , and myxalamids AD 232666.  
Myxalamids are produced by M. xanthus DK1622 and S. aurantiaca Sga15.67,68 They 
are potent inhibitors of the eukaryotic electron transfer chain and one of the first PKS/NRPS 
hybrid compounds reported from myxobacteria in 2000s.66,68 The myxalamid assembly line 
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features a promiscuous loading AT (ATL) module which accepts CoA esters of different 
short-chain carboxylic acid starter units (2-methyl-butyryl-CoA, isobutyryl-CoA, propionyl-
CoA, and acetyl-CoA) resulting in the production of myxalamids AD (2326), respectively 
(Fig. 6). It is suggested that after the ATL loads the starter unit, the second AT from MxaF 
loads methylmalonate, which is used for the first chain extension step. MxaEDC contain five 
PKS modules required for chain extension using methylmalonyl-CoA or malonyl-CoA. A 
different set of domains in each module gives various degrees of -keto processing (Fig. 6).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
According to the observed polyketide structure it seems that the DH domain from 
subunit MxaE is not involved in the reduction cycle of the module 2 ketide intermediate. 
Further on, the growing chain is then extended by splitting module 7 which is encoded on two 
separate proteins MxaB1 and MxaB2. Finally the assembled polyketide is extended via the 
NRPS subunit MxaA (module 8) to incorporate alanine.   
Normally, assembly lines harbor a terminal domain to release the fully matured chain 
which in most cases is performed by a thiosesterase (TE) domain for hydrolyzation of the 
Figure 6. Myxalamid PKS/NRPS hybrid assembly line adapted from Silakowski et al.31 23 – 26: myxalamid A–D. 
KS: ketosynthase, AT: acyltransferase, CP: carrier protein, KR: ketoreductase, DH: dehydratase, ER: enoylreductase, 
C: condensation, A: adenylation, Re: reductase, *: presumably inactive domain. Green circles represent PKS 
domains, red circles represent NRPS domains, the carbon skeleton of starter unit and extender units are marked in 
bold. The circled OH group showed myxalamid S  
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linear chain or macrocyclization. Myxalamid assembly line employs an unsual chain release 
mechanism where a reductase domain (Re) is assumed to perform the reductive release of the 
hybrid polyketide/peptide chain, giving rise to a linear aldehyde which is further reduced to 
obtain the final compound containing terminal 2-amino-propanol (alaninol). Furthermore, 
myxalamid S might be produced first and undergo water elimination either enzymatically or 
non-enzymatically giving rise to the conjugated pentadiene in the myxalamids A-D (Fig. 6). 
In general, the enormous variety of secondary metabolites that we observe today is the result 
of different domain arrangements and specificities as well as the action of various tailoring 
enzymes in post assembly modifications.   
The textbook model of PKSs was extensively studied from the erythromycin PKS and 
other synthases present in filamentous actinomycetes.69 However, the increasing interest in 
the secondary metabolites produced by bacteria from various taxa and habitats resulted in the 
unexpected discovery of a distinct multimodular PKS type. Each module in this multimodular 
PKS system lacks the AT domain and receives its acyl building block by an iteratively 
operating free-standing AT.70 To distinguish the two PKS types, the term “trans-AT PKS” 
and “cis-AT PKS” were introduced for synthases with free-standing and integrated ATs, 
respectively (Fig.7).71  
 
 
 
 
 
 
 
The trans-AT PKS system was first reported from pederin (produced by bacterial 
symbiont of Paederus beetles) 70 and the first in vitro study of this discrete AT was performed 
for LnmG in leinamycin biosynthesis which showed that this AT loads malonyl-CoA in trans 
to all six CP domains from the PKS modules of LmnIJ.72 Phylogenetic studies suggest that 
cis- and trans-AT PKS multimodularity emerged by different evolutionary pathways. The 
cis-AT system is mainly derived from gene duplication of individual modules, followed by 
diversification of the domain sets.73 In contrast, trans-AT PKS genes are DNA mosaics 
assembled from multiple gene segments via comprehensive horizontal gene transfer between 
bacteria.74 The factor that triggered such distinct evolutionary pathways remains unclear. It is 
Figure 7. Domain organization of cis-AT (left) and trans-AT (right) PKS.  
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noteworthy that both routes, producing similar enzymes architectures and similar metabolites 
outcome, contribute to the complexity of natural product evolution.  
Trans-AT PKSs harbour many different domains that are thought to exclusively exist 
in these systems and their modules can be split at unusual positions even though the first 
example of splitting modules were actually reported in cis-AT PKS system from myxalamid. 
Furthermore, some domains are also often found unused, skipped or even used iteratively.47 
This results in many more module variations compared to the cis-AT systems.  These entire 
peculiarities make the colinearity rule often not applicable. However, it was shown that a 
prediction of the product can be achieved, relying on the KS domains. Contrary to the cis-AT 
where KS have relaxed substrate specificities, the substrate specificity in trans-AT systems is 
quite limited and correlates with KS sequence.74 Utilizing this correlation, product predictions 
can be deducted from the gene cluster.75,76  
A further distinct feature from trans-AT PKS is the presence of more complex 
variations at the -keto position called -branching. Compared to the nucleophilic -position, 
the -position is electrophilic and therefore requires a nucleophilic alkyl source for 
methylation.77 The resulting -branch is less common than branching at the -position and is 
predominantly observed in the trans-AT PKS even though not exclusively.47,77 Today, the 
trans-AT PKS derived compounds are increasingly discovered from different 
microorganisms,47,78 including compounds from myxobacteria such as myxovirescins 2779, 
disorazols 2880, etnangien 2981, chivosazols 3082, sorangicin 3183, corallopyronins 2084, 
myxopyronin 1964 (Fig. 8).  
1.4 Engineering Myxobacterial Natural Product Biosynthesis 
Natural products are often produced in low quantity which hampers further studies to develop 
them as lead compounds. This problem may be addressed by chemical synthesis or classical 
strain improvement. However, as natural products generally contain many stereocenters and 
high structural complexity, total synthesis – if feasible at all – is often a very laborious and a 
time-consuming task. Classical strain improvement also has disadvantages, being a time-
consuming and undirected process, in which several rounds of mutagenesis and subsequent 
screening of the resulting mutants need to be performed in order to get the improved strain. 
Fortunately, in the past two decades, the significant developments in genomic technology 
have been greatly facilitating the discovery of biosynthetic gene clusters responsible for 
synthesizing the compounds of interest. This DNA sequence information creates the platform 
for genetic engineering of natural product biosynthetic pathways, with the aim of improving 
productions yields or producing novel derivatives.  
Introduction | 13 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Most of secondary metabolites biosynthetic gene clusters derived from myxobacteria 
possess modular, multifunctional PKS and/or NRPS.62 For manipulating these enzymes by 
exchange, insertion, deletion or site-directed mutagenesis of catalytic domains or whole 
complete modules, it is necessary to modify the original strain`s chromosome, which is 
usually performed through double crossover recombination. However, genetic manipulation 
of procedures, especially markerless mutations, for myxobacteria are often difficult to 
establish. Therefore, pathway engineering has often been limited to the inactivation of 
polyketide/non-ribosomal peptide scaffold modifying genes (such as methyltransferases, 
P450s, hydrolases, and chlorinases) through single crossover experiments conducted in only a 
few amenable myxobacterial strains. 
Figure 8. Myxobacterial trans-AT PKS compounds. The structure, name, mechanism of action, and    producer 
organisms are given. 
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 A few examples of this strategy include the inactivation of gene involved in 
ambruticin63 and spirangien85 biosynthesis in S. cellulosum, as well as ajudazol,86 
chondramide,87 and thuggacin88 biosynthesis in C. crocatus which lead to the formation of 
several derivatives. However, this type of pathway engineering only focuses on the 
mutagenesis of post-PKS/NRPS processing enzymes and therefore it did not introduce 
alterations into the polyketide/peptide backbones of the compounds. To accomplish such 
alterations, modification at the PKS and NRPS encoding genes themselves are necessary and 
require markerless mutations. Unfortunately, the techniques for this type of modification are 
limited and poorly established in myxobacteria. 
In order to facilitate biosynthetic pathway engineering, it is therefore highly desirable 
to transfer the natural product’s biosynthetic pathways into well-characterized host organism, 
an approach called ‘heterologous expression’.89–92 Before transferring the biosynthetic gene 
cluster of interest to the heterologous host, the complete set of biosynthetic genes needs to be 
subcloned. This can be achieved either by the generation of a cosmid library or by direct 
subcloning of the target region from genomic DNA using advanced cloning technologies 
such as Red/ET recombination (Fig. 9).93–96 Red/ET recombination is performed in E. coli 
and is independent of the location of restriction sites and the size of the DNA fragments.93,95 
The viability of this strategy to establish heterologous production platforms for myxobacterial 
compounds has been exemplified by the successful heterologous expression of 
myxochromide S97, myxothiazol98, and tubulysin99 pathways from their native  producer to 
heterologous hosts such as Streptomyces coelicolor, Myxococcus xanthus, Pseudomonas 
putida, Burkholderia glumae.   
Selection of the heterologous host is usually based on its system compatibility for the 
production of the compound. For example, it ideally should carry the cellular machinery 
required for successful protein production and retained activity. Sometimes a certain 
modification is also necessary to be performed on the host strain to accommodate the natural 
product of interest e.g. introduction of methylmalonyl-CoA biosynthetic pathway to 
Pseudomonas putida to allow myxothiazol production.100 It is also important that the GC 
content of the incoming genes and the host genomes are similar since the codon usage is 
usually essential for efficient expression,.91,92 Myxococcus xanthus DK1622 is often used as 
the first choice of heterologous host for producing myxobacterial compounds as it is a 
relatively fast growing and phylogenetically related myxobacterium (high GC content, 
preferential codon usage).  
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Figure 9. General strategy for the cloning and heterologous expression of complex natural product biosynthetic gene 
clusters. The entire pathway can be subcloned using two approaches: A) Generation of a genomic library, screening for 
constructs harboring overlapping parts of the gene cluster and stitching them onto one physical entity via Red/ET or B) 
By direct subcloning from genomic DNA using Red/ET-based methods. Further Red/ET-mediated engineering steps 
then yield the final expression construct, which can be transferred into an appropriate host for heterologous expression. 
 
Once a robust heterologous expression system is established, combination of 
heterologous expression with the rational genetic engineering of biosynthetic gene clusters 
will set up an important basis for the combinatorial biosynthesis and molecular engineering 
approach to obtain new compounds.92  Rational genetic engineering can be conducted by 
domain or tailoring enzyme engineering (point mutations, deletions, insertions, swapping). 
This has been exemplified by successful genetic manipulation of epothilone PKS/NRPS 
megasynthetase from S. cellulosum into heterologous host S. coelicolor and M. xanthus. 101,102 
Deletion of epoK (epoxidase) resulted in in higher amounts of epothilone D and a new 
derivative (10, 11-didehydro-epothilone D) in the new host strains.103,104 Inactivation of 
reductive domains in different PKS modules (the DH, ER domain in module 5 and KR 
domain in module 4 and 6) resulted in the accumulation of previously identified by products 
and generation of novel analogues.105–107 These experiments demonstrate the feasibility of 
using heterologous expression to modify myxobacterial PKS/NRPS megasynthetases to 
generate novel secondary metabolites analogues. For various strains pathway engineering are 
often not feasible and for many strains genetic modification is only limitedly available, 
therefore domain or tailoring enzyme engineering could be straightforwardly achieved in E. 
coli for instance by Red/ET recombineering technology before transferring to heterologous 
host. 
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The linear correlation between the catalytic units of a PKS and the product structure 
makes it possible to produce novel compounds with altered structures. There are two further 
common methods used to generate novel structural diversity via incorporation of unnatural 
building blocks (mutasynthons) namely precursor directed biosynthesis (PDB) and 
mutasynthesis. In PDB, the growth medium is supplemented with a compound used 
competitively as building block for the biosynthetic assembly (Fig. 10 c). Because of the 
structural similarity between the natural building block and the supplemented building block, 
the wild type strains are likely to accept the non-natural building block as substrate for the 
assembly line. Therefore, PDB experiment will obtain two metabolites: wild-type compound 
and its analogue as exemplified by feeding the producer strain of chondramide, 
Chondromyces crocatus, with fluorinated tryptophan extender units obtaining chondramide 
and its derivative fluorochondramide A.87 However, in PDB experiments, the mutasynthons 
are often not able to efficiently compete with the natural building block, resulting in very low 
yield or even no production of the expected analogue.   
To increase the chance of producing unnatural secondary metabolites, a combination 
of genetic engineering and feeding, termed mutasynthesis, was developed. In mutasynthesis 
approaches, a rational engineering of the biosynthetic pathway is applied. The strains are 
constructed in a way that the production of the natural precursor at certain stage is blocked, 
thus the resulting mutant strains are not able to produce the native compound anymore (Fig. 
10b).108–110 When they are supplied with mutasynthons, the mutant strains will be expected to 
incorporate them to produce structural analogues (Fig. 10 d). Compared to PDB, the microbes 
have no alternative but to use the surrogate substrate to start the assembly process.  
The mutasynthesis approach has been successfully applied for generating 
myxobacterial compound analogues from the myxalamid biosynthetic pathway shown in 
Figure 6. As explained above, the myxalamid gene cluster ATL accepts a range of starter units 
resulting in myxalamid AD 23 26 (Fig. 6, Fig. 11). Using this advantage, the PDB 
approach may lead to successful production of analogues. However, the mixture of native 
myxalamids and analogues may complicate the isolation of new analogues, and therefore the 
mutagenesis approach is preferred. In order to reduce the production of the natural 
myxalamids, branched-chain ketoacid dehydrogenase (bkd) mutants of the M. xanthus or S. 
aurantiaca were generated.111,112  Bkd is responsible for the degradation of the branched-
chain amino acids isoleucine and valine to 2-methyl-butyryl-CoA and isobutyryl-CoA, the 
starter units of 23 and 24, respectively. 
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Various non-natural carboxylic acids were then fed to the bkd mutants resulting in 
nine novel myxalamid analogues 3240 (Fig. 11).113 The biosynthetic machinery in M. 
xanthus was more flexible (resulting in 3240) than that in S. aurantiaca (resulting in 3739). 
This flexibility is in agreement with the fact that M. xanthus utilizes a larger starter unit to 
produce 23 as the major product, while S. aurantiaca uses a smaller starter unit to produce 24 
as the major product. This successful mutasynthesis experiment in myxobacteria has become 
a proof of concept and has opened opportunities to apply the approach to other myxobacterial 
biosynthetic pathways.  However, mutasynthesis approaches have not been widely applied for 
myxobacterial pathways yet due to the difficulties in mutant generation. Therefore, 
establishment of a heterologous expression platform would open various possibilities for 
pathway engineering including the construction of blocked mutants for mutasynthesis 
approaches. 
 
 
 
 
Figure 10. Schematic illustration of precursor-directed biosynthesis (PDB) and mutasynthesis (MBS). (a) Natural 
product biosynthesis by the wild type strain; (b) Biosynthesis is abolished by mutating the pathway at a crucial step 
(e.g. the assembly of a starter unit); (c) Precursor-directed biosynthesis: the culture medium is supplemented with an 
analogue of a natural building block (mutasynthon), which competes for incorporation into the natural product. Both 
native and modified products are usually obtained; (d) Mutasynthesis: biosynthesis by the non-producing mutant strain 
is reactivated by addition of mutasynthons. Only novel analogues are produced. Precursors may come from primary or 
secondary metabolisms. 
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1.5 Outline of the Present Work 
The present thesis focuses on a promising anti-infective compound family from 
myxobacteria, myxopyronins, which were recently shown to target the bacterial RNA 
polymerase (RNAP) at an intriguing new binding site, the so called “switch region” (Fig. 4).33 
Due to the different binding mode compared to clinically used RNAP inhibitors, 
myxopyronins are expected to overcome existent resistances.33,42 However, although the 
natural myxopyronin derivative was shown to be highly active in in vitro assays, it may not 
be used directly as a clinical drug due to its insufficient physicochemical and 
pharmacokinetic properties. 37,114 In a collaborative effort with the department “Drug Design 
and Optimization” at the Helmholtz-Institute for Pharmaceutical Research Saarland (HIPS) 
we intended to develop novel druggable derivatives of myxopyronin. The overall aim of the 
present thesis within this project was to establish biotechnological approaches to further 
exploit this compound family, which is naturally produced by the myxobacterium 
Myxococcus fulvus Mx f50 (Fig. 12).30  
The identification and characterization of the myxopyronin biosynthetic pathway was 
the primary goal of this work (see Chapter 2) as it represents a prerequisite for rational 
engineering and optimization of the biotechnological production. Based on shotgun genome 
sequence data of M. fulvus Mx f50 a ~53 kb gene cluster involved in myxopyronin 
biosynthesis was identified and verified via gene deletion experiments after developing a 
suitable strain mutagenesis procedure. Detailed in silico analysis of the encoded 
Figure 11. Myxalamids AD (2326) and its derivatives produced by a mutasynthesis approach (3240). R 
represents the starting unit and marks the stage where the native precursor supply was blocked by bkd mutations. 
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multimodular megasynthase led to a model for myxopyronin biosynthesis, which explains the 
observed structural differences compared to the highly related -pyrone antibiotic 
corallopyronin produced by the myxobacterium Corallococcus coralloides.31,65 In order to 
generate first myxopyronin derivatives, several gene deletion experiments were performed 
via a developed markerless mutagenesis procedure, but the access towards novel derivatives 
using this approach turned out to be very limited. Therefore, we intended to evaluate 
alternative approaches to generate myxopyronin analogs via the incorporation of unnatural 
precursors and to perform more detailed studies on the biosynthesis and substrate 
requirements.    
 
 
Figure 12. Different stages of the Myxococcus fulvus Mx f50 life cycle. (a) vegetative cells, (b) swarming colony, (c) 
fruiting bodies, and (d) myxospores (pictures: Ronald O. Garcia) 
 
 Myxopyronins are assembled from two polyketide chains, respectively a western and 
an eastern chain (Fig.13). The condensation of both chain intermediates reveals the typical -
pyrone ring structure and represents a key step during the biosynthesis of myxopyronin and 
the structurally related corallopyronin. In silico analysis predicted that a stand-alone 
ketosynthase MxnB is responsible for catalyzing this reaction. To gain deeper insights in the 
biochemistry of this crucial step detailed in vitro studies were performed (see Chapter 3). 
Based on a series of enzyme assays using different sets of chemically activated or enzyme-
bound polyketide chain substrates the MxnB reaction mechanism could be characterized in 
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detail. The study was supported by structural analysis of MxnB, which was performed in 
collaboration with the HIPS Junior Research Group “Structural Biology of Biosynthetic 
Enzymes”.  The established in vitro condensation reaction allowed for generation of novel 
derivatives in analytical amounts and provided valuable insights into the reaction mechanism 
and structural requirements of modified polyketide chain substrates.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
As it would be highly desirable to provide fermentation-based procedures for the 
production of novel myxopyronin analogs we aimed to develop a functional mutasynthesis 
system (see Chapter 4). As  initial structure-activity relationship (SAR) studies revealed that 
in general the western chain provides a broader scope for structural variations to increase the 
inhibitory effect on RNAP,115 we focused our studies on this half site of the molecule. Using 
genetic tools previously established for the native myxopyronin producer strain several 
mutants were constructed to block (or at least significantly reduce) native western chain 
assembly at different stages. A series of feeding studies with different western chain 
mutasynthons provided by our collaboration partner were carried out resulting in the 
production of novel myxopyronin analogues. Intriguingly, most of the synthesized 
mutasynthons were successfully incorporated indicating a broad western chain substrate 
tolerance in the final condensation reaction under in vivo conditions. However, productivity 
was too low to allow full characterization of the products and thus clearly has to be improved 
to provide an efficient production platform for novel myxopyronin analogs. 
Figure 13. Schematic illustration of the condensation catalyzed by the putative ketosynthase MxnB to form the α-
pyrone ring structure from western and eastern polyketide chain substrates. 
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One option to improve productivity is to switch the production strain, which 
motivated us to establish a heterologous expression system in a related host strain (see 
Chapter 5). After subcloning chromosomal fragments from the native producer, the 57 kb 
myxopyronin biosynthetic gene cluster was reconstituted and engineered by applying the 
Red/ET recombineering technology.95 Successful heterologous expression in the 
myxobacterial model strain Myxococcus xanthus DK1622 at promising production yields 
opens up many opportunities for further  pathway engineering to generate novel myxopyronin 
analogues, e.g. via mutasynthesis which turned out to be inefficient in the natural producer 
strain. 
The results achieved in the present thesis built the basis for a patent application on the 
production of myxopyronin and its derivatives (Sucipto et al., PCT/EP2014/059677) and 
resulted in three publications (Chapters 2-4). The studies on the heterologous expression of 
the entire myxopyronin pathway reported in Chapter 5 are planned to be published soon. 
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2 Molecular Basis of Myxopyronin Biosynthesis 
2.1 Abstract 
Myxopyronins and corallopyronins are structurally related α-pyrone antibiotics from 
myxobacteria. They are thought to represent a highly promising compound class for the 
development of broad-spectrum antibacterial therapeutic agents, because of their ability to inhibit 
RNA polymerase through interaction with the "switch region", a recently identified novel drug 
target. Here we describe the identification and characterization of the myxopyronin biosynthetic 
pathway from Myxococcus fulvus Mx f50. A detailed comparison with the recently identified 
corallopyronin biosynthetic pathway revealed the genetic and biochemical basis, thus explaining 
the observed structural differences between the two natural product families. Directed 
mutagenesis procedures for M. fulvus Mx f50 were developed to enable functional studies and 
pathway modifications. Our work provided new insights into myxopyronin biosynthesis and led 
to the production of a novel and unexpected myxopyronin derivative. 
2.2 Introduction 
Because of rapidly emerging antibiotic resistances, human beings have become more vulnerable 
to re-occurring and new infectious diseases.[1] For the last decades, serious health threats in this 
field keep forcing us to identify new alternative and more effective antibiotics. However, success 
rates in the field of antibiotic development have continuously decreased.[1] Importantly, natural 
products continue to play the major role as a promising source of drug discovery and 
development.[2] Not only have natural products shown remarkable structural diversity and 
complexity difficult to find using synthetic compounds, but also they exhibit complex 
mechanisms of action hardly possible to achieve by rational design. Furthermore, millions of 
years of evolution have optimized antibiotics from microorganisms regarding affinity and 
specificity to their targets.[3]  Recently, a novel drug target termed “switch region” has been 
located on bacterial RNA polymerase (RNAP) based on its interaction with three antibiotics 
myxopyronin, corallopyronin and ripostatin.[4] These substances therefore show a different target 
site and mechanism of inhibition compared to known RNAP inhibitors,  thus they are regarded as 
highly promising compound classes for the development of broad-spectrum antibacterial 
therapeutic agents.[4;5]  
The -pyrone antibiotics myxopyronin[6] with its structurally related compound 
corallopyronin[7] (Scheme 1) and the macrolactone ripostatin[8] are all produced by myxobacteria, 
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Gram-negative soil bacteria that have been established as proficient source for novel natural 
products over the last decades.[9] Complex biosynthetic machineries and regulatory networks are 
usually involved in the production of such so-called secondary metabolites posing several 
challenges for biosynthetic engineering approaches. Identification of the corresponding 
biosynthetic pathways, studies on the underlying biochemistry and appropriate genetic tools are 
required to rationally improve    structures and boost production yields of secondary metabolites 
in general. Recently, a hybrid polyketide synthase (PKS)/nonribosomal peptide synthetase 
(NRPS) system was reported to be involved in the biosynthesis of corallopyronin in 
Corallococcus coralloides.[10]  
 
 
Scheme 1.  Myxopyronin and corallopyronin 
Such multimodular mega-synthetases catalyze the stepwise assembly of simple 
precursors (activated short-chain carboxylic acids or amino acids) by using a distinct set of 
catalytic domains bundled into so-called modules each incorporating one specific biosynthetic 
unit into the growing polyketide/peptide chain.[11] After the last elongation step the biosynthetic 
intermediate is usually released from the enzyme complex in linear, cyclic or branched-cyclic 
form by simple hydrolysis or intramolecular macrocyclization. The biosynthesis of -pyrone 
antibiotics seems to involve an unusual condensation of two linear polyketide (or peptide) chains, 
the “eastern” and “western” chains of the molecule (Scheme 1). These have been proposed to be 
generated on two distinct multimodular assembly lines, based on detailed in silico analysis of the 
putative corallopyronin pathway genes from C. coralloides as well as on feeding studies, to 
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reveal the biosynthetic origin of this compound class.[10, 12] However, as no genetic manipulation 
has been reported for the corallopyronin producer, no functional in vivo studies on the presumed 
biosynthetic gene cluster have been published. 
Here we describe the pathway identification and characterization of the -pyrone antibiotic 
myxopyronin from Myxococcus fulvus Mx f50. A detailed comparison with the putative 
corallopyronin pathway revealed the genetic basis leading to the chemical diversity observed in 
the western chains of both molecules. The establishment of genetic tools for the myxopyronin 
producer allowed us to perform several gene deletion experiments for functional studies and to 
produce an unexpected novel derivative. Our studies provide further insights into the biosynthesis 
of -pyrone antibiotics and will serve as important basis to establish production platforms for this 
compound class by biosynthetic engineering. 
2.3 Results and Discussion 
2.3.1 Identification of the myxopyronin biosynthetic gene cluster 
To identify the myxopyronin biosynthetic pathway in M. fulvus Mx f50, shotgun genome 
sequence data were generated by using the Illumina HiSeq sequencing system. The 578 sequence 
contigs and 235 sequence scaffolds (spanning ~11.2 Mbp) were screened for gene loci encoding 
putative PKS/NRPS pathways with high similarity to the putative corallopyronin biosynthetic 
pathway.[10] A corresponding genomic region was identified, and the sequence of the proposed 
myxopyronin biosynthetic gene cluster was completely deciphered by manual gap closing, 
through PCR and subsequent sequencing. After establishing and applying a directed mutagenesis 
procedure for M. fulvus Mx f50, the putative PKS/NRPS-encoding gene mxnI was inactivated, to 
verify the involvement of the identified gene locus in myxopyronin biosynthesis. As expected, 
myxopyronin production was completely abolished in the mutant (Mx f50::mxnI), thus implying 
that mxnI is essential for myxopyronin biosynthesis, although polar effects on downstream genes 
(mxnJ-M), which are most likely also affected by mxnI inactivation, could also result in this 
phenotype (Scheme 2A). In addition, a markerless gene-deletion procedure was developed for M. 
fulvus Mx f50, to perform functional studies on selective pathway genes, as explained below. A 
summary of all mutants generated in this work and their corresponding phenotypes is given in 
Table S1 in the Supporting Information. The identified myxopyronin biosynthetic gene cluster is 
53 kb in length, with a high overall GC content (68.3^%, typical for myxobacteria).[13] 
Bioinformatic analysis revealed 13 open reading frames (ORFs), designated mxnA-M; all are 
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transcribed in the same direction and are assumed to represent a single transcription unit (Scheme 
2A). 
2.3.2 Comparison of the myxopyronin biosynthetic pathway with that of 
corallopyronin 
As expected, most of the proteins encoded in the myxopyronin (mxn) biosynthetic gene cluster 
show high homology (70-94 % similarity) to proteins from the recently postulated corallopyronin 
(cor) biosynthetic pathway (Table 1).[10] However, there are significant differences between these 
pathways; these are (at least in part) in accordance with the structural differences observed 
between the myxopyronin/corallopyronin scaffolds. Although the eastern chains are identical, the 
myxopyronin western chain is considerably shorter than that in the corallopyronin structure. As 
discussed in more detail below, this structural difference can be explained by various constituents 
of the western chain assembly lines (MxnK versus CorK/CorL), and the presence of additional 
modifying genes (CorN, CorO) in the corallopyronin biosynthetic pathway. The 
myxopyronin/corallopyronin assembly lines belong to the growing class of trans-AT PKS 
systems that lack integrated acyltransferase (AT) domains,[14--16] but instead exhibit discrete, free-
standing AT-activity (MxnA/CorA). In addition to a malonyl-CoA-specific AT domain, 
MxnA/CorA exhibit enoylreductase (ER) activity, which is also absent in the modular PKS 
subunits. Similar arrangements are also found in other trans-AT PKS pathways as reviewed 
recently.[15, 17] 
In general, myxopyronin and corallopyronin biosynthesis can be divided into three major steps: 
1) eastern chain assembly, 2) western chain assembly, and 3) chain condensation, thereby giving 
rise to formation of the pyrone moiety (Scheme 2B-D). The myxopyronin and corallopyronin 
eastern chains are structurally identical (Scheme 1), and, as expected, the identified assembly 
lines (MxnI/MxnJ and CorI/CorJ) show high similarities. Feeding studies with the corallopyronin 
producer have shown that the starter unit originates from bicarbonate, and that likely a 
bicarbonate-dependent ATPase activity from primary metabolism is involved in its activation.[10]
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Scheme  2. A) Myxopyronin and corallopyronin biosynthetic gene clusters, B) Eastern chain assembly line, C) Myxopyronin and corallopyronin western chain assembly lines, D) 
Chain condensation and formation of the pyrone moiety. CP: carrier protein; DH: dehydratase domain; ER: enoylreductase domain; KR: ketoreductase domain; KS: ketosynthase 
domain; MT: methyltransferase domain; X: putative inactive KR or truncated phosphoglucomutase/phosphomannomutase domain. The CP*, DH*, and KS*domains are assumed 
to be inactive. Black circles mark the carbons introduced by the -branching cassette. Unique genes or gene fragments are highlighted for the corallopyronin (gray) and  
myxopyronin (black) biosynthetic pathways. 
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The resulting (highly labile) carboxyphosphate intermediate would allow subsequent attachment 
to the carrier protein (CP) domain of the loading module, to start eastern chain biosynthesis 
(Scheme 2B). It is interesting to note that a putative N-terminal domain (X) in MxnI might 
represent an inactive ketoreductase (KR) domain (as also postulated for CorI), but we found that 
it also exhibits very weak similarity to a truncated phosphoglucomutase/phosphomannomutase, 
alpha, beta/alpha domain II (PGM PMM II). We speculate that this domain is involved in 
activation/modification of the proposed bicarbonate starter by phosphoryl group transfer. 
However, the eastern chain assembly mostly proceeds by incorporation of a glycine and three 
malonyl-CoA extender units mostly according to textbook biosynthetic logic but also involving 
several exceptions typical for trans-AT PKS systems.[15] These include the presence of an 
unusual mixed PKS/NRPS module (module 1E: KS-A-CP; KS: ketosynthase, A: adenylation 
domain) for the incorporation of glycine, and a "split module" (module 3E: KS, DH*-CP; E: 
modules from the eastern chain assembly line (as shown in Scheme 2), *: domains that are 
supposed to be inactive, DH: dehydratase), which is most likely not involved in chain elongation. 
However, the DH* domain might catalyze the double-bond shift from the α,β to the β,γ position, 
as was described in rhizoxin biosynthesis for RhiE, which shows a similar "split module" 
arrangement.[18] The following module, module 4E, lacks the ER activity required to complete the 
reduction cycle, which might be provided by MxnA in trans, as discussed above. The next 
module is assumed not to be involved in chain elongation because it contains a mutated 
ketosynthase domain (module 5E: KS*-CP); it should not be able to catalyze a condensation 
reaction. Another deviation from textbook biochemistry is the presence of tandem-CP domains 
within the last module (module 6E: KS-CP*-CP; CP* seems to be inactive), which incorporates 
the third malonyl-CoA extender to generate the final eastern chain β-keto intermediate. The 
terminal carboxy moiety is assumed to be methylated by the putative carboxy methyltransferase 
(MxnH/CorH) encoded in each pathway. This modification would increase the stability of the 
starter unit as well as of eastern chain assembly line intermediates, and therefore likely takes 
place at an early stage of eastern chain biosynthesis. 
In contrast to the eastern chains, the western chains of myxopyronins and corallopyronins 
show significant structural differences (Scheme 1). This is reflected in the domain arrangements 
of the corresponding western chain assembly lines. A single pentamodular subunit, MxnK, is 
found in the myxopyronin pathway; in contrast, a heptamodular dual subunit system, CorK/CorL, 
is found for corallopyronin western chain formation (Scheme 2C). 
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Table 1. Proposed function of the proteins involved in myxopyronin biosynthesis and homologues from the 
related corallopyronin biosynthetic pathway.  
 
Myxopyronin 
protein 
(amino acids) 
 
Corallopyronin 
protein 
(amino acids) 
Homology between 
Mxn and Cor proteins 
Identity/Similarity [%] 
Putative function 
[Catalytic domains] 
MxnA (798) CorA (763) 77/86 acyltransferase – enoylreductase [AT-ER] 
MxnB (335) CorB (335) 84/94 ketosynthase [KS] 
MxnC (83) CorC (83) 76/90 acyl carrier protein [CP] 
MxnD (423) CorD (423) 74/83 ketosynthase [KS] 
MxnE (410) CorE (410) 82/92 
hydroxymethylglutaryl-CoA (HMG-CoA) 
synthase 
MxnF (253) CorF (261) 75/83 enoyl-CoA hydratase/isomerase [ECH] 
MxnG (254) CorG (254) 83/92 enoyl-CoA hydratase/isomerase [ECH] 
MxnH (286) CorH (286) 86/93 carboxyl-methyltransferase [MT] 
MxnI (3906) CorI (3883) 71/80 
hybrid polyketide synthase (PKS, trans-AT 
type ) /nonribosomal peptide synthetase 
(NRPS) 
[PM-CP-KS-A-CP-KS-DH-KR-CP-KS] 
MxnJ (3862) CorJ (3817) 70/80 
polyketide synthase (PKS, trans-AT type) 
[DH-CP-KS-DH-KR-MT-CP-KS-CP-KS-
CP-CP] 
MxnK (6045) 
CorK (4068) 70/78 
polyketide synthase (PKS, trans-AT type) 
[KS-DH-KR-CP-KS-CP-KS-CP-KS-DH-
KR-MT-CP-KS-CP-CP] CorL (4981) 68/78 
MxnL (582) Orf1 (573) 75/86 hypothetical protein (SorT) 
MxnM (326) Not found - acyltransferase 
Not found CorM (240) - thioesterase 
Not found CorN (724) - enoyl CoA hydratase 
Not found CorO (449) - cytochrome P450 
 Domain abbreviations as in Scheme 2. 
 
Sequence alignment of the two western chain assembly lines revealed that modules 3W and 4W of 
CorK/CorL are absent in MxnK, which also lacks the reductive domains (DH-KR) in module 2W. 
The assembly is most likely initiated with an acetyl-CoA (myxopyronin A) or propionyl-CoA 
(myxopyronin B) starter unit, which is assumed to be directly loaded onto the N-terminal KS 
domain of module 1W, as no typical loading module could be identified. After elongation with the 
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first malonyl-CoA extender unit, the resulting β-keto intermediate is then fully reduced, for 
which the final reduction step is again likely catalyzed in trans by MxnA. The KS domain of the 
next module (module 2W: KS*-CP) seems to be inactive, and is therefore not involved in chain 
elongation. The downstream modules (modules 3W, 4W, 5W) incorporate three additional malonyl-
CoA extender units (according to textbook polyketide chemistry) to generate the final western 
chain β-keto intermediate. Chain elongation on module 3W includes β-branching, which is 
another feature typical for trans-AT PKS systems[15, 19] and results in a methyl group at C-20. The 
genes for this modification show the typical cluster organization (mxnCDEFG), as also observed 
in the corallopyronin biosynthetic pathway (corCDEFG). They encode an acyl carrier protein 
(CP; MxnC) to load malonyl-CoA, which is subsequently decarboxylated by a mutated, 
nonelongating ketosynthase (MxnD). Aldol addition of the generated acetate unit to the 
biosynthetic intermediate bound to module 3W is catalyzed by the 3-hydroxy-3-methylglutaryl-
CoA (HMG-CoA) synthase homologue (MxnE). The resulting product then undergoes 
dehydration and decarboxylation by two enoyl-CoA hydratase (ECH) homologues (MxnF and 
MxnG). Based on sequence comparison with the functionally characterized homologues CurE 
and CurF, we assume that MxnF and MxnG are involved in dehydration and decarboxylation, 
respectively (Scheme S1).[20] It is interesting to note that a second β-branch is introduced into the 
corallopyronin western chain (C-26 in addition to C-21), whereas the shorter myxopyronin chain 
contains only one such β-branch (C-21). Furthermore, corallopyronin western chain biosynthesis 
includes a double bond isomerization (from position Δ24,25 to Δ25,27), which is likely catalyzed by 
CorN. A further hydroxylation at C-24 is probably introduced by the putative cytochrome P450 
CorO. CorN and CorO enzyme activities are not required and are not encoded in the 
myxopyronin biosynthetic pathway. 
In the last stage of the biosynthesis, the eastern and western chain β-keto intermediates are 
released from the PKS complex and undergo condensation to form the characteristic pyrone ring 
(Scheme 2D). We assume that the discrete ketosynthase (MxnB/CorB) is involved in this 
transformation. For corallopyronin, it was speculated that an additional thioesterase (TE) activity, 
catalyzed by CorM, is involved in this process, by cleaving the intermediate from CorL--PKS 
and building the lactone moiety.[10] As no CorM homologue is encoded within the myxopyronin 
pathway we postulate that MxnB should be sufficient for pyrone ring formation. This is 
consistent with a recent study by Leadlay and co-workers, who showed in vitro formation of a 
tetronate polyketide in the presence of RkD (a FabH-like 3-oxoacyl-(acyl carrier protein) 
synthase III) and acyl-carrier-protein-bound substrates.[21] However, from the in silico analysis 
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we cannot completely exclude the involvement of the hypothetical protein MxnL in the final 
chain release and condensation steps. MxnL and its homologue from cor pathway (Orf1) show 
very weak similarity to a hypothetical protein from the sorangicin pathway, SorT, for which a 
possible role in chain release from the PKS complex was speculated. The last gene in the mxn 
pathway encodes a putative acyltransferase, MxnM, which has no counterpart in the 
corallopyronin pathway. Therefore, MxnM as well as the hypothetical protein MxnL represented 
interesting candidates for functional studies (described in the next section). 
2.3.3 MxnL and MxnM are not essential for myxopyronin biosynthesis 
The presence of the hypothetical protein MxnL and the putative acyltransferase MxnM (with no 
obvious roles in myxopyronin biosynthesis) motivated us to perform functional studies through 
gene deletion experiments. Genetic tools and mutagenesis protocols for myxobacteria are rather 
limited, not widely applicable, and usually have to be established for each strain individually.[22] 
To develop a markerless gene-deletion procedure for the myxopyronin producer M. fulvus Mx 
f50 we made use of the sacB counterselection method, which has been successfully applied in the 
myxobacterial model strain Myxoccoccus xanthus.[23] Appropriate procedures for efficient DNA 
transfer were evaluated, to establish a robust genetic system for markerless gene deletion in M. 
fulvus Mx f50; this was used to generate five gene-deletion mutants, as described below (Figure 
1). The genotypes of all mutants were confirmed by PCR or Southern blot analysis (see the 
Supporting Information). 
The mxnL gene was excised from the chromosome, and the obtained mutant strain, M. 
fulvus Mx f50ΔpHSU-mxn20 (ΔmxnL), was analyzed, in parallel with the wild-type strain, for 
myxopyronin production. Interestingly, comparable myxopyronin production levels were 
detected (Figure S8), thus indicating that MxnL is not essentialindeed, not even 
promotionalfor myxopyronin biosynthesis, in terms of production yield under the tested 
conditions. However, we cannot exclude that possible MxnL deficits might be complemented by 
enzymes encoded elsewhere in the genome. Significant bottlenecks in other stages of the 
production line or a minimal positive impact of MxnL in the wild-type strain under the tested 
production conditions (e.g., due to low mxnL expression levels) might also explain the absence of 
detectable effects upon mxnL deletion. 
 
Molecular Basis of Myxopyronin Biosynthesis| 39 
 
 
Figure 1. HPLC-MS chromatograms for myxopyronin gene cluster variants. Culture extracts of M. fulvus Mx f50 (Mx f50 
WT) and the deletion mutants of M. fulvus Mxf50ΔpHSU-mxn23 (ΔmxnH), M. fulvus Mxf50ΔpHSU-mxn21 (ΔmxnC-G), 
M. fulvus Mxf50ΔpHSU-mxn22 (ΔmxnC-H), M. fulvus Mxf50ΔpHSU-mxn20 (ΔmxnL), M. fulvus Mxf50ΔpHSU-mxn34 
(ΔmxnM) were analyzed in comparison with an authentic reference (standard myxopyronin A). In ΔmxnH, ΔmxnC-G, and 
ΔmxnC-H no myxopyronin A was detected. Asterisk shows the peak of the novel myxopyronin derivative identified in the 
ΔmxnC-G mutant. Vertical symbols (           ) show the position of deleted genes in the variants. 
Another interesting candidate for functional studies was MxnM, a putative discrete 
acyltransferase (AT) with no homologue in the corallopyronin biosynthetic pathway. Whereas 
the MxnA AT activity was proposed to load the PKS with malonyl units, the function of the 
second AT copy (MxnM) was unclear. A recent study by Piel and co-workers described a 
proofreading function for such "additional" AT copies (to remove aberrant acyl units from 
blocked trans-AT PKS modules), and a novel group of editing acyl hydrolases (AHs) was 
discovered.[24] These studies were carried out with PedC from the pederin pathway from a 
Pseudomonas sp. Symbiont of Paederus fuscipes beetles, and, interestingly, MxnM falls into the 
same clade in phylogenetic analysis (Figure S7). Another member of this "AT2 clade" is MmpC-
AT1 from the mupirocin pathway Pseudomonas fluorescens; a negative effect on overall 
production yield was shown upon deletion of the AT1–encoding fragment of the mmpC.
[25, 26] 
Production titers in the mutant strain were around 13.5% of wild-type. Although an unfavorable 
effect on the malonyl loading ability of AT MmpC-AT2 could not be excluded (due to the 
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disruption of the bifunctional MmpC-AT1-AT2 protein), the observed negative impact on 
production yield also supports a proof-reading function for MmpC-AT1. In light of these results, 
we considered that MxnM might represent an editing acyltransferase-like protein that positively 
influences the overall productivity of the myxopyronin PKS and/or plays a role in chain release 
during final pyrone ring formation. As the corallopyronin pathway lacks an MxnM homologue, 
we further speculated that MxnM might be specific for the significantly different western chain 
assembly line, or that the productivity of the corallopyronin pathway is lower because of the 
absence of such an editing AT. To study the impact of mxnM on myxopyronin production, the 
gene was deleted to yield the mutant strain M. fulvus Mx f50ΔpHSU-mxn34 (ΔmxnM). Analysis 
of products revealed no obvious effects on yield (Figure S8) relative to the wild-type, thus 
suggesting that MxnM is neither essential nor beneficial for myxopyronin production under the 
tested conditions. Again, we cannot exclude complementation by other enzymes (encoded 
elsewhere in the genome) or crucial bottlenecks in other stages of the production that might mask 
"beneficial factors", such as proofreading. In addition, it is possible that MxnM does not mediate 
strong activity in the wild-type strain (e.g., due to low expression levels), so its deletion showed 
no detectable effect. Overall, the presence of MxnM might be useful, but is not essential for 
myxopyronin biosynthesis. For forthcoming studies, it would be interesting to investigate 
whether overexpression of MxnM in the myxopyronin producer (and also in the corallopyronin 
producer) boosts production yield. 
2.3.4 Unexpected myxopyronin A derivative from -branching cassette deletion 
In order to generate modified myxopyronin derivatives we aimed to delete the entire β-branching 
cassette mxnCDEFG by using the markerless mutagenesis procedure established in this study. 
Production in the mutant strain, M. fulvus Mx f50ΔpHSU-mxn21 (ΔmxnC--G), was compared 
with wild-type. As expected, HPLC-MS analysis of the extracts revealed no production of the 
native derivatives myxopyronin A or B in the ΔmxnC--G mutant, but a novel myxopyronin 
derivative was detected. The high-resolution mass spectrum (HRMS) displayed an [M+H]+ peak 
at m/z 404.2065 (calcd for C22H30O6N: 404.2067; Δ 0.5 ppm) which is 14 amu lower than for 
myxopyronin A and consistent with the molecular formula C22H29O6N. In order to confirm the 
structure of this novel derivative, 0.35 mg was purified from 10 L culture and subjected to NMR 
analysis (Table S4 and Figures S1-S4). 1H NMR and HSQC spectra of the isolated compound 
show the absence of the Me-21 β-branch (compared to myxopyronin A). Detailed analysis of the 
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2D NMR data allowed us to determine it as a 21-desmethyl analogue of myxopyronin A (Figure 
2).  
 
 
Figure 2. Key correlations of HMBC and COSY of 21-desmethyl-myxopyronin A isolated from M. fulvus Mxf50ΔpHSU-
mxn21 (ΔmxnC-G). 
In particular, uninterrupted COSY correlations from the olefinic proton at δ=6.93 ppm (H-18) to 
the methyl protons δ=0.93 ppm (Me-23) and HMBC correlations from the methyl vinyl protons 
at δ=1.93 ppm (Me-17) to the carbon resonances at δ=201.0 (C-15), 136.7 (C-16), and 141.5 ppm 
(C-18) confirmed its structure. Subsequent studies on its biological activity against a small panel 
of microorganisms revealed that the 21-desmethyl derivative was less active than myxopyronin A 
(Table S3). 
However, the structure of 21-desmethyl-myxopyronin A did not completely correlate with 
the structural variation expected from this genetic modification. In fact, removal of the β-
branching machinery should have resulted in retention an unmodified C-20 carbonyl 
functionality instead of the observed Δ19,20 double bond. This reduction can be explained by 
downstream KR and DH activities by module 4W, which might act on both the C-18 β-carbonyl 
and the C-20 O-carbonyl functionality of the biosynthetic intermediate. However, the production 
yield of the novel derivative was about fiftyfold lower than that of native myxopyronin in the 
wild-type strain; not even trace amounts of the originally expected derivative (retained C-20 
carbonyl functionality) could be detected. If we exclude general negative effects on gene 
expression in the modified mxn biosynthetic operon (ΔmxnC--G), these results might be 
explained by two scenarios: 1) the conjugated olefinic system might be essential for pyrone ring 
formation, and C-20 carbonyl intermediates bound to 5W-CP are not processed further, or 2) O-
carbonyl reduction on module 4W is highly efficient, but because of the lack of the C-21 β-
branch, the overall productivity of the condensation step is significantly decreased. Future studies 
on the final condensation reaction, especially on substrate specificity of the involved enzymes(s) 
(most likely MxnB), should provide deeper insights into this crucial biosynthetic step. 
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2.3.5 O-methylation by MxnH is essential for myxopyronin biosynthesis 
The successful biosynthetic engineering of the β-branching cassette motivated us to generate 
further pathway variants: deletion of another modifying gene (mxnH), which encodes a putative 
carboxy-methyltransferase. MxnH and its homologue CorH (corallopyronin biosynthetic 
pathway) are assumed to introduce the O-methyl functionality during eastern chain biosynthesis. 
Using the established gene-deletion procedure, we constructed two additional mutant strains, M. 
fulvus Mx f50ΔpHSU-mxn22 (ΔmxnC-H), in which mxnH and the β-branching cassette (mxnC-
G) were deleted, and M. fulvus Mx f50ΔpHSU-mxn23 (ΔmxnH), in which exclusively mxnH was 
deleted. This modification might lead to the production of myxopyronin derivatives with a free 
carbamic acid moiety instead of the eastern chain methyl carbamate. 
Interestingly, HPLC-MS analysis of culture extracts revealed that myxopyronin production 
was completely abolished in both mutants (Figure 1). As discussed by Erol and co-workers for 
corallopyronin biosynthesis, the starter unit carbonic acid functionality might be rather unstable, 
especially after the first elongation step with glycine.[10] It was speculated that CorH might attach 
the O-methyl group to the starter unit immediately or, alternatively, to the carbamate moiety after 
the first chain elongation. The missing methylation activity in mxnH deletion mutants thus might 
cause a breakdown in myxopyronin biosynthesis due to the instability of eastern chain 
intermediates. Additionally (or alternatively), it should be considered that the altered 
intermediates are not processed because of certain substrate specificities in the eastern chain 
assembly line or at the final chain condensation step. However, to exclude that the genetic 
modifications (ΔmxnH or ΔmxnC-H) had negative impacts on the functional expression of the 
remaining mxn biosynthetic genes, we performed chemical and genetic complementation studies 
with the ΔmxnH mutant strain. After reintegration of mxnH by insertional mutagenesis at the 3' 
end of the gene cluster, myxopyronin production was restored. The production yields were 
tenfold lower than wild-type, thus indicating that the genetic modifications within the mxn 
biosynthetic operon might (partially) reduce gene expression levels. However, the successful 
complementation suggests that the mxn biosynthetic genes should in principle be functional in the 
mxnH deletion mutants, and thus that formation of a methyl carbamate might be essential for 
eastern chain biosynthesis. At which stage of the biosynthesis methylation occurs is currently 
unknown. Because of the instability of the methyl carbamate moiety we assume that methylation 
occurs, at the latest, after the first elongation step (condensation with glycine). Feeding of 
triethylmethylammonium methyl carbonate did not restore myxopyronin production, thus 
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indicating that a methylated starter unit precursor might not be accepted. However, further 
experiments, for example feeding studies including mimics of putative intermediates bound to the 
loading module or module 1E, have to be performed to shed more light on the methylation 
scenario. 
2.4 Conclusion 
The α-pyrone class of antibiotics exhibits promising antibacterial activity, specifically by 
interaction with the RNA polymerase "switch region". In this study we have identified the gene 
cluster for myxopyronin biosynthesis and revealed the overall similarity (but also significant 
differences) to the structurally related compound corallopyronin. Bioinformatic analysis and a set 
of gene deletions have revealed interesting features of myxopyronin biosynthesis. The O-
methylation in eastern chain assembly seems to be a key reaction that eventually affects 
myxopyronin biosynthesis. Furthermore, an unexpected derivative was obtained from the β-
branching cassette deletion. This gene cluster information will be the basis for the generation of 
novel myxopyronin analogues by genetic engineering. 
2.5 Experimental Section 
Bacterial strains and culture conditions 
Bacterial strains and plasmids used during this study are listed in Table S1. Myxococcus fulvus 
Mx f50 wild type and mutants were grown in Casitone Yeast (CY) medium (0.3 % casitone, 0.1 
% yeast extract, 0.1 % CaCl2 x 2 H2O) supplemented with 5 x 10
-4  µg L-1 vitamin B12 after 
autoclaving. For liquid cultures, the strains were grown at 30 C and 105 rpm on an orbital 
shaker and harvested after 3 days. E. coli strains were cultured in lysogeny broth (LB) medium (1 
% tryptone, 0.5 % yeast extract, 0.5 % NaCl) at 37 C. Appropriate antibiotic selection at a final 
concentration of 100 µg ml-1 ampicillin, 50 µg ml-1 kanamycin, 5 µg ml-1 tetracycline or 6.25 µg 
ml-1 oxytetracycline was added whenever necessary. 
 
DNA preparations and PCR 
M. fulvus Mx f50 genomic DNA was prepared either via the Phenol Chloroform Isoamyl alcohol 
extraction method[27] or by using the Gentra Puregene Genomic DNA Purification Kit (Qiagen) 
according to the manufacturer’s protocol. Plasmid DNA was either purified by standard alkaline 
lysis[27] or by using the GeneJet Plasmid Miniprep Kit (Thermo Fisher Scientific). The PCR 
reactions were carried out in a peqSTAR 96 Universal Gradient thermocycler (Peqlab): initial 
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denaturation (3 min, 95 C); 30 cycles of denaturation (30 s, 95 C), annealing (30 s, 53 or 57 C) 
and elongation (varied based on PCR product length 1 kb/min, 72 C); and final extension (10 
min, 72 C). DNA fragments were separated by agarose gel electrophoresis and isolated using the 
peqGold Gel Extraction (Peqlab). The PCR products were cloned into pCRII-TOPO (Invitrogen) 
or pJET1.2 blunt (Thermo Fisher Scientific) vector and sequenced using the primers 
M13For/M13Rev or pJET1.2For/pJET1.2Rev, respectively. Primer sequences are listed in Table 
S2. 
 
Genome sequence and bioinformatic analysis of sequences 
The shotgun genome sequence data were generated on Illumina Hi-Seq2000 instrument (Fasteris 
SA, Switzerland). The assembly revealed 578 sequence contigs, which could be combined to 235 
scaffolds. The myxopyronin gene cluster was identified by homology search against the 
identified corallopyronin gene cluster. We performed analysis on protein sequence homology 
searches using BLAST (http://blast.ncbi.nlm.nih.gov/) and Pfam 
(http://pfam.sanger.ac.uk/search/sequence) searches. The prediction of PKS/NRPS region was 
performed with online application NRPS-PKS (http://nrps.igs.umaryland.edu/nrps/).[28] Analysis 
and annotation of DNA and protein sequences were performed with Geneious 6.0.3 software 
packages (Biomatters, New Zealand). Sequencing data are accessible at GenBank under 
accession number KF356280. 
 
Construction of in-frame deletion mutants mxnCDEFG (ΔmxnC-G), mxnCDEFGH 
(ΔmxnC-H), mxnH, mxnL, mxnM  
In general, construction of in-frame deletion mutants was carried out by amplifying 1000-1250 
bp homology regions on each side of the desired deletion area by PCR (see Supporting 
Information). Each fragment was subcloned to the pJET1.2 blunt vector and sequenced using the 
primers pJET1.2For and pJET1.2Rev. After sequence verification the homology regions were 
cloned into the pSWU41 vector[23], which contains a neomycin phosphotransferase (nptII) and 
levansucrose (sacB) gene cassette, by using restriction sites indicated in Table S2. The resulting 
constructs were subsequently electroporated into M. fulvus Mx f50. M. fulvus Mx f50 was grown 
in baffled flask with CY medium until an OD600 between 0.6-0.9 was reached. Cells were then 
harvested from 2-4 ml culture (1-2 x 109 cells ml-1) by centrifugation at 12500 rpm for 1 min at 
room temperature. After two washing steps with 1 ml H2O at room temperature, cells were 
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resuspended in 65 µl H2O. Plasmid DNA (1-2 µg) was mixed with the cell suspension, and 
electroporation was carried out under the following conditions: 25 µF, 400 Ω, 650 V using 0.1 
cm electroporation cuvettes and a GenePulser XCell device (Bio-Rad). 1 ml CY medium was 
directly added to the cell suspension immediately after electroporation and the cells were 
transferred into a 2 ml centrifuge tube. After 6-8 h cultivation at 30 C and 800 rpm on a 
thermomixer, the cells were mixed with 2 ml CY soft agar (CY medium containing 0.7 % agar) 
and plated on CY agar plates (CY medium containing 1.7 % agar) supplemented with 50 µg ml-1 
kanamycin or 6.25 µg ml-1 oxytetracycline. The plates were incubated at 30 C for 7-10 days 
until colonies became visible.  
For the construction of markerless double crossover mutants the following strategy was 
applied: After verification of the single crossover mutants (kanamycin-resistant mutants) by PCR 
(integration via two different homology regions was possible), a selected single cross over 
mutant was grown in CY medium in the absence of antibiotics. After 3-4 days 1 ml of the well-
grown culture was transferred into 50 ml fresh medium to start another cultivation cycle at 30 °C 
for 3-4 days. This procedure was repeated for three times to increase the possibility for a second 
cross over event, which would result in the loss of the inactivation plasmid. Depending on the 
homology region used for the second cross over this can yield either the wildtype genotype 
(‘revertants’) or the expected mutant strain, in which the targeted region is deleted (double cross 
over mutant). To select for clones in which a second cross over took place, a counter selection 
system based on the sacB gene was used.[23] For this, different dilutions of the cell population 
were plated on CY agar supplemented with 6 % sucrose for counterselection. After 7-10 days, 
first colonies became visible, which were then grown in liquid culture (CY medium) to isolate 
genomic DNA for genotypic verification and to extract the cultures for phenotypic analysis as 
described below. 
 
Construction of the mxnI mutant by insertional mutagenesis 
To inactivate mxnI by insertional mutagenesis, the knock-out plasmid pHSU-mxn13 was 
constructed. A 1474 bp fragment for homologous recombination was amplified from M. fulvus 
Mx f50 genomic DNA by PCR using the primers mxn50 and mxn51 containing BamHI and 
EcoRV restriction sites. The resulting fragment was cloned into pCRII-TOPO vector to generate 
pHSU-mxn13. The plasmid was transformed into M. fulvus Mx f50 by electroporation as 
described above. For genotypic analysis, a set of different PCRs using the primer combinations 
46 | Gene Cluster Elucidation 
 
mxn58/pTOPO-in and mxn59/pTOPO-out was carried out to verify the correct integration of the 
inactivation plasmid. 
 
Phenotypic analysis of wild-type and mutant strain 
Well-grown pre-cultures (OD600 = 0.7-1.0) of M. fulvus Mx f50 and mutants thereof were used to 
inoculate production cultures in 300 ml baffled flask containing 40 ml CY medium (1 % 
inoculum). After cultivation for 3 days at 30 C and 105 rpm, the cultures were harvested by 
centrifugation. Myxopyronin A is almost exclusively present in the supernatant, which was 
extracted twice with an equal volume of ethyl acetate after pH adjustment (pH 6.0-7.0). After 
evaporation of the organic phase, the residue was dissolved in 1 ml methanol. A 2 µl aliquot of 
the extract was analyzed by High Performance Liquid Chromatography-Mass Spectrometry 
(HPLC-MS) (Thermo Ultimate 3000 RSLC, coupled to a Bruker Daltonics Amazon Electrospray 
Ionization (ESI)-MS ion trap instrument) operating in positive ionization mode. Compounds 
were separated on a Waters Acquity BEH C18 column (50 x 2.1 mm; 1.7 µm particle diameter) 
at a flow rate of 600 µl min-1 and 45 C by a linear gradient with (A) H2O + 0.1 % formic acid 
(FA) to (B) acetonitrile (ACN) + 0.1 % FA at a flow rate of 600 µl min-1 and 45 °C. The gradient 
was initiated by a 0.33 min isocratic step at 5 % B, followed by an increase to 95 % B in 9 min to 
end up with a 1 min flush step at 95 % B before re-equilibration with initial conditions. Detection 
was carried out by both diode array (DAD) and ESI-MS. For high resolution mass spectrometry 
analysis, measurements were performed on a Dionex Ultimate 3000 RSLC system using a 
Waters BEH C18 column (50 x 2.1 mm, 1.7 µm dp) by injecting 2 µl of the methanolic extract. 
Separation was achieved by the same gradient as above with 0.33 min isocratic step at 5 % B.  
UV and MS detection were performed simultaneously. Coupling the HPLC to 
the MS was supported by an Advion Triversa Nanomate nano-ESI system attached to a Thermo 
Fisher Orbitrap. Mass spectra were acquired in centroid mode ranging from 200-2000 m/z at a 
resolution of R = 30000. 
 
Isolation of 21-desmethyl-myxopyronin A from the ΔmxnC-G mutant 
A 10 L cultivation was performed in 5 L Erlenmeyer flasks, each containing 2 L CY medium. 
The flasks were inoculated with 25 ml preculture and incubated on a rotary shaker (130 rpm) at 
30 C. After 3 days, the culture was centrifuged for 20 min at 8000 rpm and the supernatant was 
extracted two times with a total volume of 5 L ethyl acetate. After evaporation of the organic 
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phase, the residue was dissolved in 125 ml of methanol-water (95:5), and partition between 
methanol-water phase and heptane was performed. The methanol-water phase was then 
evaporated to dryness to yield 460 mg crude extract, which was subjected to a Waters 
Autopurifier system  (XBridge C18 150 x 19 mm, 5 µm dp)  with a mobile phase consisting of 
(A) H2O + 0.1 % FA and (B) ACN + 0.1 % FA. A linear gradient of 10 % (B) to 85 % (B) in 21 
min at a flow rate of 25 ml min-1 was applied. The fractions containing the derivative were 
combined and dried in vacuo to give 1.1 mg that was subsequently purified by semipreparative 
reverse-phase HPLC (Phenomenex Luna C18, 250 x 4.6 mm, 5 µm dp column, DAD at 220 and 
310 nm). Separation was achieved by a linear gradient of 10 % to 85 % ACN + 0.1 % FA in 20 
min at a flow rate of 2.5 ml min-1 and 30 °C of column temperature to afford 21-desmethyl-
myxopyronin A (0.35 mg, tR = 25.3 min).  NMR data of pure compound were acquired in 
CD3OD at Bruker Ascend 500 MHz. 
2.6 Supporting Information 
Inactivation of mxnCDEFG  by in-frame deletion: To disrupt mxnCDEFG by in-frame 
deletion, a gene inactivation plasmid harbouring two fragments, which are 1016 bp and 1250 bp 
in size and homologous to the upstream and downstream area of the chromosomal target region, 
was constructed. These fragments were amplified from M. fulvus Mx f50 genomic DNA by PCR 
using the primers mxn85/mxn119 and mxn87/mxn88. After hydrolysis of the upstream fragment 
(mxn85/mxn119 product) with PvuI and NotI, and the downstream fragment (mxn87/88 product) 
with NotI and BamHI, the fragments were ligated into pSWU41 hydrolyzed with PvuI and 
BamHI to generate pHSU-mxn21. For genotypic analysis of the single cross-over, a set of 
different PCRs using the primer combinations mxn102/mxn104 and mxn105/mxn103 was carried 
out to verify the correct integration of the inactivation plasmid. For genotypic analysis of the 
putative double cross-over mutants, PCRs using the primers mxn102/mxn104, mxn105/mxn103 
and mxn102/mxn150 were carried out. 
 
Inactivation of mxnCDEFGH by in-frame deletion: To disrupt mxnCDEFGH by in-frame 
deletion, a gene inactivation plasmid harbouring two fragments, which are 1016 bp and 1237 bp 
in size and homologous to the upstream and downstream area of the chromosomal target region, 
was constructed. These fragments were amplified from M. fulvus Mx f50 genomic DNA by PCR 
using the primers mxn85/mxn119 and mxn83/mxn84. After hydrolysis of the upstream fragment 
(mxn85/mxn119 product) with PvuI and NotI, and the downstream fragment (mxn83/84 product) 
48 | Gene Cluster Elucidation 
 
with NotI and SpeI, the fragments were ligated into pSWU41 hydrolyzed with PvuI and SpeI to 
generate pHSU-mxn22. For genotypic analysis of the single cross-over, a set of different PCRs 
using the primer combinations mxn102/mxn104 and mxn106/mxn107 was carried out to verify 
the correct integration of the inactivation plasmid. For genotypic analysis of the putative double 
cross-over mutants, PCRs using the primers mxn102/mxn104, mxn106/mxn107 and 
mxn102/mxn149 were carried out. 
 
Inactivation of mxnH by in-frame deletion: To disrupt mxnH by in-frame deletion, a gene 
inactivation plasmid harbouring two fragments, which are 1121 bp and 1250 bp in size and 
homologous to the upstream and downstream area of the chromosomal target region, was 
constructed. These fragments were amplified from M. fulvus Mx f50 genomic DNA by PCR 
using the primers mxn117/mxn118 and mxn83/mxn84. After hydrolysis of the upstream 
fragment (mxn117/mxn118 product) with PvuI and NotI, and the downstream fragment 
(mxn83/84 product) with NotI and SpeI, the fragments were ligated into pSWU41 hydrolyzed 
with PvuI and SpeI to generate pHSU-mxn23. For genotypic analysis of the single cross-over, a 
set of different PCRs using the primer combinations mxn110/mxn111 and mxn112/mxn107 was 
carried out to verify the correct integration of the inactivation plasmid. For genotypic analysis of 
the putative double cross-over mutants, PCRs using the primers mxn110/mxn111, 
mxn112/mxn107 and mxn110/mxn149 were carried out. 
 
Complementation of ΔmxnH by insertational mutagenesis: To complement ΔmxnH by 
insertional mutagenesis, the knock-out plasmid pHSU-mxn47 was constructed. A 981 bp 
fragment covering part of mxnL and mxnM for homologous recombination was amplified from 
M. fulvus Mx f50 genomic DNA by PCR using the primers mxn155 and mxn156. In another 
PCR, the mxnH was amplified from the genomic DNA using the primers mxn157 and mxn158. 
After gel purification, both PCR products were stitched together by overlapping PCR using the 
primers mxn155 and mxn158. The resulting product was hydrolysed with PvuI and NotI and 
ligated to pSWU41 vector hydrolysed with the same enzymes to generate pHSU-mxn47. The 
plasmid was transformed into M. fulvus Mx f50ΔpHSU-mxn23 (ΔmxnH) by electroporation as 
described above. For genotypic analysis, a set of different PCRs using the primer combinations 
mxn162/mxn70 and pSWU41-F/mxn163 was carried out to verify the correct integration of the 
complementation plasmid. 
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Inactivation of mxnL by in-frame deletion: To disrupt mxnL by in-frame deletion, a gene 
inactivation plasmid harbouring two fragments, which are 1232 bp and 1109 bp in size and 
homologous to the upstream and downstream area of the chromosomal target region, was 
constructed. These fragments were amplified from M. fulvus Mx f50 genomic DNA by PCR 
using the primers mxn113/mxn114 and mxn115/mxn116. After hydrolysis of the upstream 
fragment (mxn113/mxn114 product) with PvuI and NotI, and the downstream fragment 
(mxn115/116 product) with NotI and BamHI, the fragments were ligated into pSWU41 
hydrolyzed with PvuI and BamHI to generate pHSU-mxn20. For genotypic analysis of the single 
cross-over, a set of different PCRs using the primer combinations mxn98/mxn100 and 
mxn101/mxn99 was carried out to verify the correct integration of the inactivation plasmid. 
Confirmation of the deletion mutant was obtained by Southern Blot analysis (see Figure S1). 
 
Inactivation of mxnM by in-frame deletion: To disrupt mxnM by in-frame deletion, a gene 
inactivation plasmid harbouring two fragments, which are 1110 bp and 1199 bp in size and 
homologous to the upstream and downstream area of the chromosomal target region, was 
constructed. These fragments were amplified from M. fulvus Mx f50 genomic DNA by PCR 
using the primers mxn132/mxn133 and mxn134/mxn135. After hydrolysis of the upstream 
fragment (mxn132/mxn133 product) with PvuI and SacI, and the downstream fragment 
(mxn134/135 product) with SacI and BamHI, the fragments were ligated into pSWU41 
hydrolyzed with PvuI and BamHI to generate pHSU-mxn34. For genotypic analysis of the single 
cross-over, a set of different PCRs using the primer combinations mxn140/mxn141 and 
mxn142/mxn143 was carried out to verify the correct integration of the inactivation plasmid. For 
notypic analysis of the putative double cross-over mutants, PCRs using the primers 
mxn140/mxn141, mxn142/mxn143 and mxn140/mxn143 were carried out.  
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Table S1. List of Strains and Plasmids used in this study 
Strain/Plasmid Characteristics Reference 
E.coli strains 
HS996 Host for general cloning Invitrogen 
SCS110 Host for cloning to prepare plasmid DNA, free of 
Dam or Dcm methylation 
Stratagene 
Myxococcus fulvus strains 
Mx f50 Myxopyronin producing wild-type strain [1] 
Mx f50::pHSU-mxn13 Mx f50 harbouring pHSU-mxn13 integrated via 
a 1474 bp homologous fragment of mxnI; no 
myxopyronin production 
 
this study 
Mx f50ΔpHSU-mxn20 
(ΔmxnL) 
mxnL in-frame deletion mutant; myxopyronin 
production 
this study 
Mx f50ΔpHSU-mxn21 
(ΔmxnC-G) 
mxnCDEFG in-frame deletion mutant; producing 
of a myxopyronin derivative (21-desmethyl-
myxopyronin A) 
this study 
Mx f50ΔpHSU-mxn22 
(ΔmxnC-H) 
mxnCDEFGH in-frame deletion mutant; no 
myxopyronin production 
this study 
Mx f50ΔpHSU-mxn23 
(ΔmxnH) 
mxnH in-frame deletion mutant; no myxopyronin 
production 
this study 
Mx f50ΔpHSU-mxn34 
(ΔmxnM) 
mxnM  in-frame deletion mutant; myxopyronin 
production 
this study 
Mx f50ΔpHSU-
mxn23::pHSU-mxn47 
(ΔmxnH 
complementation) 
ΔmxnH  complementation mutant; myxopyronin 
production 
 
this study 
Plasmids 
  
pSWU41 
 
Vector contains a neomycin phosphotransferase 
(nptII) gene for selection and a levansucrose 
(sacB) gene for counter selection 
[2] 
pHSU-mxn13 mxnI gene disruption construct containing 1474 
bp homologous  fragment of mxnI   
this study 
pHSU-mxn20 mxnL gene deletion construct, in which a 1632 
bp fragment of mxnL was deleted in-frame  
this study 
pHSU-mxn21 mxnC -mxnG gene deletion construct, in which a 
4219 bp fragment of mxnC-mxnG was deleted in-
this study 
Molecular Basis of Myxopyronin Biosynthesis| 51 
 
frame  
pHSU-mxn22 mxnC -mxnH gene deletion construct, in which a 
5097 bp fragment of mxnC-mxnH was deleted in-
frame  
this study 
pHSU-mxn23 mxnH gene deletion construct, in which a 756 bp 
fragment of mxnH was deleted in-frame  
this study 
pHSU-mxn34 mxnM gene deletion construct, in which a 786 bp 
fragment of mxnM was deleted in-frame  
this study 
pHSU-mxn47 ΔmxnH complementation  construct containing 
861 bp fragment of mxnH  
this study 
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   Table S2. List of primers used in this study 
Primer 
name 
Sequence (5’3’) 
Restriction   
sites  
 (in bold) 
mxn50 CATGTAGATATCGAACGGCTC CGGTACATC EcoRV 
mxn51 TGTCTAGGATCCACAGCCGCTCCAGGATTC BamHI 
mxn58 GTACGTGCCGTTGGAT  
mxn59 GAGGGGTACTTGAAGAGC  
mxn70 CTTGCGCCCTGAGTGCTT  
mxn79 GGAGGAATACGTCGGAGA  
mxn80 CAATCTGGAGGATCTGCC  
mxn83 GAGCGGCCGCCTCGAGATGAAGGTGGAT NotI 
mxn84 ATGACTAGTCTCCTCGCTCTCGAAGTC SpeI 
mxn85 GACACGATCGCAACAGCGGTTCTTTCTCTTTG PvuI 
mxn87 CAAGGCGGCCGCCGGGTGATCGCAGGTGAG NotI 
mxn88  TCTGGGATCCTTCGACCTCGGACAGCAG BamHI 
mxn102 CGTCATTCATCCTTGCTCG  
mxn103 TCCAGGCCTCGTAGTTCC  
mxn104 TTTCCTCACGTCTCATGG  
mxn105 TGTCGCTGTTGAAGGCAC  
mxn106 TTCTCATCGCGGACTACG  
mxn107 GAGAGAGATTGACGCGAC  
mxn110 GATTCTCTGGGGGCTCCT  
mxn111 CAATCACAAACGCAGTCC  
mxn112 TTCTCATCGCGGACTACG  
mxn113  GATACGATCGCCTGGAGGAATACGTCGG PvuI 
mxn114  GTCGCGGCCGCCTTTCGTCATGGTGGCTCC NotI 
mxn115  GATACGCGGCCGCTTGAAGGGACTGGGCAAG NotI 
mxn116  TTGCGGATCCACAATCTATCGCGGGTCG BamHI 
mxn117  GACACGATCGGCATGCATGAGGCCTACA PvuI 
mxn118  AATCGCGGCCGCGCATCAGGATTCCCCAAGG NotI 
mxn132 GATACACGATCGCGAGCAGGAGGGGTATGT PvuI 
mxn133 TCTATGGAGCTCCATTCCGAAGAACTGGGA SacI 
mxn134 GATACAGAGCTCTTCCTCAATCACCACGGT SacI 
mxn135 TCTATGGGATCCTGACTGACGACGATGAGC BamHI 
mxn140 ACATGTTGGAAGCCGACG  
mxn141 GCTCAGCGTGAAGAGGCT  
mxn142 ACCGTGGAACAGCTCAGG  
mxn143 CGAGATCCAGCACACCAT  
mxn149 GCTTCGCGTGGAGGTCAT  
mxn155 GATACACGATCGGCCGTGCAGGACTACTTG PvuI 
mxn156 ACAATCTATCGCGGGTCG  
mxn157 
ATCGACCCGCGATAGATTGTGGAGCTGCAGCG
GGTGAT 
 
mxn158 TCTATGGCGGCCGCTCATGAGTGGCCTCGGCT NotI 
mxn162 GCTTTCCCATCATGACGC  
mxn163 CTCCGCGGTGGTATGTC  
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pSWU41-F GTGCAAAAAAGCGGTTAG  
pTOPO-in CCTCTAGATGCATGCTCGAG  
pTOPO-out TTGGTACCGAGCTCGGATCC  
pJET1.2For CGACTCACTATAGGGAGAGCGGC  
pJET1.2Rev AAGAACATCGATTTTCCATGGCAG  
 
 
 
 
 
Table S3. Antimicrobial activity of myxopyronin A and its derivative 
Test Organism 
MIC50 (µg / mL) 
Myxopyronin A 
21-Desmethyl-myxopyronin 
A 
Staphylococcus aureus Newman 0.3 11.2 
Escherichia coli DH5 14 >64 
Escherichia coli TolC 0.2 0.67 
Pseudomonas aeruginosa PA14 >64 >64 
Mucor hiemalis 3.5 10.5 
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Table S4. NMR Spectroscopic Data for 21-desmethyl-myxopyronin A (CD3OD) 
 
 
 
 C
a
 H
b
 (J in Hz) COSY
 c
 HMBC
 d
 
2 no    
3 102.5    
4 no    
5 107.2 5.74 s (7.4)  3, 6 
6 168.8    
7 38.6 2.50 m Me-8 6, Me-8, 9 
Me-8 18.4 1.22 d (7.04) H-7 6, 7, 9 
9 
 
35.7 
 
1.53 
1.74 m 
  
10 28.4 2.02 m H-9, H-11 11, 12 
11 110.8 5.06 m H-10, H-12  
12 125.5 6.4 d (14.1) H-11  
13 156.5    
OMe-14 52.5 3.66 s  13 
15 201.0    
16 136.7    
Me-17 11.8 1.93 s H-18 15, 16, 18 
18 141.5 6.93 d (10.82) Me-17, H-19 15 
19 143.9 6.48 t (14.0) H-18, H-20 no 
20 128.2 6.04m H-19, H-21 no 
21 36.3 2.18 m H-20, H-22 19, 20, 22, 23 
22 23.2 1.46 m H-21, H-23 20, 21, 23 
23 13.9 0.93 t (7.3) H-22 21, 22 
 
a Recorded at 125 MHz; referenced to residual CD3OD at  49.15 ppm. b Recorded at 500 MHz; referenced to 
residual CD3OD at  3.31 ppm. c Proton showing COSY correlation to indicated proton. d Proton showing 
HMBC correlation to indicated carbon No: not observed.  
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Figure S1. 1H NMR spectrum of 21-desmethyl-myxopyronin A in CD3OD 
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Figure S2. HSQC spectrum of 21-desmethyl-myxopyronin A in CD3OD 
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Figure S3. HMBC spectrum of 21-desmethyl-myxopyronin A in CD3OD. Signal of the carbonylic  C-15 is dropped 
(21.0 ppm instead of 201.0 ppm) due to a SW of 180.0 ppm. 
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Figure S4.COSY spectrum of 21-desmethyl-myxopyronin A in CD3OD 
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Figure S5. Schematic representation of the in-frame deletion of a 1.6 kb mxnL fragment using the construct pHSU-mxn20 
(a), confirmation by Southern blot (b) and the expected fragment size after hydrolysis of wild type and mutant genomic 
DNA with a set of three restriction enzymes and a DIG-labeled 602 bp probe amplified from Mx f50 genomic DNA using 
the primers mxn79 and mxn80. M: Marker III (Roche), 1: hydrolysis with KpnI, 2: hydrolysis with SphI, 3: hydrolysis with 
AgeI.               
 
c 
a 
b 
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CP-L            GGAHFDSISL 
CP-E1           G---FTSVTL 
CP-E2           G---YDSISF 
CP-E3           G---LTSLSL 
CP-E4           G---VDSLIG 
CP-E5           G---LDSIRV 
CP-E6           G---LDSIMT 
CP-E6*          G---FDQLAL 
CP-W1           G---LDSLIL 
CP-W2           G---FDSITF 
CP-W3           G---LDSILA 
CP-W4           G---VDSLVN 
CP-W5*          G---VDHLDM 
CP-W5           G---LDSINV 
                              
                                
KS-E1           SEAVDAACASSLVALH-----VEAHGTGT-----IGHAE 
KS-E2           SEAVDTACSSSLVAIH-----IETHGTGT-----IGHLE 
KS-E3           SEPVDTLCSSSLVAIH-----IEAHGTGT-----VGHLE 
KS-E4           SEAIDTACSSSLVAIH-----IEAHGTGT-----IGHLE 
KS-E5*          SFAVDSACSASLTAIH-----VECAAAGS-----VGHLE 
KS-E6           SEPVDTACSSSLIAVQ-----IEAHGTGT-----IGHLE 
KS-W1           SFTIDAACASSLVALH-----VEAHGTGT-----IGHLE 
KS-W2*          SLAVDTACSSSLAAIH-----VECQATGT-----IGHLE 
KS-W3           SEPCDTACSSSLIAIH-----IEAHGSGT-----IGHLE 
KS-W4           AMQVDTACSSSLVAVH-----VEAHGTGT-----IGHTS 
KS-W5           SLMVDTACSSSLTALH-----VEAHGTGT-----IGHLE 
MxnB            AITVNASCLSFFVALE-----EYLPKFTE-----IPHQP 
MxnD            GCTVGGASASGNVALA-----INAHGSAS-----VGHCL 
                                         
                        
DH-E2           LRDHVIGGKKLLP 
DH-E3           LRDHTVFGQRVLL 
DH-E4           LRDHVVGSRGVLP 
DH-W1           IRDHVVGGNRLIP 
DH-W4           VSQHQVHGRPVFP 
                   HXXXGXXXXP 
             
KR-E2           TGGAGALG-----HAAGQRQDQ-----FSSLVALTGNVGQTDYAFANA 
KR-E4           VGGTGGIG-----HSALVLQDA-----FSSAVGIAGGAGQSNYAAASR 
KR-W1           VGGGGGLG-----HLGGVLSDK-----FSSIVSLLGNVGQADYAAGNS 
KR-W4           VGGLGGLG-----HSAIVLKDA-----FSSAESFICEAGQSNYAAASR 
                  
Figure S6. Amino acid alignments of conserved regions of the PKS domains by ClustalW. CP: carrier protein;[3] KS: 
ketosynthase;[4] DH: dehydratase;[5] KR: ketoreductase.[6] The active sites or the key conserved amino acid residues are 
marked in bold. Putative inactive domains are marked with asterisk. 
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Figure S7. Phylogram of AT-like enzymes from various trans-AT pathways. Protein sequences were aligned using 
MUSCLE. Phylogenetic analysis was performed by maximum likelihood interference using PhyML with a Jones-Taylor-
Thornten amino acid replacement model.[7]  Tip labels consist of the protein name with the domain architecture. Sequences 
from the following pathways were used: BaeC (YP_001421285), BaeD (YP_001421286) and BaeE (YP_001421287) - 
bacillaene (Bacillus amyloliquefaciens); BatH (ADD82949), BatJ (ADD82951) - batumin/kalimantacin (Pseudomonas 
fluorescens); BryP (ABK51299) - bryostatin (Candidatus Endobugula sertula); DfnA (ABK51299) - difficidin (B. 
amyloliquefaciens);  DszD (AAY32968) - disorazol (Sorangium cellulosum); ElsB (YP_003124936) - elansolid 
(Chitinophaga pinensis); KirCI (CAN89639) - kirromycin (Streptomyces collinus); LnmG (AAN85520) - leinamycin 
(Streptomyces atroolivaceus); MlnA (YP-001421027) – macrolactin (Bacillus amyloliquefaciens); MmpIII (AAM12912) - 
mupirocin (Pseudomonas fluorescens); OzmM (ADI12766) - oxazolomycin (Streptomyces bingchenggensis); PedC 
(AAS47559) and PedD (CAE01104) - pederin (Paederus fuscipes); PsyH (ADA82589) - psymberin (uncultured symbiont of 
sponge Psammocinia aff. bulbosa); RhiG (YP_004029399) - rhizoxin (Burkholderia rhizoxina); SorO (ADN68489) - 
soraphen (Sorangium cellulosum). Outgroup is the E. coli AT from fatty acid biosynthesis, FabD (YP_489360).  
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Figure S8. Myxopyronin A production profile. Production profile of myxopyronin A by a) M. fulvus Mxf50 wild-type 
(WT), b) M. fulvusΔpHSU-mxn20 (ΔmxnL), and c) M.  fulvusΔpHSU-mxn34 (ΔmxnM). The data presented in the graph 
represent the means of three measurements from three independent supernatants 
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Scheme S2. Possible reaction mechanism of MxnC-MxnG in myxopyronin A biosynthesis 
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3 In Vitro Reconstitution of -Pyrone Ring Formation 
in Myxopyronin Biosynthesis 
3.1 Abstract 
Myxopyronins are -pyrone antibiotics produced by the terrestrial bacterium Myxococcus fulvus 
Mx f50 and possess antibacterial activity against Gram-positive and Gram-negative pathogens. 
They target the bacterial RNA polymerase (RNAP) “switch region” as non-competitive inhibitors 
and display no cross-resistance to the established RNAP inhibitor rifampicin. Recent analysis of 
the myxopyronin biosynthetic pathway led to the hypothesis that this secondary metabolite is 
produced from two separate polyketide parts, which are condensed by the stand-alone 
ketosynthase MxnB. Using in vitro assays we show that MxnB catalyzes a unique condensation 
reaction forming the -pyrone ring of myxopyronins from two activated acyl chains in form of 
their -keto intermediates. MxnB is able to accept thioester substrates coupled to either N-
acetylcysteamine (NAC) or a specific carrier protein (CP). The turnover rate of MxnB for 
substrates bound to CP was 12-fold higher than for NAC substrates, demonstrating the 
importance of protein-protein interactions in multimodular polyketide synthases (PKSs). The 
crystal structure of MxnB reveals the enzyme to be an unusual member of the ketosynthase group 
capable of binding and condensing two long alkyl chains bound to carrier proteins. The geometry 
of the two binding tunnels supports the biochemical data and allows us to propose an order of 
reaction, which is supported by the identification of novel myxopyronin congeners in the extract 
of the producer strain. Insights into the mechanism of this unique condensation reaction do not 
only expand our knowledge regarding the thiolase enzyme family but also opens up opportunities 
for PKS bioengineering to achieve directed structural modifications. 
3.2 Introduction 
Pathogens are becoming resistant to clinical antibiotics at an accelerating rate. Hence there is an 
urgent need for new antibacterials, which either act upon new antibiotic targets or exploit novel 
binding sites in established ones.1 Myxobacteria are a rich source of bioactive compounds, most 
of which are derived from polyketide synthase (PKS) and non-ribosomal peptide synthetase 
(NRPS) pathways.2 The underlying biosynthetic principles provide a fascinating modular 
platform to accomplish difficult chemical reactions and became a major source for current 
clinical drugs. PKS systems are classified into various subtypes according to their functions and 
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architecture.3 To date, three types of bacterial PKSs are known; Type I PKSs are composed of 
multifunctional enzymes organized in modules responsible for non-iterative catalytic steps of one 
cycle of polyketide chain elongation.4 Type II PKSs are multi-enzyme complexes that carry a 
single set of iteratively acting activities.5 Type III PKSs, or chalcone synthase-like PKSs, also act 
iteratively as condensing enzymes.6 One hallmark activity of all PKS pathways are ketosynthases 
(KSs), usually catalyzing the Claisen condensation of an acyl thioester and a malonyl thioester. 
 Myxopyronins (1) belong to the -pyrone compound class and have been isolated from 
the Gram-negative soil bacterium Myxococcus fulvus Mx f50.7 Myxopyronins (together with 
corallopyronin (2) and ripostatin) bind to the “switch region” of bacterial RNA polymerase 
(RNAP), which represents a novel binding site for RNAP-binding antibiotics. They also display a 
different mode of inhibition compared to existing RNAP-targeting drugs. Since RNAP is a highly 
conserved protein, myxopyronins represent a very promising compound class for the 
development of broad spectrum antibacterial therapeutic agents.8,9 Feeding studies and the 
analysis of the biosynthetic gene cluster revealed that myxopyronins as well as corallopyronins 
are most likely derived from two linear polyketide chains, the eastern and western parts of the 
molecule. These chains were proposed to be produced by two distinct multimodular PKS/NRPS 
megasynthetases (Scheme 1).10–12 It has been postulated that in the last step of myxopyronin and 
corallopyronin biosynthesis the fully matured -keto intermediates of the eastern and western 
chains undergo condensation catalyzed by the stand-alone ketosynthase (KS) enzyme MxnB and 
CorB, respectively, to form the characteristic -pyrone ring.11,12 The -pyrone ring structure 
proved to significantly contribute to the bioactivity of myxoypronin since the replacement of the 
pyrone ring with the more stable N-methyl pyridone or phenol led to the loss of its antibacterial 
activity.13 Furthermore, the crystal structure of RNAP with myxopyronin showed interactions of 
the oxygens of the -pyrone ring with RNAP residues indicating the importance of this moiety 
towards its bioactivity.8 
 In fact, there are a number of natural products containing pyrone rings derived from type 
II and type III PKS systems such as wailupemycin14 and csypyrone,15 respectively (Fig. 1). 
Recently, CsyB has been biochemically characterized as a type III PKS that couples two -
ketoacyl-CoAs, forming the -pyrone ring in csypyrone.16 Only one example of 5-membered 
ring formation by a type I PKS has been reported so far; a stand-alone KS (RkD, 22 % sequence 
identity to MxnB) condenses the carrier protein (CP)-bound substrate, forming the tetronate ring 
during the biosynthesis of the phosphatase inhibitor RK-682.17 To the best of our knowledge, to 
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date 6-membered pyrone ring formation by a stand-alone KS has not been reported for a type I 
PKS pathway.  
 
 
 
Scheme 1. Model for myxopyronin biosynthesis based on analyses of the native producer strain Myxococcus fulvus 
Mxf50.12 Western and eastern chain biosynthesis are catalyzed by two separate assembly lines, MxnK shown in red and 
MxnI/J shown in blue. Abbreviations for assembly line domains: A: adenylation domain, CP: carrier protein domain, DH: 
dehydratase domain, KR: ketoreductase domain, KS: ketosynthase domain, MT: methyltransferase domain, X: putative 
inactive KR or truncated phosphoglucomutase/phosphomannomutase domain. Domains marked with an asterisk are 
assumed to be inactive; assembly line modules 2W, 3E and 5E do presumably not participate in chain elongation. Required 
acyltransferase (AT) and enoylreductase (ER) activities are indicated for each module and supplied in trans by MxnA. The 
module 3W intermediate is modified by a ß-branching cassette shown in yellow-green consisting of a CP (MxnC), a KS 
(MxnD), a hydroxymethylglutaryl (HMG)-CoA synthase (HCS; MxnE) and two enoyl-CoA hydratases/isomerases (ECH; 
MxnF and MxnG). As highlighted in orange, the eastern chain starter unit is modified by an O-methyltransferase (O-MT; 
MxnH). After chain assembly, the ketosynthase (KS) MxnB is proposed to catalyze pyrone ring formation, which is 
investigated in the present study. 
 
Here we demonstrate that MxnB is responsible for the condensation of the eastern and the 
western chains giving rise to myxopyronin. We show that MxnB exhibits substrate flexibility for 
-ketoacyl intermediates linked through a thioester bond to either NAC or CP. In addition, the 
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crystal structure of MxnB reveals an overall typical thiolase fold, which is altered to 
accommodate the binding and condensation of two long alkyl chains. Structural analysis supports 
the biochemical findings and allows us to propose an order of reaction for -pyrone ring 
formation in myxopyronin biosynthesis. 
 
 
Figure 1. Structures of natural products, which are biosynthesized by type I, II, and III PKSs and contain -pyrone rings (1a 
and 2, 3, and 4 respectively). Compound 5 is generated by a type I PKS and contains a tetronate ring. 
 
3.3 Results and Discussion 
3.3.1 MxnB is Responsible for α-Pyrone Ring Formation in Myxopyronins 
MxnB belongs to the thiolase superfamily of proteins that catalyzes the formation of carbon-
carbon bonds via Claisen condensation. BLAST search results identified MxnB as a homolog of 
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FabH, a -ketoacyl-[acyl carrier protein (ACP)] synthase III (KAS III), highlighted by the 
presence of the archetypical cysteine-histidine-asparagine (CHN) catalytic triad.18,19 The catalytic 
cysteine (C112 in FabH from E. coli) is responsible for the transacylation process, while the 
histidine and asparagine residues are required for the Claisen-like condensation reaction, 
interacting with the incoming malonylated CP to enable enolization of the substrate.19 
 We could not identify any protein exhibiting more than 40% sequence identity to MxnB 
which has been previously biochemically characterized (Table S2). Based on the CHN catalytic 
triad, KAS III belongs to the same subgroup as chalcone synthase (CHS) enzymes in the thiolase 
superfamily.4 CHSs act as homodimeric iterative PKSs catalyzing a series of decarboxylation, 
condensation, and cyclization reactions.14;15 Phylogenetic analysis places MxnB between FabH-
like and CHS-type enzymes (Fig. S1). Therefore, characterization of MxnB can be seen as a 
valuable addition to widen the scope of biochemical mechanisms catalyzed within the KAS III 
family. 
 In order to provide first experimental evidence that MxnB is responsible for α-pyrone 
ring formation we aimed to establish the cyclization reaction in vitro. Soluble recombinant MxnB 
protein with an N-terminal His6-tag was overproduced in E. coli BL21 (DE3) and purified using 
one-step Ni-NTA affinity chromatography, to yield 0.3 mg of MxnB from 100 mL of liquid 
culture. The purified His-tagged MxnB protein had the expected molecular weight of 
approximately 38.7 kDa (Fig. 2B). The enzyme was incubated with NAC thioesters of the 
western (6) and eastern chains (7), serving as mimics of the CP’s phosphopantetheine arm bound 
substrates (Fig. 2A). During biosynthesis the western and eastern chains are assumed to be bound 
to CP-W5 and CP-E6, respectively (Scheme 1). Analysis of the reaction products using LC-MS 
showed the formation of 1a exhibiting an MS2 fragmentation pattern that was identical to 
authentic myxopyronin A (Fig. S2). 
 The limited quantity of available native eastern NAC thioester forced us to use an 
analogous eastern chain lacking a methyl group and a double bond (8) for detailed in vitro studies 
(Fig. 2A). This eastern chain mimic (8) was found to be loaded onto MxnB equally well as the 
native eastern chain (7) (Fig. S2). When the experiment was repeated using this modified eastern 
chain a new product corresponding to the expected myxopyronin derivative 9 (Fig. 2C, assay 3) 
was detected in the LC-MS analysis. High-resolution mass spectrometry (HRMS) of the 
compound displayed an ion with m/z 406.2221 (calc. for C22H32NO6, 406.2224), which was 
assigned as [M+H]+ of 9. Its fragmentation was slightly different to standard myxopyronin A, 
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which is due to the variance in the eastern part of the molecule (Fig. S3). In order to confirm the 
structure of this novel derivative, it was isolated from an in vitro assay and subjected to NMR 
analysis (Table S3, Fig. S4). To rule out a non-enzymatic condensation, the assay was repeated in 
the absence of MxnB (assay 1) and in the presence of heat-inactivated MxnB (assay 2). In both 
cases the reaction did not occur (Fig. 2C). These data provided clear evidence that MxnB is the 
enzyme responsible for pyrone ring formation. 
 
 
 
 
 
 
 
 
 
 
                                                                
 
 
 
 
 
 The small amount of product formed when using NAC substrates suggested that the 
interaction between cognate CPs and MxnB might be an important factor for efficient 
A) 
C) B) 
Figure 2. Substrates and myxopyronin analogue, SDS Page and LC-MS Analysis of in vitro assays. A) SNAC 
substrates as native western mimic (6), native eastern mimic (7), analogue mimic of native eastern (8), and 
myxopyronin derivative (9). B) Lane 1: His-MxnB (38.7 kDa), lane 2: His-CP-E co-expressed with MtaA (14.7 kDa), 
and lane 3: His-CP-W co-expressed with MtaA (14.6 kDa) on a 15% SDS gel; C) LC-MS analysis of in vitro assays 
showing extracted ion chromatograms (EIC) [M+H]+ = 406.2 : assay 1 (6 and 8 only); assay 2 (6, 8, and boiled 
MxnB); assay 3 (6, 8, and MxnB); assay 4 (6-CP-W, 8-CP-E, and MxnB). 
74 | In Vitro Reconstitution of Myxopyronin 
 
condensation. It has been shown that CP-bound substrates were processed much faster than the 
corresponding NAC thioesters in a study of 6-deoxyerythronolide B synthase.20 To optimize the 
in vitro assay we attempted to mimic the in vivo conditions by overexpressing CPs from the last 
module of the western (CP-W5) and eastern (CP-E6) chain assembly lines (hereafter referred to 
as CP-W and CP-E, respectively). Soluble recombinant CP-W and CP-E proteins with N-
terminal His6-tags were overproduced in E. coli BL21 (DE3) cells and purified by one-step Ni-
NTA affinity chromatography, to yield 2.5 mg of each, CP-W or CP-E, from 100 mL of liquid 
culture. The purified His-tagged CP-W and CP-E proteins had molecular weights of 14.3 kDa 
and 14.4 kDa, respectively. To simplify the phosphopantetheinylation of the CPs, CP-W and CP-
E were phosphopantetheinylated in vivo by co-expressing mtaA, a gene encoding a broad 
spectrum 4´-phospantetheinyl transferase from Stigmatella aurantiaca.21 We thereby obtained 
holo-CP-W and holo-CP-E exhibiting masses of 14.6 kDa and 14.7 kDa, respectively (Fig. 2B, 
Fig. S5-S6).  
It is known that CPs are able to perform self-acylation using CoA or SNAC esters.22 
Thus, we analyzed the ability of holo-CP-W and holo-CP-E to conduct self-acylation with 
substrates 6 and 8, respectively. LC-MS analysis of the product showed a mass shift of 192 Da 
for holo-CP-W indicating the formation of 6-S-CP-W and a mass shift of 213 Da for holo-CP-E 
in agreement with the generation of 8-S-CP-E (hereafter referred to as 6-CP-W and 8-CP-E, 
respectively) (Fig. S5-S6). 
 Incubation of MxnB, 6-CP-W, 8-CP-E resulted in a 12-fold increase of product formation 
compared to the reactions with NAC substrates (Fig. 2C, assay 4). This revealed the importance 
of CP-MxnB interactions for pyrone ring formation. It also highlights the effect of protein-
protein interactions compared to substrate-protein interactions in PKS and especially carrier 
protein dependent biosynthetic systems.23 
3.3.2 Overall Structure of MxnB 
Since the condensation of western and eastern chain requires MxnB to bind two long 
acyl chain substrates we intended to investigate if there is a structural rationale for this 
ability. Full-length MxnB (335 residues) with an N-terminal His6-tag was expressed and 
purified as described in the materials and methods section. MxnB crystals belonged to space 
group P1 and diffracted to 1.67 Å. The structure of MxnB (PDB ID 4V2P) was determined 
by molecular replacement using the E. coli FabH structure (PDB ID 1EBL) as a search 
model. The crystals contained one biological dimer in the asymmetric unit and the refined 
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model includes residues 8 - 335 in chain A and 7 – 335 in chain B (Fig. 3A). The missing 
residues are presumed to be disordered. The MxnB monomer displays the overall typical 
ketosynthase fold consisting of a five-layered core structure, α-β-α-β-α, similar to that of 
thiolase I.
24
 Although the sequence identity of MxnB to E. coli FabH is low (29 %), pairwise 
alignment of the structures gives a Cα rmsd of just 1.5 Å over 254 (monomer) and 2.1 Å over 
508 (dimer) residues, respectively. The active site of MxnB contains the catalytic CHN triad 
(C121, H264 and N292, Fig. 3B). The active site C121 is oxidized to cysteine sulfinic acid, 
but this modification appears to be either transient or a result of crystallization / data 
collection, since LC-MS analysis of the intact protein showed the expected mass for MxnB 
with unmodified cysteines. 
 
     
Figure 3. A. cartoon representation of the MxnB dimer structure, with monomers colored in cyan and green. The 
active-site cysteines (C121) are shown as sticks. B. Cartoon representation of the MxnB active site. The residues 
comprising the catalytic triad are shown as sticks. C. Top view and D. Side view of the two proposed substrate-
binding tunnels in MxnB. Canonical tunnel (red) and additional tunnel (blue). Tunnels were predicted using Mole 
2.0.27  
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Unlike other ketosynthases such as FabH, MxnB is required to bind and condense two 
long alkyl chains bound to carrier proteins. The only ketosynthase catalyzing a similar 
reaction characterized structurally to date (although from a completely unrelated pathway) is 
OleA.
25
 This enzyme aids in synthesizing long chain olefins in Xanthomonas campestris and 
was proposed to possess a second substrate-binding tunnel. Although sequence conservation 
is low (25 % over 301 residues) the structures are reasonably well conserved (Cα rmsd of 2.5 
Å over 231 residues, PDB ID 3S23). It was argued that the two helices forming the new 
hydrophobic binding tunnel were spread apart further in OleA than in other FabH-like 
structures, where binding of a second long alkyl chain is not required (Fig. S7).
25
 
The enzyme CsyB was very recently reported to carry out a similar α-pyrone ring 
formation reaction.
26
 The sequence identity between MxnB and CsyB (PDB ID 3WXY) is 17 
% and pairwise alignment of the structures gives a Cα rmsd of 3.7 Å over 262 residues 
(monomer). The core of both proteins is quite similar on the level of secondary structure and 
the main structural differences can be found in the periphery, removed from the active site. 
The relative position of the catalytic triad forming residues (CHN) is conserved in both 
proteins. CsyB has an additional histidine (H377), which was described as essential for 
enzymatic activity. In MxnB, this position (CsyB H377) is occupied by a serine (S324). 
Compared to the structures of MxnB and OleA, the proposed second substrate-binding tunnel 
is blocked in CsyB. 
In MxnB the catalytic C121 is located at a crossroads between two substrate-binding 
tunnels (Fig. 3C, D). The first, canonical, tunnel (red) and the second (blue) tunnel, 
positioned as proposed for OleA, have amphipathic character (based on electrostatic surface 
potential maps generated in ccp4mg
28
). The position of the catalytic C121 in relation to both 
tunnel entrances strongly suggests that binding of substrate in the blue tunnel and its 
subsequent transacylation from the CP to MxnB C121 results in the obstruction of the red 
tunnel entrance. Therefore, we propose that binding of substrate in the red tunnel would have 
to precede binding in the blue tunnel. Since only one major product is formed by MxnB, it is 
likely that each tunnel has a chain preference (“eastern chain tunnel” and “western chain 
tunnel”). Based on the above-mentioned geometry considerations, the substrate accepted by 
the tunnel marked in red is transferred first during the transacylation process. 
 
In Vitro Reconstitution of Myxopyronin | 77 
 
3.3.3 Initial Biochemical Characterization of MxnB 
Catalytic site of MxnB. In general, condensation reactions catalyzed by KSs start by loading of 
the enzyme with the acyl chain. The chain is transferred from the CP and covalently attached to 
the active site cysteine residue via a thioester bond prior to condensation. We investigated the 
covalent attachment of 6 or 8 to MxnB and LC-MS analyses confirmed transfer of both substrates 
to the enzyme (Fig. S8). We then expressed and purified the putative active site mutant C121A 
(MxnB#) to investigate if substrates could still be transferred. We did not observe any mass shift 
after incubation of MxnB# with 6 or 8 and no myxopyronin derivative was formed employing this 
mutant (loss of catalytic function). These results confirmed that C121 is the catalytic cysteine 
playing a major role in the transacylation process. 
Substrate Preference for MxnB Priming. To obtain deeper insights into the reaction 
mechanism we first addressed the question whether the eastern or western chain substrate is 
preferentially loaded onto MxnB prior to condensation with the second chain. We performed 
transacylation experiments with MxnB and primed CPs (6-CP-W and 8-CP-E). Free substrate 
was completely removed before incubation with MxnB to avoid any interference in the assays. 
As complete CP priming could not be achieved via self-acylation, the percentages of substrate-
loaded CPs were normalized using the deconvoluted mass peak heights in order to establish 
comparable assay conditions.29 After incubation of MxnB with a slight excess of either 6-CP-W 
(assay 5) or 8-CP-E (assay 6) the substrate transfer was analyzed at specific time-points using 
LC-MS. As shown in Figure 4A, the percentage of 6-CP-W (in relation to unprimed CP-W) 
decreased much faster than the amount of 8-CP-E (in relation to CP-E). At the same time, the 
amount of primed MxnB increased faster in the western chain assay than in the eastern chain 
assay (6-MxnB vs. 8-MxnB). These results suggest that during myxopyronin biosynthesis MxnB 
is first loaded with the western chain and then condensed with the eastern chain to form the α-
pyrone ring structure. 
Substrate Preference for the Condensation Reaction. To further investigate this finding we set 
up a series of in vitro condensation assays including experiments where MxnB was already 
preloaded with either 6 or 8 to give 6-MxnB and 8-MxnB, respectively. The percentages of 
substrate-loaded MxnB were calculated using the same method as applied to the CPs. The 
experiments were set up as follows: assay 7 (6-MxnB and 8-CP-E), assay 8 (MxnB, 6-CP-W and 
8-CP-E), assay 9 (8-MxnB and 6-CP-W), and assay 10 (MxnB, 6, and 8). Formation of the 
myxopyronin derivative (9) was analyzed at specific time points as summarized in Fig. 4B. Most 
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efficient production of 9 was observed in assay 7 containing 6-MxnB and 8-CP-E. Production 
yields in assay 9 (the reverse experiment) were significantly reduced and even lower than in 
assay 8 with non-primed MxnB. These results indicate that priming of MxnB with the western 
chain (6), which was the preferred scenario in the transacylation experiment (assay 5 vs. assay 6), 
is important for efficient product formation.  
 
 
Figure 4. LC-MS analysis of substrate transfer and competition assays. A) Percentage of primed MxnB and the 
remaining loaded-CP B) Time-course for the production of 9 from 15 s to 10 min. Peak area of extracted ion 
chromatograms for 8 were used for quantification. Assay 7-10: assay 7 (6-MxnB and 8-CP-E), assay 8 (MxnB, 6-
CP-W and 8-CP-E), assay 9 (8-MxnB and 6-CP-W), and assay 10 (MxnB, 6, and 8). Values for assay 9 and 10 data 
points overlay. Error bars represent the standard error of the mean from three repeats. 
 
Formation of Myxopyronin Side-products by MxnB 
Surprisingly, in addition to the major product 9 we also observed trace amounts of MxnEW (13) 
(reverse orientation), MxnEE (14) and MxnWW (12) (homo-condensation) in the in vitro assays 
(Fig. 5, Fig. S3). To date, myxopyronin A (1a) and myxopyronin B (1b) have been the only -
pyrone compounds reported from the native producer M. fulvus Mx f50.7 To investigate whether 
these side-products were an artifact of the in vitro assays or also produced in vivo we performed 
detailed LC-MS analysis of the M. fulvus Mx f50 culture extract. We detected a compound that 
eluted 0.8 min earlier than 1a (MxnWE) with an m/z of 418.22 Da, suggesting the formation of 
10 (MxnEW). Comparative MS2 fragmentation of 1a and 10 showed three identical fragments: 
[M+H-H2O]
+, [M+H-CH3OH]
+, [M+H-H2N-CO2CH3]
+ while no further related fragments were 
observed in 10 due to structural differences (Fig. 5, Fig. S9). HRMS of two additional peaks 
showed an [M+H]+ signal at m/z 451.2077 (calc. for C22H30N2O8, 451.2074) indicating the 
presence of MxnEE (11) and an [M+H]+ signal at m/z 385.2374 (calc. for C24H33O4, 385.2373), 
matching MxnWW (12) (Fig. 5, Fig. S9). The pathway is therefore permissive to the formation of 
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MxnEW, -WW and -EE, even though MxnWE is the main product. Due to the small amounts of 
these derivatives full structure elucidation by NMR could not be performed. 
 
 
Figure 5. Compounds produced by the myxopyronin wild type producer and in the scope of in vitro assays. Red 
represents the western chain, blue represents the eastern chain and black represents the C-C bond formed during the 
condensation reaction. 
 
 The observed production of additional myxopyronin derivatives indicates that in general 
the biochemistry of α-pyrone ring formation tolerates a ‘switch’ of one (MxnWW, MxnEE) or 
even both chains (MxnEW). However, as MxnWE is clearly the dominant product the question 
arose whether the CPs, the substrates, or a combination of both confers specificity during the 
transacylation and condensation reaction. 
3.3.4 Biochemical Insights into -Pyrone Ring Formation 
To investigate possible routes to side-product formation we performed in vitro competition 
assays consisting of MxnB and equal amounts of CP-W and CP-E primed with either substrate 6 
or 8 (Fig. S5-S6). Both CPs could be loaded with either substrate and displayed no obvious 
preference for their native cargo.30 As expected, rapid product formation (MxnWE) was observed 
in the presence of 6-CP-W and 8-CP-E (assay 11) (Fig. 6). We also detected a small amount of 6-
MxnB, which we assume to be the reaction intermediate. After substrate swapping to 8-CP-W 
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and 6-CP-E (assay 12), MxnWE production decreased significantly (~90-fold after 10 min) 
indicating that one or both CPs have an impact on the reaction sequence (Fig. 6, Fig. S10). In 
contrast to assay 11, we observed an additional, large peak corresponding to 8-MxnB. This might 
be due to the formation of a ‘catalytically incompetent’ species (8-MxnB) as a result of fast 
eastern chain transfer by CP-W. A similar observation was made in assay 13 where both chains 
were loaded on CP-W (Fig. 6). Transacylation occurs, but only a very small amount of product is 
formed (~20-fold decrease after 10min). When both substrates are loaded onto CP-E (assay 14) 
we observed MxnWE production comparable to assay 11 (Fig. S10). 
 
 
Figure 6. LC-MS analysis of competition assays at 1 min. Competition assay 11 (MxnB, 6-CP-W, 8-CP-E), assay 
12 (MxnB, 8-CP-W and 6-CP-E), assay 13 (MxnB, 6-CP-W, 8-CP-W) and assay 14 (MxnB, 6-CP-E and 8-CP-E). 
Competition assays were performed in a time course of 15 s to 10 min observing transfer of substrate to MxnB 
(loading status). EIC of 9 at [M+H]+ = 406.22 for product formation are shown. Peak with asterisk (*) is the isomer 
of 9. 
 
Detection of side-product formation in the above assays proved difficult. Since we 
observed a much higher production rate of MxnWE in our preloading experiments (assay 7), we 
repeated them with two additional combinations. 6-MxnB incubated with 8-CP-E (assay 15, a 
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repeat of assay 7) showed very fast formation of MxnWE (9) again. 6-MxnB incubated with 6-
CP-W (assay 16) results in only trace amounts of MxnWW (11) after prolonged incubation. 
When 8-MxnB is incubated with 6-CP-W (assay 17, a repeat of assay 9), we could not observe 
product formation of the expected MxnEW (13). Finally, we tested 8-MxnB with 8-CP-E (assay 
18) and observed rapid formation of MxnEE (14) (Fig. S11). 
Overall, these data indicate that substrate transfer (transacylation) by CP-W is rapid and 
highly specific. In contrast, the results demonstrate that CP-E is able to efficiently mediate both 
the transacylation as well as the condensation reaction, which may be the result of a less specific 
substrate transfer. On the substrate side the western chain appears to be more readily transferred 
to MxnB but we cannot exclude that use of the native eastern chain could alter this observation. 
We believe that a combination of both CP and substrate confers specificity for -pyrone ring 
formation. 
 The complexity of the MxnB catalyzed condensation reaction involving CPs and small 
molecule specificities render a general analysis of substrate specificity in vitro difficult. 
However, we recently indirectly addressed this question in vivo in a mutasynthesis study 
employing a M. fulvus mutant unable to biosynthesize the western chain. This study revealed that 
MxnB is capable of condensing a wide variety of activated synthetic western chains with the CP 
bound native eastern chain.31 We used a set of substrate combinations from the mutasynthesis 
experiments in vitro, including those that did not give product in vivo. These additional in vitro 
assays (Fig. S12) show a high tolerance of MxnB for non-native SNAC substrates. Even 
substrates lacking the α–methyl group and the α,β-double bond of the western chain, which did 
not give product in vivo, were condensed in vitro to produce the expected analogues. It is not 
clear whether the differences between in vivo and in vitro experiments are due to difficulties in 
incorporating the non-native analogs into the biosynthetic pathway, or a result of relaxed enzyme 
specificity in the in vitro system. Due to the limited availability of substrates as well as the 
overall complexity of the reaction we did not attempt further analyses. 
3.3.5 Mechanism Proposal 
The MxnB structural data suggested that binding of substrate in the red tunnel precedes binding 
in the blue tunnel. In agreement with the biochemical data, we propose that the western chain is 
preferentially delivered to and/or bound in the red tunnel, while the eastern chain is preferentially 
supplied via the blue tunnel. We sought to investigate the existence of the blue tunnel by 
blocking it via mutagenesis. However, the half of the blue tunnel proximal to the catalytic 
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cysteine is not trivial to block by mutagenesis. It consists of two helices engaged in complex 
hydrophobic interactions with each other and a central β-sheet. Only one residue (T322) offers a 
side-chain orientation suitable for a straightforward mutation (i.e. not contacting other residues). 
Unfortunately, the candidate residue T322 is close to the junction connecting both tunnels. 
Therefore mutations are likely to affect binding of chains in both tunnels. In line with this 
hypothesis mutation of T322 to Leu negatively affected loading of the eastern chain almost twice 
as much as that of the western chain, but also led to a 7-fold reduction in enzyme activity (Fig. 
S13, Table S7). 
 Based on the series of assays described above, we propose the mechanism of pyrone ring 
formation in myxopyronin as follows: first, CP-W interacts with MxnB and transfers its bound 
polyketide chain to the MxnB active-site cysteine (C121) (Scheme 2A). CP-E delivers/provides 
the condensation partner (eastern chain) to the western-chain primed MxnB. Pyrone ring 
formation results from nucleophilic attack of the -enol-thioester of the KS-bound western 
chain on the thioester carbonyl of CP-E bound eastern chain to form a diketothioester via a C-C 
bond formation (i). Subsequently lactonization via an enolate intermediate of the eastern chain 
(ii) occurs to form a C-O bond (Scheme 2A). Although we have no experimental evidence for the 
timing of the two condensation reactions (i and ii) we consider it more likely that C-C bond 
formation happens first. Following the same proposed mechanism, all four products, MxnWE 
and MxnEW, as well as MxnWW and MxnEE could be formed (Scheme 2B). Due to the 
complexity of the reaction cascade kinetic parameters could not be determined in this study. 
 An intriguing mechanism proposal was very recently reported for CsyB.26 This enzyme is 
a fungal type III PKS involved in acylalkylpyrone (AcAP) formation. In the CsyB catalyzed 
reaction, acetoacetyl-CoA is loaded onto the active site cysteine C155 and the thioester 
subsequently undergoes hydrolysis by a water molecule activated through hydrogen bonding to 
C155 and H377, generating the -keto acid intermediate. This intermediate was proposed to 
move to a position of CsyB corresponding to the entrance of the blue tunnel in MxnB. Once the 
-keto acid intermediate is relocated, a second reaction cycle occurs: the enzyme is loaded with a 
fatty acid, which is elongated with one molecule of malonyl-CoA. This -ketoacyl unit then 
reacts with the -keto acid giving rise to AcAP (Fig. S14). A series of in vitro assays using H2
18O 
supported thioester bond cleavage, as this mechanism explains the enzymatic incorporation of 
one 18O atom into the product. A similarly positioned water molecule hydrogen bonded to C121 
and S324 is observed in the MxnB structure.  
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Scheme  2. A) Proposed mechanism for -pyrone ring formation in myxopyronin biosynthesis; B) A flow chart illustrating 
the reactions that occur during myxopyronin production in vitro and in vivo. Bold arrow represents the preferred product 
formation 
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To investigate whether a similar mechanism exists in the MxnB catalyzed reaction, we 
performed in vitro assays in a similar manner to the work of Mori and coworkers.26 After 
quenching of the reaction with iodoacetamide, we could not observe significant incorporation of 
18O into 9 (Table S9). Thus, in myxopyronin biosynthesis two -ketoacyl chains are condensed to 
form the -pyrone ring without generating a -ketoacid intermediate through hydrolysis. We 
therefore hypothesize that the MxnB catalyzed reaction proceeds via a different mechanism than 
described for CsyB. 
3.4 Conclusion 
The insights gained from this study enable us to propose a biochemical mechanism for -pyrone 
ring formation in myxopyronin biosynthesis. It should be noted that other biochemically 
characterized ketosynthases related to ring formation and condensation of two substrates such as 
RkD and CsyB significantly differ from MxnB. RkD is a type I PKS ketosynthase that condenses 
CP-bound substrates forming the tetronate ring in RK-682 biosynthesis.17 Furthermore, CsyB 
represents a type III PKS from Aspergillus oryzae that condenses two -ketoacyl-CoAs to form 
an -pyrone ring.16 Through biochemical and crystallographic studies, we here elucidated the 
reaction mechanism of MxnB as catalyzing -pyrone formation and thus establish MxnB as a 
novel member of the ketosynthase family. The unique biochemical features of MxnB might also 
be used as a starting point to expand the variety of -pyrone compounds formed by in vitro and 
in vivo reactions. 
3.5 Experimental Section 
Materials. The PCR reactions were carried out using Phusion or Taq DNA polymerase 
(Fermentas) in a peqSTAR 96 Universal Gradient thermocycler (Peqlab): Initial denaturation (3 
min, 95 C); 30 cycles of denaturation (30 s, 95 C), annealing (30 s, 53 or 57 C) and elongation 
(varied based on PCR product length 1 kb/min, 72 C); and final extension (10 min, 72 C). DNA 
fragments were separated by agarose gel electrophoresis and isolated using the peqGold Gel 
Extraction (Peqlab). The PCR products were cloned into the pJET1.2 blunt (Thermo Fisher 
Scientific) vector and sequenced using the primers pJET1.2For/pJET1.2Rev. 
 
Cloning of MxnB. mxnB was amplified from M. fulvus Mx f50 genomic DNA by PCR using 
primers mxn9: 5’-GTC AGA CAT ATG AAC AAC AGC GGT-3’ (NdeI site is underlined) and 
mxn10: 5’- CGT CGT AAG CTT TCA GTA GGT GAA AAC CA-3’ (HindIII site is underlined). 
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The PCR products were subcloned into the pJET1.2 blunt vector resulting in pJET-HSU-mxn5 
and sequenced. pJET-HSU-mxn5 was digested with NdeI and HindIII and the DNA fragment 
harboring the MxnB encoding region was cloned into the NdeI and HindIII site of pColdI 
resulting in pColdI-HSU-mxn5 encoding MxnB with an N-terminal hexahistidine tag. All strains 
and plasmids used in this study are listed in Table S1. 
 
Mutagenesis of MxnB. MxnB mutants was generated by adapting the method from the 
QuikChange II XL Site-Directed Mutagenesis (Stratagene) and pColdI-HSU-mxn5 as the 
template. For the C121A mutation, primers mxn236: 5’-
CCATCACCGTCAACGCCTCCGCCCTGAGTTTCTTCGTCGC-3’ and mxn237: 5’-
GCGACGAAGAAACTCAGGGCGGAGGCGTTGACGGTGATGG-3’ (mutated nucleotides 
are underlined) were used. For the T322L mutation, primers mxn296: 5‘-
GCCGTGCTGACCGGCCTGGGCTCCGGAGTCTCCTTCGTGG-3‘ and mxn297:5‘-
CCACGAAGGAGACTCCGGAGCCCAGGCCGGTCAGCACGGC-3‘. The primers were used 
to amplify the template to obtain pColdI-MxnB-C121A, pColdI-mxnB-T322L. The clones were 
verified by sequencing. 
 
Cloning of CP-E6 and co-expression with MtaA. CP-E6 was amplified from M. fulvus Mx f50 
genomic DNA by PCR using the primers mxn214: 5‘-GAT ACG CAT ATG GTC CCC TTC 
GAG TCG AGC-3’ (NdeI site is underlined) and mxn215: 5’-TCT ATG AAG CTT TCA TGG 
CTT CGC TCC CGC-3’ (HindIII site is underlined). The PCR products were subcloned into the 
pJET1.2 blunt vector resulting in pJET-HSU-mxn59 and sequenced. pJET-HSU-mxn59 was 
digested with NdeI and HindIII and the DNA fragment harboring the CP-E6 encoding region was 
cloned into the NdeI and HindIII site of pColdI resulting in pColdI-HSU-mxn59 (CP-E6) 
encoding CP-E6 with an N-terminal hexahistidine tag. Consequently, pColdI-HSU-mxn59 and 
pSUMtaA were co-transformed. Subsequent co-expression enabled phosphopantetheinylation of 
apo-CP-E6 in vivo forming holo-CP-E6. 
 
Cloning of CP-W5 and co-expression with MtaA. CP-W5 was amplified from M. fulvus Mx 
f50 genomic DNA by PCR using the primers mxn230: 5‘-CTG AGG CAT ATG CGT GCG TTC 
GAG TCG-3’ (NdeI site is underlined) and mxn231: 5‘- TCT ATG AAG CTT TCA GGC ACA 
CCA CTC ATT-3’ (HindIII site is underlined). The PCR products were cloned into the pJET1.2 
blunt vector resulting in pJET-HSU-mxn63 and sequenced. pJET-HSU-mxn63 was digested with 
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NdeI and HindIII and the DNA fragment harboring the CP-W5 encoding region was cloned into 
the NdeI and HindIII site of pColdI resulting in pColdI-HSU-mxn63 (CP-W5) encoding CP-W5 
with an N-terminal hexahistidine tag. Furthermore, pColdI-HSU-mxn63 was co-transformed with 
pSUMtaA to obtain a strain co-expressing pColdI-HSU-mxn63 and pSUMtaA. This co-
expression enabled phosphopantetheinylation of apo-CP-W5 in vivo forming holo-CP-W5. 
 
Expression and purification of proteins. For expression and purification of MxnB, MxnB# 
(C121A), Mxn104 (T322L), holo-CP-E6 and holo-CP-W5, the expression plasmids pHSU-mxn5, 
pHSU-mxnB#, pHSU-mxn104, respectively, were introduced into Escherichia coli BL21(DE3). 
For co-expression of pColdI-HSU-mxn59 and pSUMtaA as well as coexpression of pColdI-
HSU-mxn63 and pSUMtaA the respective plasmids were introduced into Escherichia coli 
BL21(DE3). The E. coli BL21(DE3) strains carrying the expression plasmids were cultured in 
LB medium containing 100 g/mL of ampicillin or with additional 25 g/mL chloroamphenicol 
for co-expression with MtaA at 37C until they reached an OD600 = 0.5 – 0.6. Expression was 
induced by addition of isopropyl--D-thiogalactopyranoside (IPTG, 0.15 mM) and cultivation 
was continued at 16C for 20 h. The cells were harvested by centrifugation (8,000 rpm; 20 min) 
and resuspended in lysis buffer (40 mM Tris-HCl buffer pH 7.5 containing glycerol 10%, 300 mM 
NaCl and 10 mM imidazole). Cells were lysed by sonication and a cell-free extract was prepared 
by removing cell debris by centrifugation at 8,000 rpm for 10 min at 4C. The cell-free extract 
was purified by using Ni-NTA Superflow resin (Qiagen), washed sequentially with buffer 
containing imidazole (10 mM and 20 mM), and eluted with high imidazole (100 mM for CPs and  
200 mM for MxnB; MxnB#) in the same buffer. The elution buffer was exchanged with buffer (40 
mM Tris-HCl buffer pH 7.5 containing glycerol 10%, 300 mM NaCl) using Amicon Ultra 10-k or 
30-k (Milipore) to remove imidazole and also to concentrate the proteins. Protein concentrations 
were estimated based on Bradford assays (Bio-Rad) employing bovine serum albumin as a 
standard.1 The purified proteins were flash frozen in liquid nitrogen and stored at -80C until 
further use. The recombinant protein masses are listed in Table S4. 
 
Expression and purification for crystallography. Full-length mxnB with an N-terminal His6-
tag was cloned into the pCold1 plasmid. The protein was expressed in Escherichia coli BL21 
(DE3) grown on Lysogeny broth. Cells were grown at 37 °C to an OD600 = 0.6, cultures subjected 
to a cold-shock for 30 min and expression induced by addition of 0.1 mM IPTG. Cells were 
harvested after 16 h growth at 16 °C by centrifugation at 4,000 x g, 4 °C for 15 min and re-
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suspended in lysis buffer (200 mM NaCl, 20 mM Tris pH 8.5, 20 mM imidazole, 10 % glycerol 
and 3 mM -mercaptoethanol (BME)) with the addition of complete EDTA-free protease 
inhibitor tablets (Roche) and 0.4 mg DNase g-1 wet cells (Sigma). Cells were lysed by passage 
through a cell disruptor at 30 kPSI (Constant Systems Ltd) and the lysate was cleared by 
centrifugation at 40,000 x g, 4 °C for 20 min. The cleared lysate was applied to a Nickel 
Sepharose 6 Fast Flow (GE Healthcare) column pre-washed with lysis buffer and protein eluted 
with 250 mM imidazole in the same buffer. The protein was then subjected to size-exclusion 
chromatography (Superdex™ 200, GE Healthcare) in 200 mM NaCl, 10 mM Tris pH 8.5, 1 mM 
TCEP, 10 % glycerol and concentrated to 4.5 mg mL-1. 
 
Crystallization, data collection, and crystallographic analysis. Crystallization trials of MxnB 
were set up at 4.5 mg ml-1. MxnB crystals were obtained in 0.2 M Ammonium phosphate, 0.1 M 
Tris pH 8.5 and 50 % MPD. The crystals did not need additional cryoprotection and were flash-
cooled in liquid nitrogen. The crystals belonged to space group P1 with cell dimensions a = 50.19 
Å b = 58.79 Å, c = 62.82 Å,  = 104.75,  = 105.48 and  = 93.90. Diffraction data was collected 
at ESRF beamline ID29 at 100 K and processed with xia2. The structure of MxnB was 
determined by molecular replacement using Phaser2,3 with the Crystal structure of 3-oxoacyl-
[acyl-carrier-protein] synthase III from Aquifex aeolicus VF5 as a search model (PDB: 2EBD). 
Complete manual rebuilding was performed with COOT4 and refinement was performed using 
CCP4 REFMAC55 and Phenix Refine.6 The statistics of data collection and refinement are 
summarized in Table S4. All molecular graphics figures were generated with the program 
Pymol.7 
 
In vitro reconstitution of myxopyronin (or derivatives) formation. The one pot reaction 
mixture in 40 mM Tris-HCl buffer pH 7.5, glycerol 10%, 300 mM NaCl (100 L) containing 100 
M CP-W5, 100 M CP-E6, 30 M MxnB and 1 mM substrates (6 with 7 or 6 with 8 or S1-S4 
with 8) was incubated at 37 C for 2 h. Reaction mixtures were extracted with ethyl acetate and 
the organic layer was evaporated. The residue was dissolved in 100 l methanol and a 5 µl 
aliquot of the extract was analyzed by HPLC-MS. 
 
Isolation of in vitro product. Large scale of in vitro assay containing 100 M CP-W5, 100 M 
CP-E6, 30 M MxnB and 0.5 mM 6 and 8 was incubated in 40 mM Tris-HCl buffer pH 7.5, 
glycerol 10%, 300 mM NaCl (total 9 mL) for 9 h at 37 C.  Reaction mixtures were extracted with 
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ethyl acetate and the organic layer was concentrated in vacuo. The crude extract was 
subsequently purified by semi preparative reverse-phase HPLC (Phenomenex Jupiter 4 m 
Proteo 90 Å, C12, 250 x 10 mm, DAD at 220 and 310 nm). Separation was achieved by a linear 
gradient of 10% ACN + 0.1 % FA for 6 min, 10 % to 85 % ACN + 0.1 % FA in 4 min, 85% to 
100% ACN + 0.1 % FA in 20 min at a flow rate of 2.5 ml min-1 and 30 °C of column temperature 
to afford semipure 9 (0.3 mg, tR = 17.5 min). A full set of NMR spectra was recorded with the 
semipure fraction (due to low quantity) before final purification was achieved. NMR data of 
semipure and pure compound (0.1 mg) were acquired in CD3OD on a 700 MHz Avance III 
(Ascend) spectrometer by Bruker BioSpin GmbH, equipped with a 5mm TXI cryoprobe, at 
298 K. 
 
In vitro self-acylation of the CPs and MxnB. A reaction mixture containing 100 M of CP-W5 
or 100 M of CP-E6 or 30 M of MxnB with 1 mM of 6 (JHS486) or 8 (JHS274) was incubated at 
37C for 2 h in 40 mM Tris-HCl buffer pH 7.5, glycerol 10%, 300 mM NaCl to obtain 6-CP-W, 8-
CP-W, 6-CP-E, 8-CP-E, 6-MxnB, and 8-MxnB. For the purpose of competition assays, the 
leftover substrates were removed by gel filtration using a PD-10 column and further concentrated 
with Amicon Ultra 10-K or 30-K concentrators as described above. Substrate transfer to CPs was 
confirmed by LC-ESI-MS and the percentage of loaded-substrate CPs were calculated using the 
deconvoluted mass peak heights. 
 
Assays 5-6 and Assays 15-18. The reaction master mixture in the same buffer as above (225 L) 
containing 3.76 M of loaded CPs final concentration as produced in the assay above was 
aliquoted to 10 eppendorf tubes which were kept on ice. In these assays, we keep the ratio 
between the non-acylated and acylated CPs constant. When the experiment was started, the 
eppendorf tube was incubated at 30 C for 1 min before addition of MxnB (2.3 M a final 
concentration). The reaction was stopped by putting the tubes into liquid N2 at time points: 15 s, 
30 s, 1 min, 2 min, 5 min, 10 min. Liquid N2 was chosen as a way to avoid MxnB precipitation. 
One part of the sample was used for protein analysis and another part of the sample was 
quenched by the addition of ice-cold 40% MeOH for product analysis. All sample preparations 
were performed in the cold room and the autosampler of the HPLC was kept at 5 C to avoid 
occurrence of any further reactions. 
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Competition Assays 7-10 and Assays 11-14. The reaction master mixture in the same buffer as 
above (200 L) containing 4 M of loaded CPs and 4 M of loaded MxnB was incubated at 30 C, 
and samples of 20 µL were taken at time points: 15 s, 30 s, 1 min, 2 min, 5 min, 10 min. In these 
assays, we keep the ratio between the non-acylated and acylated CPs constant.For assay 10, 
14.81 M of MxnB was and 0.5 mM of 6 or 8 was used. The reaction was quenched by the 
addition of 30 µL ice-cold 40% MeOH. The samples were then measured by HPLC-MS for 
product detection. 
 
H2
18O water experiments. A 50 l reaction mixture in 40 mM Tris-HCl buffer pH 7.5 containing 
2 M of loaded CPs and 7.5 M of MxnB in 75% H2
18O was incubated at 37 C for 2 h. The 
mixture was then quenched with iodoacetamide (final 1 mM). After centrifugation at 15,000 rpm 
for 2 min, the supernatant was divided into two aliquots. One volume of MeOH was added to the 
first aliquot for LCMS measurement. The second aliquot was dried using a Genevac evaporator 
and dissolved in H2
16O for 5 h further incubation. One volume of MeOH was added to the aliquot 
for LCMS measurement. 
 
LC-ESI-MS measurements for protein analysis. All ESI-MS-measurements for intact proteins 
were performed on a Dionex Ultimate 3000 RSLC system using an Aeris Widepore XB-C8, 
150 x 2.1 mm, 3.6 µm dp column (Phenomenex, USA). Separation of 1 µl sample was achieved 
using a linear gradient from (A) H2O + 0.05 % FA to (B) ACN + 0.05 % FA at a flow rate of 300 
µl min-1 and 45 °C. The gradient was initiated by a 1.0 min isocratic step at 2 % B, followed by 
an increase to 60 % B at 8 min to end up with a 3 min step at 60 % B before reequilibration in 
initial conditions. UV spectra were recorded with a DAD in the range from 200 to 600 nm. The 
LC flow was split to 75 µl/min before entering the maXis 4G hr-ToF mass spectrometer (Bruker 
Daltonics, Bremen, Germany) using the standard Bruker ESI source. In the source region, the 
temperature was set to 180 °C, the capillary voltage was 4000 V, the dry-gas flow was 6.0 l/min 
and the nebulizer was set to 1.1 bar. Mass spectra were acquired in positive ionization mode 
ranging from 600 – 1800 m/z at 2.5 Hz scan rate. Protein masses were deconvoluted by using the 
Maximum Entropy algorithm (Copyright 1991-2004 Spectrum Square Associates, Inc.). 
 
HPLC-MS measurements to analyze the products of in vitro assays. High Performance 
Liquid Chromatography-Mass Spectrometry (HPLC-MS) (Thermo Ultimate 3000 RSLC, 
coupled to a Bruker Daltonics amaZon Electrospray Ionization (ESI)-MS ion trap instrument) 
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was operated in positive ionization mode. Compounds were separated on a Waters Acquity BEH 
C18 column (50 x 2.1 mm; 1.7 µm particle diameter) at a flow rate of 600 l min-1 and 45 C by 
a linear gradient with (A) H2O + 0.1 % formic acid (FA) to (B) acetonitrile (ACN) + 0.1 % FA at 
a flow rate of 600 µl min-1 and 45 °C. The gradient was initiated by a 0.33 min isocratic step at 5 
% B, followed by an increase to 95 % B in 9 min to end up with a 1 min flush step at 95 % 
B before re-equilibration with initial conditions. Detection was carried out by both diode array 
(DAD) and ESI-MS. For high-resolution mass spectrometry analysis, measurements were 
performed on a Dionex Ultimate 3000 RSLC system using a Waters BEH C18 column (50 x 2.1 
mm, 1.7 µm dp) by injecting 5 µl of the methanolic extract. Separation was achieved using the 
same gradient as above with a 0.33 min isocratic step at 5 % B. UV and MS detection were 
performed simultaneously. Coupling the HPLC to the MS was supported by an Advion Triversa 
Nanomate nano-ESI system attached to a Thermo Fisher Orbitrap. Mass spectra were acquired in 
centroid mode ranging from 200-2000 m/z at a resolution of R = 30000. 
 
HPLC-MS measurements to analyze the products of in vitro competition assays. All 
measurements were performed on a Dionex Ultimate 3000 RSLC system using a Waters BEH 
C18, 50 x 2.1 mm, 1.7 µm dp column. Separation of 10-15 µl sample was achieved by a linear 
gradient with (A) H2O + 0.1 % FA to (B) ACN + 0.1 % FA at a flow rate of 600 µl/min and 45 
°C. The gradient was initiated by a 1 min isocratic step at 5 % B, followed by an increase to 95 % 
B in 6 min to end up with a 1.5 min step at 95 % B before reequilibration with initial conditions. 
UV spectra were recorded by a DAD in the range from 200 to 600 nm. The LC flow was split to 
75 µl/min before entering the maXis 4G hr-ToF mass spectrometer (Bruker Daltonics, Bremen, 
Germany) using the standard ESI source. Mass spectra were acquired in centroid mode ranging 
from 50 – 1000 m/z at 2 Hz scan speed. 
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3.6 Supporting Information 
Full supporting information is available online: 
http://www.rsc.org/suppdata/c5/sc/c5sc01013f/c5sc01013f1.pdf 
 
Table S1. List of strains and plasmids used in this study 
Strain/Plasmid Characteristics Reference 
E.coli strains 
HS996 Host for general cloning Invitrogen 
BL21 (DE3) Host for protein expression Invitrogen 
Myxococcus fulvus strains 
Mx f50 Myxopyronin producing wild-type strain 7 
 
Plasmids 
pColdI E. coli protein expression vector Takara 
pSUMtaA containing a 4’-phosphopantetheinyl transferase 
sfp gene 
8 
pHSU-mxn5  
(pColdI-MxnB) 
MxnB protein expression construct with N-
terminal His-tag based on pColdI 
this study 
pHSU-mxn5# 
(pColdI-MxnB#) 
MxnB mutant (C121A) protein expression 
construct with N-terminal His-tag based on 
pColdI 
this study 
pHSU-mxn104 
(pColdI-MxnB-T322L) 
MxnB mutant (T322L) protein expression 
construct with N-terminal His-tag based on 
pColdI 
this study 
pHSU-mxn68 
(pColdI-CP-W5-MtaA) 
CP-E6 protein expression construct with N-
terminal His-tag based on pColdI co-expressed 
with pSUMtaA 
this study 
pHSU-mxn69  
(pColdI-CP-E6-MtaA) 
CP-W5 protein expression construct with N-
terminal His-tag based on pColdI co-expressed 
with pSUMtaA 
this study 
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3.7 Supplementary Results 
Table S2. Blast search of MxnB. First 20 hits of the BLAST search of MxnB from the NCBI 
database (non-redundant) sorted by their E-values (as per 09 March 2015).  
Accession 
Number 
Description 
E 
Value 
AGS77282.1  ketosynthase [Myxococcus fulvus]  0.0 
ADI59524.1  CorB [Corallococcus coralloides]  0.0 
WP_012507654.1  
3-oxoacyl-ACP synthase [Pelodictyon 
phaeoclathratiforme]  
8e-97 
WP_006366404.1  3-oxoacyl-ACP synthase [Chlorobium ferrooxidans]  2e-91 
WP_036102127.1 3-oxoacyl-ACP synthase [Lysobacter capsici]  1e-90 
WP_025696271.1  3-oxoacyl-ACP synthase [Paenibacillus forsythiae]  2e-85 
WP_026559228.1  3-oxoacyl-ACP synthase [Bacillus sp. J37]  5e-84 
WP_000833196.1  3-oxoacyl-ACP synthase [Bacillus cereus]  7e-83 
WP_000833203.1  3-oxoacyl-ACP synthase [Bacillus cereus]  3e-82 
WP_020062449.1  3-oxoacyl-ACP synthase [Bacillus sp. 123MFChir2]  3e-82 
WP_001989055.1  3-oxoacyl-ACP synthase [Bacillus cereus]  4e-82 
WP_000833206.1  3-oxoacyl-ACP synthase [Bacillus cereus]  4e-82 
NP_845551.1  
putative 3-oxoacyl-ACP synthase III [Bacillus anthracis 
str. Ames]  
4e-82 
WP_000833198.1  
MULTISPECIES: 3-oxoacyl-ACP synthase [Bacillus 
cereus group]  
6e-82 
WP_029438921.1  3-oxoacyl-ACP synthase [Bacillus thuringiensis]  7e-82 
YP_037326.1  
3-oxoacyl-ACP synthase [Bacillus thuringiensis serovar 
konkukian str.97-27]  
7e-82 
WP_016083203.1  
3-oxoacyl-[acyl-carrier-protein] synthase 3 [Bacillus 
cereus]  
1e-81 
WP_000833202.1  3-oxoacyl-ACP synthase [Bacillus thuringiensis]  2e-81 
KGZ76433.1  3-oxoacyl-ACP synthase [Bacillus anthracis]  2e-81 
WP_000833204.1 
3-oxoacyl-[acyl-carrier-protein] synthase 3 [Bacillus 
cereus]  
2e-81 
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Figure S1. Phylogram of ketosynthases from various pathways. Protein sequences were aligned using ClustalW. Phylogenetic 
analysis was performed with a maximum-likelihood estimation approach (Whelan-and-Goldman 2001) in Geneious 8.1.4. Tip 
labels reflect the protein names. The proteins explained in the main text are marked bold. The scale bar indicates the degree of 
divergence as substitutions per sequence position. The following list comprises the locus name, the organism, and the access 
number of all given proteins: 2-PS (Gerbera hybrida, CAA86219), Act_KS (Streptomyces lividans, WP_003973890), Act_KSa 
(S. coelicolor A3(2),CAC44200), Act_KSb (S. coelicolor A3(2),CAC44201), BaeL-KS5 (Bacillus amyloliquefaciens subsp. 
plantarum AS43.3, WP_040238120.1),  BaeL-KS6 (Bacillus amyloliquefaciens subsp. plantarum AS43.3, WP_040238120.1), 
CHS2 (Medicago sativa, P30074), CHS_Nar (S. fulvissimus DSM 40593, AGK75504), CHS_Ncr (Neurospora crassa OR74A, 
XP_960427), CorB (Corallococcus coralloides, ADI59524), CsyB (Aspergillus oryzae, BAD97391), CUS (O. sativa Japonica, 
Q8LIL0), EncA (S. maritimus, AAF81728), EncA (S. maritimus, AAF81729), EryAII-KS (Sacchropolyspora erythraea NRRL 
2338, CAA44448.1), FabH_Burk (Burkholderia xenovorans, WP_011490245), FabH_Paer (Pseudomonas aeruginosa PAO1, 
Q9HYR2), FabH_Saur (Staphylococcus aureus, Q8NXE2), FABH_Sliv (S. lividans, Q9F6D4), Gcs (S. coelicolor, 
WP_011031521), HedC (S. griseoruber, AAP85362), HedD (S. griseoruber, AAP85361), LnmI-KS (S. atroolivaceus, 
AAN85522.1), MxnB (Myxococcus fulvus Mx f50, AGS77282.1), MxnI-KS-E1 (M. fulvus Mx f50, AGS77289.1), MxnI-KS-E2 
(M. fulvus Mx f50, AGS77289.1), MxnK-KS-W1 (M. fulvus Mx f50, AGS77291.1),  MxnK-KS-W2 (M. fulvus Mx f50, 
AGS77291.1), NcnA (S. arenae, AAD20267),  NcnB (S. arenae, AAD20268),  OleA  (Xanthomonas campestris,  
WP_011035468), PCS (Aloe arborescens, Q58VP7), PedF-KS (symbiont bacterium of Paederus fuscipes, AAS47564.1),  PpyS 
(Photorhabdus luminescens, AGO97060), PqsD (P. aeruginosa, P20582), RkD (Streptomyces sp. 88-682,  ACZ65477), RppA (S. 
griseus, BAA33495), TcmK  (S. davawensis, WP_015657287), TcmL (S. davawensis, WP_015657288), ZhuH (Streptomyces sp. 
R1128, AAG30195). 
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Figure S2. ESI-MS analysis of myxopyronin A produced in vitro using substrates 6 and 7 and LC-MS analysis for the in vitro 
formation of MxnB with 7 or 8. (A) MS spectrum in positive mode of myxopyronin A (1a). (B) Fragment spectrum of the parent 
ion [M+H]+ m/z = 418.2224 corresponds to 1a (calc. for C23H31NO6, 418.2224). The related MS
2 fragments are marked in bold. 
(C) LC-MS of the reaction mixtures containing MxnB and 7 forming 7-S-MxnB (38,986 Da, top) and MxnB and 8 forming 8-S-
MxnB (38,974 Da, bottom). (D) MS analysis of the loading of 7 or 8 (0.025 mM) onto MxnB (7.5 µM). Percentages were 
calculated using the deconvoluted mass peak heights and they are relative to the total amount of protein species present. 
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Table S3. NMR Spectroscopic Data for Myxopyronin Derivative (9)  
 
Chemical shifts measured in CD3OD: 
No δC
a δH(J in Hz)
b COSYc HMBCd 
1 199.4 - - - 
2 164.2 - - - 
3 158 - - - 
4 147.9 - - - 
5 136.5 7.32 7 - 
6 134.5 - - - 
7 121.2 6.26 5 - 
8 106 5.75 - 2 
9 101 - - - 
10 50.7 3.61 (s) - 3 
11 42.1 2.17 (t, J=7.4) 17 4,7,17 
12 40.1 3.09 14 3,14,15 
13 32.8 2.42 (t, J=7.3) 15 2,15 
14 29.5 1.51 (m) 12,16 12 
15 25.9 1.68 (sxt, J=7.3) 13,16 13,14 
16 22.5 1.38 (m) 14,15 - 
17 20.4 1.53 (m) 11,19 4,11,19 
18 15.5 1.79 (s) - 4,7,11 
19 12.2 0.92 (J=7.3) 17 11,17 
20 9.9 1.92 (s) - 1,5,6 
aRecorded at 176 MHz; referenced to residual CD3OD at =49.1. 
bRecorded at 700 MHz; referenced to residual CD3OD at  
3.30. aProton showing COSY correlation to indicated proton. dProton showing HMBC key correlations to the indicated carbon. 
Signals corresponding to quarternary carbon atoms C-1, C-2 and C-9 were assigned from HMBC spectra of an impure fraction 
(see Experimental Procedures: Isolation of In Vitro Product). 
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Figure S3. ESI-MS analysis of myxopyronin derivative produced in vitro by using substrate 6 and 8. (A-D) MS spectrum of myxopyronin derivatives (9, 13, 12, 14) was recorded 
in positive mode. (E-H) Fragment spectrum of its corresponding parent ion, respectively. The related MS2 fragments are marked with bold. The mass at [M+H]+ m/z = 406.2221 or 
406.2224 corresponds to 9 and the mass at [M+H]+ m/z = 406.2224 (calc. for C22H32NO6, 406.2224) to 13. The mass at [M+H]
+ m/z = 385.2372 Da corresponds to 12 (calc. for 
C24H33O4, 385.2373) and the mass at [M+H]
+ m/z =  427.2075 to 14 (calc. for C20H30N2O8, 427.2074). (F-H) MS
2 analyses for MxnWE (9), MxnEW (13), MxnWW (12), and 
MxnEE (14) (also see Table S6). 
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  Figure S4a. 1H NMR Spectrum of 9 in CD3OD at 700 MHz 
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Figure S4b. COSY NMR Spectrum of 9 in CD3OD at 700 MHz 
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 Figure S4c. HMBC NMR Spectrum of 9 in CD3OD at 700 MHz 
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Figure S4d. HSQC NMR Spectrum of 9 in CD3OD at 700 MHz 
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Table S4. ESI-MS Analysis of the Recombinant Proteins 
Protein Calculated average mass (Da) Observed mass  
(Da) Intact protein Protein – Methionine 
MxnB 38761 38630 38761 and 38629 
MxnB
#
 (C121A) 38729 38598 38729 and 35898 
MxnB

 (H264A) 38695 38564 38695 and 38564 
MxnB (T322L) 38773 38642 38772.7 and 38642 
MtaA/ACP-W5 14628 14497 14627.7 and 14496.7 
MtaA/ACP-E6 14771 14640 14771 and 14640 
       All proteins were expressed with an N-terminal His6-tag 
 
 
Table S5. MS analysis of the loading of 6 or 8 onto MxnB, CP-E and CP-W, which were used in the competition 
assays. 
 
 
 
 
 
 
 
 
 
 
Percentages are calculated using the deconvoluted mass peak heights and they are relative to the total amount of protein species 
present. 
 
 
 
 
 
 
 
 
Protein Substrate Product 
MxnB 
6 6-S-MxnB 46.45% 
8 8-S-MxnB 27% 
CP-E 
6 6-S-CP-E 50.05% 
8 8-S-CP-E 16.35% 
CP-W 
6 6-S-CP-W 37.57% 
8 8-S-CP-W 19.94% 
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Figure S5. LC-MS analysis of the formation of 6-S-CP-W and 8-S-CP-W. The deconvoluted spectra correspond to (a) holo-CP-W 
(CP-W), (b) the reaction mixture containing CP-W and 6 forming 6-S-CP-W (14820 Da) and (c) the reaction mixture containing 
CP-W and 8 forming 8-S-CP-W (14841 Da). The additional peak at M-131 represents the loss of the N-terminal methionine during 
expression of the recombinant protein in E. coli. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure S6. LC-MS analysis for formation of 8-S-CP-E and 6-S-CP-E. The deconvoluted spectra correspond to (a) holo-CP-E (CP-
E), (b) the reaction mixture containing CP-E and 8 forming 8-S-CP-E (14984 Da) and (c) the reaction mixture containing CP-E 
and 6 forming 6-S-CP-E (14963 Da). The additional peak at M-131 represents the loss of the N-terminal methionine during 
expression of the recombinant protein in E. coli. 
(a) 
(b) 
(c) 
(a) 
(b) 
(c) 
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Figure S7. A and B: Superposition of MxnB (green) (PDB ID 4V2P) and OleA (yellow) (PDB ID 3S23). Active site residues of 
MxnB are shown as sticks. The Xe atom used to identify the second long-chain fatty acid binding channel in OleA is shown as a 
purple sphere. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure S8. LC-MS analysis for the in vitro formation of MxnB. LC-MS analysis for the formation of 6-S-MxnB and 8-S-MxnB. 
The deconvoluted spectra correspond to (a) MxnB, (b) the reaction mixture containing MxnB and 6 forming 6-S-MxnB (38953 
Da) and (c) the reaction mixture containing MxnB and 8 forming 8-S-MxnB (38974 Da). The additional peak at M-131 represents 
the loss of the N-terminal methionine during expression of the recombinant protein in E. coli. 
(a) 
(b) 
(c) 
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Table S6. Characterization of Myxopyronin A and Its Analogues with Representative Fragmentation Patterns Observed  
 
Chemical 
Formula 
Calculated mass 
m/z [M+H]+ 
Observed 
m/z [M+H]+ 
Fragmentation due to losses of 
H2O 
(m/z = 18) 
CH3OH 
(m/z = 32) 
H2N-CO2CH3 
(m/z = 75) 
H2N-CO2CH3, CO2 
(m/z = 119) 
Other fragment 
MxnA (1a) C23H32NO6 418.2224 418.2224 400.2114 386.1958 343.1899 299.2002  
MxnA (1a) 
from in vitro 
assay 
C23H32NO6 418.2224 418.2223 400.2103 386.1953 343.1888 299.1992  
10 C23H32NO6 418.2224 418.2224 400.2118 386.1950 343.1895 n.o.  
11 C22H30N2O8 451.2074 451.2076 n.o. n.o. n.o. n.o.  
12 C24H33O4 385.2373 385.2375 367.2255 N/A N/A N/A 
C9H16  (m/z = 124) 
261.1155 
 
 
Chemical 
Formula 
Calculated mass 
m/z [M+H]+ 
Observed 
m/z [M+H]+ 
Fragmentation due to losses of 
H2O 
(m/z = 18) 
CH3OH 
(m/z = 32) 
C9H16 
(m/z = 124) 
 
C12H16NO5 
(m/z = 255) 
 
Other fragment 
2CH3OH (m/z = 64) 
 
9 C22H31NO6 406.2224 406.2219 388.2110 374.1957 282.0966 151.1112 N/A 
13 C22H31NO6 406.2224 406.2224 n.o. 374.1954 n.o. n.o. N/A 
14 C20H30N2O8 427.2074 427.2075 n.o. 395.1804 n.o. n.o. 363.1544 
15 C
21
H
29
NO
6
 392.2067 392.2065 374.1953 360.1797 282.0962 137.0952 N/A 
16 C20H27NO6 378.1911 378.1910 360.1794 346.1637 282.0961 123.0796 N/A 
17 C21H31NO6 394.2224 394.2222 376.2099 362.1949 n.o. 139.1107 N/A 
18 C21H33NO6 396.2380 396.2377 378.2262 264.2104 n.o. n.o. N/A 
n.o. = not observed, N/A = not applicable 
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Figure S9.  ESI-MS Analysis of myxopyronin and its derivatives produced in vivo. (A-D) ESI-MS spectra of myxopyronin A (1a) and its derivatives 10, 12 and 11 in positive 
mode. (E-G) Fragment spectra of the corresponding parent ion, respectively. The related MS2 fragments are labelled in bold. The mass at [M+H]+ m/z = 418.2224 correspond 
to 1a and 10 (calc. for C23H31NO6, 418.2224). The mass at [M+H]
+ m/z = 385.2375 Da correspond to 12 (calc. for C24H33O4, 385.2373) and the mass at [M+H]
+ m/z = 
451.2076 correspond to 11 (calc. for C22H30N2O8, 451.2074). (E-G) MS
2 analyses for MxnWE (1a), MxnEW (10), and MxnWW (12) (also see Table S6), while only high-
resolution mass spectrometry (HRMS) could be obtained for MxnEE (11). 
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Figure S10. LC-MS analysis of Assays 11-14. Time-course of the production of 9 from 15 s to 10 min. The peak area of 
extracted ion chromatograms (EIC) for 9 was used for quantification. Assay 11-14: Assay 11 (MxnB, 6-CP-W and 8-CP-E), 
Assay 12 (MxnB, 8-CP-W, and 6-CP-E), Assay 13 (MxnB, 6-CP-W and 8-CP-W), and Assay 14 (MxnB, 6-CP-E and 8-CP-
E). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure S11. LC-MS analysis of Assays 15-18. The peak area of the EIC for 9 at [M+H]+= 406.22 was used for Assay 15 (6-
MxnB and 8-CP-E) and the EIC for 14 at [M+H]+= 427.20 was used for Assay 18 (8-MxnB with 8-CP-E). Assay 16 (6-
MxnB incubated with 6-CP-W) and Assay 17 (8-MxnB is incubated with 6-CP-W) are not shown due to the very low 
amount observed. Assays were performed as a time course between 15 s to 10 min. 
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Figure S12. ESI-MS analysis of other myxopyronin derivatives produced in vitro in positive mode. The in vitro assays were 
performed using MxnB, CP-W, CP-E and western SNAC (S1-S4) independently with 8, resulting in 15-18, respectively. 
Left panel: MS spectra; right panel: Fragment spectra of the parent ion of 15 [M+H]+ m/z = 392.2065, 16 [M+H]+ m/z = 
378.1910, 17 [M+H]+ m/z = 394.2377, 18 [M+H]+ m/z = 396.2377 (see also Table S6)  
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Figure S12 continued. ESI-MS analysis of other myxopyronin derivatives produced in vitro in positive mode. The in vitro 
assays were performed using MxnB, CP-W, CP-E, western SNAC (S1-S4) independently with 8, resulting in 15-18, 
respectively. Left panel: MS spectrum; right panel: Fragment spectrum of the parent ion of 15 [M+H]+ m/z = 392.2065, 16 
[M+H]+ m/z = 378.1910, 17 [M+H]+ m/z = 394.2377, 18 [M+H]+ m/z = 396.2377 (see also Table S6)  
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4 Mutasynthesis Studies on Myxopyronin 
4.1 Abstract 
Myxopyronin is a natural -pyrone antibiotic from the soil bacterium Myxococcus fulvus Mx 
f50. Myxopyronin inhibits the bacterial RNA polymerase (RNAP) by binding to a part of the 
enzyme not targeted by the clinically used rifamycins. This mode of action makes 
myxopyronins promising molecules for the development of novel broad-spectrum 
antibacterials. We describe the derivatization of myxopyronins by an advanced mutasynthesis 
approach as a first step towards this goal. Site-directed mutagenesis of the biosynthetic 
machinery was used to block myxopyronin biosynthesis at different stages. The resulting 
mutants were fed with diverse precursors that mimic the biosynthetic intermediates to restore 
production. Mutasynthon incorporation and production of novel myxopyronin derivatives was 
analyzed by HPLC-MS/MS. This work sets the stage for accessing numerous myxopyronin 
derivatives, thus significantly expanding the chemical space of the class of -pyrone 
antibiotics. 
4.2 Introduction 
The current evolving of bacterial resistances against clinic antibiotics is alarming. Resistant 
Mycobacterium tuberculosis (MTB) strains, for example, represent a major health threat; 
approximately 1.5 million patients die from tuberculosis infections each year.[1] The evolved 
multidrug-resistant tuberculosis (MDR-TB) strains in recent decades are resistant to the first-
line TB drugs rifampicin and isoniazid.[2] These strains gave rise to the increasingly prevalent 
extensively drug-resistant tuberculosis strains (XDR-TB). These strains are also resistant to at 
least one of the second-line TB drugs.[3, 4] Rifampicin is the most prominent anti-TB drug; it 
binds at the active site of the bacterial RNA polymerase (RNAP), thus inhibiting the initiation 
of RNA synthesis and hence transcription.[5, 6] Widespread rifampicin resistance dramatically 
hampers tuberculosis therapy,[7] thus highlighting the importance of developing new 
antibiotics to overcome existing resistance.  
Substances addressing known and exploited targets involve the risk of cross-
resistance. It is more promising to identify inhibitors of novel targets and binding sites to 
avoid such effects.[8–10] Recently the switch region of bacterial RNAP was discovered as a 
new binding site. It is targeted by the natural -pyrone antibiotic myxopyronin,[11] which was 
isolated from the terrestrial myxobacterium Myxococcus fulvus Mx f50.[12, 13] It was shown 
that rifampicin-resistant mutants exhibit no cross-resistance to myxopyronin, thus making 
myxopyronins a promising starting point for drug development.[14] Corallopyronins, which 
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are structurally closely related to myxopyronins, are further members of the -pyrone class of 
antibiotics.  
Despite the close structural similarity between myxopyronins and corallopyronins, 
there are remarkable differences in their pharmacodynamic profiles. Whereas corallopyronin 
completely blocks RNA synthesis in vitro, myxopyronin only achieves inhibition to a certain 
extent, even at high concentrations.[15] Nevertheless, myxopyronin shows a lower minimal 
inhibitory concentration (MIC, 1.6 µg mL-1) against several pathogens (including M. 
tuberculosis H37Rv) than does corallopyronin (MIC 3.1 µg mL-1).[16]  
The total synthesis of myxopyronin, corallopyronin, and several derivatives has been 
reported.[17–19] Because of the complexity of the compounds the described procedures are 
laborious, comprise many steps with relatively low final yields, and are not economically 
viable. 
 
 
 
Mutasynthesis represents an attractive approach for the generation of derivatives of 
complex natural products, without the necessity of multi-step organic synthesis.[20–23] In this 
method, small and chemically relatively simple precursors (mutasynthons, mimicking 
biosynthetic intermediates) are added to the culture of a mutagenized microbe in which 
natural product biosynthesis has been blocked at a particular stage. The mutasynthons enter 
the cells and are incorporated into the modified biosynthetic pathway thereby resulting in 
structurally diverse compounds. Currently, most successful examples have targeted 
biosynthesis precursors, such as the 3-amino-5-hydroxybenzoicacid (AHBA) moiety of 
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ansamitocins.[24, 25] The technology has rarely been used to incorporate more-advanced 
biosynthetic intermediates or even complex parts of the final molecule. 
Recently, the biosynthetic pathways of myxopyronin (Figure 1A) and corallopyronin 
were elucidated, thus establishing the basis for mutasynthesis approaches. [26, 27] The natural 
products are composed of a central pyrone core decorated with two side chains (“western” 
(green) and “eastern” (blue), Figure1A). The western and eastern moieties are synthesized by 
two enzymatic machineries that independently catalyze the assembly of each chain (here 
described for myxopyronins). The western chain is generated by the polyketide synthase 
(PKS) MxnK, and the carbamate-containing eastern chain is produced by the hybrid 
PKS/non-ribosomal peptide synthetase (NRPS) system MxnI/MxnJ. Such multimodular 
megasynthetases catalyze the stepwise assembly of simple precursors into complex molecules 
by using a distinct set of catalytic domains ordered in modules. Each module incorporates one 
specific unit into the growing biosynthetic intermediate. After chain assembly, the halves are 
condensed by the ketosynthase MxnB to result in the characteristic -pyrone core structure.  
 
Figure 1. A) Biosynthetic pathway of myxopyronin.[26] The western chain (green) is produced by the PKS system 
MxnK. The eastern chain (blue) is derived from the PKS/NRPS hybrid system MxnI/MxnJ. The two chains are 
connected by the ketosynthase MxnB. B) Mutasynthesis approach. Synthetic western chains (red) are fed to a M. fulvus 
ΔmxnK mutant (incapable of producing the native western chain). During fermentation, the synthetic precursors are 
combined with the native eastern chain to yield novel myxopyronin derivatives. 
 
The physicochemical properties of myxopyronin are more complex than those of 
common clinical antibiotics.[7, 28] Its high lipophilicity results in decreasing MIC in the 
presence of serum albumin. The compound also features a conjugated doublebond system, 
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which makes it unstable and sensitive to UV light.[7, 29] Moreover, its high flexibility incurs a 
significant entropic penalty when binding to its target site, thus probably reducing its potency.  
This work sets the stage for the advanced mutasynthesis based development of new 
myxopyronin derivatives (Figure 1B), which could potentially overcome these problems and 
would ideally display higher inhibitory potency. So far the corallopyronin producer 
Coralloccocus coralloides Cc c127 was not amenable to the genetic modifications required 
for mutasynthesis, and we therefore focused on myxopyronin. The major aim of this study 
was to elucidate the structural requirements for mutasynthons to be taken up by the producing 
strain and to be accepted by the myxopyronin biosynthetic machinery. Because of the high 
structural similarity between myxopyronin and corallopyronin it is expected that our results 
will be transferable to the corallopyronin system. 
4.3 Results and Discussion 
Myxopyronin adopts a U-shaped conformation inside the switch region of the bacterial 
RNAP (Figure 2). The eastern chain extends into a narrow channel delimited by V1037, 
W1038, and E1041 of the RNAP -subunit and by K1097, V1099, D1100, H805, K1463, 
V1466, and I1467 of the ’-subunit. Its polar carbamate function forms several crucial water-
mediated hydrogen bonds with D1100, K1463 (’), and W1038 (). Initial structure–activity 
relationship (SAR) studies showed that slight variations in the eastern part of the molecule 
result in a dramatic loss of inhibitory activity, with one exception: the derivative lacking the 
R methyl group, adjacent to the -pyrone core (desmethyl myxopyronin), possesses the 
highest activity so far, approximately three times that of the natural product.[19]  
 
Figure 2. Crystal structure of myxopyronin inside the switch region of Thermus thermophilus RNAP (PDB-ID; 
3DXJ).[11] 
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The western chain of myxopyronins provides wider scope for structural variation. It is 
composed of only hydrophobic functionalities, which do not significantly contribute to 
interactions with the RNAP switch region. Potentially, however, interactions with several 
polar amino acids and protein backbones are possible in this region. Establishment of a single 
specific hydrogen bond could therefore result in improved RNAP inhibition. Moreover, the 
larger RNAP binding pocket in this area provides the option to introduce bulkier groups, 
thereby resembling corallopyronins, which are significantly larger in the western chain. Thus, 
we focused on the production of myxopyronin derivatives with modified western chains. N-
acetyl cysteamine (NAC) thioesters were chosen as substrates for feeding experiments, as 
they mimic carrier protein (CP)-bound biosynthetic intermediates of the assembly line. The 
application of NAC thioesters for mutasynthesis approaches with PKS/NRPS assembly lines 
is well established. They are known to enter cells and to be accepted as substrates by 
biosynthetic enzymes.[20]  
In a first attempt we aimed to synthesize mimics of the fully matured western chain 
intermediate, which should directly enter the chain-condensation reaction catalyzed by 
MxnB. Synthesis of the required -keto NAC-thioesters from the corresponding -ketoacids 
is intractable because of instability of the free acids or undesired side products under coupling 
conditions.[30] Therefore, we developed a synthetic route that involves dioxinones as protected 
-ketoacid equivalents. Most of the desired -keto NAC thioesters were obtained according 
to the synthesis route shown in Scheme 1. The first step involves acylation of Meldrum’s acid 
(I) [31] followed by a rearrangement to yield dioxinone II.[32] After conversion to the 
dioxinone phosphonate III,[33] the resulting compound was coupled with the appropriate 
aldehyde in a Horner–Wadsworth–Emmons reaction to yield the unsaturated dioxinone IV.[34] 
Final conversion with NAC gave the desired -keto-NAC-thioester V.[30]  
The generated mutasynthons 1–12 (details of the synthesis can be found in the 
Supporting Information) are mimics of fully matured western chain intermediates bound to 
the terminal CP domain of MxnK (Table 1). In order to block native western chain 
biosynthesis (to avoid competition with the mutasynthons), MxnK was inactivated by 
deletion of a 5.6 kb internal fragment of the 18 kb mxnK gene. This chromosomal 
modification was performed according to a previously established procedure for markerless 
site-directed mutagenesis in M. fulvus Mx f50.[26] LC-MS analysis revealed that, as expected, 
myxopyronin production was completely abolished in the mutant strain ΔmxnK (Mx 
f50ΔpHSU-mxn18, Table S1). 
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Scheme  1. Synthesis of the -keto intermediates. a) pyridine, CH2Cl2, 0C–RT; b) toluene, Δ; c) LDA, THF, -78 C; d) 
P(OEt)2Cl, -78 C; e) H2O2, 0C–RT; f) R’CHO, LDA, HMPA, THF, -78–0 C. 
 
Subsequently, mutasynthesis experiments were carried out by feeding the precursors to small-
scale ΔmxnK cultures. Analysis of the culture extracts by HPLC-MS/MS revealed the 
successful incorporation of most of the mutasynthons (see below). Production of the expected 
myxopyronin derivatives was verified by high-resolution MS and fragmentation pattern 
analysis (Table 2 and Figures S3–S18 in the Supporting Information).  
As a proof of concept, 1 (the -keto NAC thioester; representing the exact mimic of 
the native biosynthetic intermediate) was investigated. Myxopyronin production was restored 
when 1 was fed to ΔmxnK. The successful incorporation and restoration of myxopyronin 
production demonstrated that the mutasynthesis system is fully functional. Functional groups 
of the “natural” precursor were then systematically removed to analyze whether they are 
mandatory for the chain condensation catalyzed by MxnB. Although removal of the methyl 
group in the -position (2) was tolerated and resulted in the production of the novel derivative 
W2, additional elimination of the methyl at the a-position (3) did not yield the expected 
product. Compound 4 (lacking the -methyl and the γ-double bond) was accepted, whereas 
the completely saturated precursor 5 was not incorporated. 
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Table 1. Synthetic western side-chain mimics. If accepted, the red part is incorporated into the resulting 
myxopyronin derivative. 
 
 
 
Formula 
Myx 
derivative 
1 
 
W1 
2 
 
W2 
3 
 
n.p.[a] 
4 
 
W4 
5 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
n.p.[a] 
6 
 
W6 
7 
 
W7 
8 
 
W8 
9 
 
W9 
10 
 
W10 
11 
 
W11 
12 
 
W12 
                                               [a] n.p. no product 
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Table 2. Characterization of novel myxopyronin A analogues with representative fragmentation patterns 
observed 
 
Chemical 
formula 
m/z [M+H]+ Fragmentation due to losses of 
Calcd Obs. 
H2O 
(m/z = 18) 
CH3OH 
(m/z = 32) 
H2N-CO2CH3 
(m/z = 75) 
H2N-CO2CH3,  
CO2 (m/z = 119) 
Myx A C23H32NO6 418.22241 418.22217 400.21129 386.19576 343.18988 299.20017 
W1 C23H32NO6 418.22241 418.22227 400.21112 386.19567 343.18981 299.20007 
W2 C22H30NO6 404.20676 404.20666 386.19588 372.18020 329.17446 285.18464 
W4 C
22
H
32
NO
6
 406.22241 406.22250 388.21078 374.19559 331.18951 287.19987 
W6 C25H28NO6 438.19111 438.19103 420.17930 406.16392 363.15828 319.16866 
W7 C26H30NO6 452.20676 452.20686 434.19544 420.18146 377.17400 333.18430 
W8 C25H30NO6 440.20676 440.20659 422.19529 408.17954 365.17410 321.18438 
W9 C25H28NO7 454.18602 454.18643 436.17468 n.o
[a] 379.15314 335.16345 
W10 C25H26NO6Br 516.10163 516.10175 498.09073 484.07530 441.06942 397.07952 
W11 C21H26NO6 388.17546 388.17557 n.o
[a] n.o[a] 313.14233 269.15311 
W12 C22H30NO7 420.20167 420.20148 402.19059 n.o
[a] 345.16920 301.17982 
W13 C23H32NO6 418.22241 418.22232 400.21163 386.19590 343.18984 299.19999 
W14 C
26
H
30
NO
6
 452.20676 452.20670 434.19736 420.18027 377.17516 333.18508 
W16 C23H32NO6 418.22241 418.22235 400.21137 386.19598 343.18972 299.20000 
W17 C22H30NO6 404.20676 404.20675 386.19635 372.18204 329.17496 285.18512 
W18 C25H28NO6 438.19111 438.19118 420.18041 406.16491 363.15886 319.16910 
[a] n.o. : not observed 
 
We concluded that both the -methyl group and the -double bond are essential for substrate 
acceptance and pyrone ring formation by MxnB. Hence, these structural features were 
included in all further synthesized mutasynthons, in order to maximize the probability of 
incorporation. Next we tested whether mutasynthons with terminal phenyl substituents are 
incorporated. Such aromatic systems allow easy introduction of a variety of functional 
groups; when attached at the appropriate positions of the ring, these groups can be used to 
engineer new and specific interactions with bacterial RNAP. A closer look at the crystal 
structure of bacterial RNAP complexed with myxopyronin (PDB ID: 3DXJ) revealed that the 
pocket accepting the western part should be wide enough to accommodate this dramatic 
structural change. Compound 6 was initially tested, and it resulted in production of the 
desired derivative W6 (Figure 3). Replacement of the -methyl group by an ethyl function 
(7) or omitting the γ-double bond (8) also allowed incorporation.  
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Figure 3. W6 detected in an extract from a culture of Mx f50 ΔmxnK after feeding with 6. Top: MS spectrum; bottom: 
fragment spectrum of the parent ion m/z 438.19 [M+H]+ (Table 2). 
Molecular modeling studies with W6 suggested that a hydroxy function in the meta 
position of the phenyl ring might lead to a water-mediated H-bond with W1434 (’-subunit). 
Moreover, the additional hydrophilic function could lead to improved physicochemical 
properties. Thus, 9 was synthesized and successful incorporation yielded derivative W9. 
Encouraged by these results, a precursor with a bromo substituent (10) instead the hydroxy 
function was synthesized and fed; this enabled the production of the expected myxopyronin 
analogue (W10). Such a brominated derivative provides possibilities for further derivatization 
(e.g., under Suzuki [35] or Buchwald Hartwig [36] conditions) to attain a broader chemical 
space.  
We next attempted to introduce a terminal alkyne functionality, in order to allow 
subsequent synthetic modifications of the expected mutasynthesis product. The resulting 
myxopyronin analogue could, for example, react with different azides under mild conditions 
(click chemistry) [37] to generate triazole containing myxopyronin derivatives with various 
substitution patterns. A corresponding mutasynthon (11) was synthesized and successfully 
incorporated, thereby resulting in the production of derivative W11. Inspired by 
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corallopyronin, we finally synthesized a mutasynthon bearing a terminal hydroxy group (12) 
at the same position as in the corallopyronin western chain. There is no X-ray structure of a 
corallopyronin–RNAP complex, but because of the close similarity to myxopyronin (as well 
as several mutagenesis studies),[38] its binding mode can be assumed to be analogous to that 
of myxopyronin. The additional alkyl chain of corallopyronin likely extends into an adjacent 
lipophilic pocket to interact with -L1326 (Figure 4).[11, 16] The hydroxy function presumably 
contributes to its activity by forming a hydrogen bond with the protein. A corresponding 
myxopyronin derivative (W12) might therefore benefit from an additional interaction (similar 
to corallopyronin) and was obtained after feeding 12 to ΔmxnK.  
 
                   
Figure 4. Myxopyronin (black) and corallopyronin (black+blue) inside the switch region. Adapted from 
Mukhopadhyay et al.[11] 
 
The first attempts to isolate sufficient quantities of the new myxopyronin derivatives 
generated by mutasynthesis failed (low production yields). Possible bottlenecks might be 
limited uptake of the -keto NAC thioesters, their fast degradation after feeding to the 
culture, or inefficient incorporation by the biosynthetic process. Closer analysis of the 
fermentation culture extracts revealed that trace amounts of the mutasynthons were left, thus 
indicating that precursor degradation/instability might be a limiting factor. Therefore we 
decided to increase the chemical stability of the mutasynthons and to re-design the 
myxopyronin mutasynthesis approach. In the experiments described above, western chain 
biosynthesis was completely blocked, and complementation was achieved by feeding mimics 
of fully matured western-chain intermediates. Thus, -keto thioesters are required as 
mutasynthons to enable the final pyrone ring formation by Claisen condensation. In order to 
circumvent the use of the rather unstable -keto thioesters (which precludes long-term 
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storage), we aimed to block and complement western chain biosynthesis at earlier stages. 
This would enable feeding experiments with simplified and more stable mutasynthons 
(Figure S2A and B). Two additional mutants were generated by site-directed mutagenesis to 
inactivate the carrier protein (CP) domains from modules 1 and 4 (CP-1W or CP-4W). In both 
cases, the CP active-site serine required for post-translational modification [39] was mutated to 
alanine (strains ΔCP-1W and ΔCP-4W, respectively). Interestingly, western chain biosynthesis 
was not completely abolished, as trace amounts of myxopyronin A could still be detected in 
culture extracts of both mutants. We reasoned that in the case of ΔCP-1W, butyryl-CoA might 
act as starter unit, which would be directly elongated and incorporated into the assembly 
process at module 3. However, the production of myxopyronin A by ΔCP-4W is difficult to 
explain with standard PKS biochemistry. One possible scenario involves an additional 
(iterative) elongation round without keto reduction by module 1W and subsequent 
modification of the -keto moiety, possibly on CP-2W (or CP-1W) to introduce the methyl 
branch.  
Although myxopyronin biosynthesis was not completely inhibited, feeding experiments 
with simplified and more-stable mutasynthons were performed. Cultures of ΔCP-1W were 
supplemented with precursors 13–15, and myxopyronin production was analyzed by HPLC-
MS/MS (Table 3). As expected, myxopyroninA was produced after feeding 13 in larger 
quantities than in the control (without feeding). Precursor 14 was also accepted, as 
myxopyronin derivative W14 was detected. Interestingly, 15 (hydroxy group in the meta 
position) did not result in the production of a hydroxylated myxopyronin derivative, as was 
observed when the -keto thioester (9) was fed. It is possible that selectivity issues of 
downstream catalytic domains in the PKS are responsible, as these are circumvented in 
feeding experiments with fully matured western-chain mimics like 9.  
Mutant ΔCP-4W was analyzed by using extended NAC-thioesters 16–18 to mimic 
module 4W intermediates. All substrates were accepted, and the respective myxopyronin 
derivatives were detected by HPLC-MS/MS analysis (increased levels of myxopyronin A in 
the ΔCP-4W culture fed with 16 compared to the control). Although the NAC-thioesters 
without a -keto function were more stable, the yields of the final products were still too low 
for product isolation (1–10 µg mL-1) for bioactivity testing. The detection of large amounts of 
substrates in the culture supernatants suggested that insufficient uptake into cells was a 
limiting factor. To address this, modified feeding procedures were evaluated: addition of 
detergents like poly(ethylene glycol) (PEG), Tween, or DMSO to increase cell permeability, 
as well as increasing the number of feeding events. However, improved myxopyronin 
production yields could not be obtained. Further experiments to improve yield will be carried 
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out to fully exploit the established mutasynthesis systems and to access compounds from the 
culture extracts after biotechnological process optimization. With regard to this bottleneck, 
engineering the efflux pumps of the producer strain might hold promise to improve precursor 
uptake. Furthermore, we shall focus on establishing a heterologous production system to 
improve yields. 
 
Table  3. Synthetic western side-chain mimics. 
 Formula Myx 
derivative 
13 
 
W13 (=W1) 
14 
 
W14 
15 
 
n.p.[a] 
16 
 
W16 (=W1) 
17 
 
W17 
18 
 
W18 
[a]
 
n.p. : no product 
 
4.4 Conclusion 
Mutasynthesis represents a powerful approach to produce libraries of natural product 
derivatives that are difficult to access by purely synthetic routes. Here we established such an 
approach for the bacterial RNAP inhibitor myxopyronin. Mutants of the native myxopyronin 
producer M. fulvus Mx f50 were generated to block (or, at least, significantly reduce) native 
western-chain assembly. Intriguingly, most of the synthesized mutasynthons were 
successfully incorporated by the mutasynthesis systems. This indicates that the participating 
enzymes display relatively high tolerance to variation in substrate structure. The substrate 
specificity of MxnB, which is responsible for the last step of myxopyronin biosynthesis, 
could be evaluated. The mutant with a nonfunctional MxnK required feeding of -keto NAC 
thioesters (1–12) to generate products. On the one hand, these substrates allow the highest 
flexibility in variation of the resulting myxopyronin derivatives, because of the late stage of 
incorporation. On the other hand, their synthesis is more laborious, and the compounds are 
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relatively unstable. Mutants expressing a partly functional western-chain assembly line 
enabled feeding experiments with shorter precursors without a -keto function. These 
mutasynthons are more stable and easier to synthesize in large quantities. However, the 
variability in terms of tolerated structural variations is more restricted compared to the b-keto 
mutasynthons. Although productivity is currently too low to allow full characterization of the 
products (and thus clearly has to be improved), the established mutasynthesis systems provide 
a comprehensive basis for planned studies to generate new myxopyronin derivatives. This 
will allow us to further exploit this promising class of -pyrone antibiotics. The broad 
western-chain substrate tolerance in the final condensation reaction even allows exploration 
of the corallopyronin chemical space by this mutasynthesis system. The resulting compounds 
could be streamlined to improve their physicochemical properties and potentially overcome 
the problems of current antibiotic resistance. 
4.5 Experimental Section 
Bacterial strains and culturing conditions  
Bacterial strains and plasmids used in this study are listed in Table S1. Wild-type M. fulvus 
Mx f50 and mutants were grown in Casitone Yeast (CY) medium (casitone (0.3 %), yeast 
extract (0.1 %), CaCl2·2H2O (0.1 %)) supplemented with vitamin B12 (500 mgmL) after 
autoclaving. For liquid cultures, the strains were grown at 30 8C in an orbital shaker (105 
rpm) and harvested after 3 days. Escherichia coli strains were cultured in lysogeny broth (LB: 
tryptone (1 %), yeast extract (0.5 %), NaCl (0.5 %)) at 37 8C, with ampicillin (100 µg mL-1)) 
or kanamycin (50 µg mL-1)) where necessary.  
 
DNA preparations and PCR  
M. fulvus Mx f50 genomic DNA was prepared either by the phenol/chloroform/isoamyl 
alcohol extraction method [40] or by using the Gentra Puregene Genomic DNA Purification 
Kit (Qiagen) according to the manufacturer’s protocol. Plasmid DNA was either purified by 
standard alkaline lysis[40] or by using a GeneJET Plasmid Miniprep Kit (Thermo Fisher 
Scientific). PCR reactions were carried out in a peqSTAR 96 Universal Gradient 
thermocycler (Peqlab, Erlangen, Germany): initial denaturation (3 min, 95 C); 30 cycles of 
denaturation (30 s, 95 C), annealing (30 s, 53 or 57 C), and elongation (duration depends on 
PCR product length, 1 kb min-1, 72 C); final extension (10 min, 72 C). DNA fragments 
were separated by agarose gel electrophoresis and isolated with a peqGold Gel Extraction kit 
(Peqlab). The PCR products were cloned into pJET1.2 blunt (Thermo Scientific) vector and 
sequenced with primers pJET1.2For/pJET1.2Rev (all primer sequences used in this study are 
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given in Table S2). General procedure for site-directed mutagenesis of mxnK by in-frame 
deletion and point mutation: In general, construction of in-frame deletion mutants was carried 
out by amplifying 1000–1250 bp homology regions on each side of the desired deletion area 
by PCR. Each fragment was subcloned to pJET1.2 and sequenced. After sequence 
verification the homology regions were cloned into the pSWU41 vector, [41] kindly provided 
by Dale Kaiser, by using the restriction sites indicated in Table S2. The vector contains a 
neomycin phosphotransferase (nptII) and levansucrose (sacB) gene cassette and derives from 
pSWU35 [41] by deletion of the 1045 bp PvuI fragment (Samuel Wu, personal 
communication). The resulting constructs were electroporated into M. fulvus Mx f50. The 
culture was grown in CY medium in a baffled flask. At OD600=0.6–0.9, the cells were 
harvested from the culture (2–4 mL; 1–2x109 cells mL-1) by centrifugation (14900 g 1 min, 
RT). After washing with H2O (2x1 mL) at room temperature, cells were resuspended in H2O 
(65 µL). Plasmid DNA (1–2 mg) was mixed with the cell suspension, and electroporation was 
carried out in 0.1 cm electroporation cuvettes in a GenePulser XCell device (Bio-Rad; 25 mF, 
400 W, 650 V). CY medium (1 mL) was added to the cell suspension immediately after 
electroporation, and the cells were transferred into a 2 mL centrifuge tube. After 6–8 h 
culturing on a thermomixer (30 C, 800 rpm), the cells were mixed with CY soft agar (2 mL, 
CY medium containing agar (0.7 %)) and plated on CY agar plates (CY medium containing 
agar (1.7 %)) supplemented with kanamycin (50 µg mL-1)). The plates were incubated at 30 
8C until colonies became visible (7–10 days). Construction of markerless double-crossover 
mutants: After verification of the single crossover mutant (kanamycin resistant) by PCR 
(integration at two different homology regions is possible), a selected single-crossover mutant 
was grown in CY medium in the absence of antibiotics. After 3–4 days the culture (1 mL) 
was transferred into fresh medium (50 mL) for further culturing at 30 C for 3–4 days. This 
procedure was repeated three times to increase the possibility of a second crossover event, 
which would result in loss of the inactivation plasmid. Depending on the homology region 
used for the second crossover, this can yield either the wild-type genotype (“revertant”) or the 
expected double-crossover mutant strain, in which the targeted region is deleted. To select 
clones in which a second crossover had taken place, a counter selection system based on the 
sacB gene was used. [41] For this, different dilutions of the cell population were plated on CY 
agar supplemented with sucrose (6 %). After 7–10 days, the first colonies appeared; these 
were grown in CY medium to isolate genomic DNA for genotypic verification and to extract 
the cultures for phenotypic analysis. 
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Inactivation of mxnK by in-frame deletion 
To disrupt mxnK by in-frame deletion, a gene-inactivation plasmid harboring two fragments 
(1001 and 1262 bp, homologous to upstream and downstream regions around the 
chromosomal target) was constructed. These fragments were amplified from M. fulvus Mx 
f50 genomic DNA by PCR with primers mxn54/mxn55 and mxn56/mxn57 (Table S2). After 
digestion of the upstream fragment (mxn54/mxn55 product) with BamHI and NotI, and the 
downstream fragment (mxn56/57 product) with NotI and SacI, the fragments were ligated 
into pSWU41 digested with BamHI and SacI to generate pHSU-mxn18. All subcloning steps 
were performed in E. coli HS996 (Invitrogen). For genotypic analysis of the single crossover, 
PCRs with primers mxn68/mxn69, mxn70/mxn72, and mxn73/mxn71 were carried out to 
verify correct integration of the inactivation plasmid. For genotypic analysis of putative 
double-crossover mutants, PCR was performed with primers mxn68/mxn71. Confirmation of 
the deletion mutant was obtained by Southern blot analysis (Figure S1). 
 
Inactivation of mxnK by point mutation at CP-1W  
A gene inactivation plasmid harboring a 2445 bp fragment was constructed. The fragment 
was amplified from M. fulvus Mx f50 genomic DNA by overlap PCR with primer pairs 
mxn169/mxn170 and mxn171/mxn172. After digestion of the fragment and vector with PvuI 
and NotI, ligation into pSWU41 generated pHSU-mxn48. For genotypic analysis of the single 
crossover, PCR with mxn185/mxn70 and pSWU41-F/mxn187 was carried out to verify 
correct integration of the inactivation plasmid. For genotypic analysis of the double 
crossover, PCR with mxn189/mxn205 was performed, and the amplified product was 
sequenced. 
 
Inactivation of mxnK by point mutation at CP-4W  
A gene inactivation plasmid harboring a 2486 bp fragment was constructed. The fragment 
was amplified from M. fulvus Mx f50 genomic DNA by overlap PCR with primers 
mxn174/mxn175 and mxn176/mxn177. After digestion of the fragment and vector with PvuI 
and NotI, ligation into pSWU41 generated pHSU-mxn49. Correct integration of the 
inactivation plasmid was verified by PCR with mxn191/mxn70, pSWU41-F/mxn193, and 
mxn195/mxn70. For genotypic analysis of the double crossover, PCR with mxn195/mxn206 
was performed, and the amplified product was sequenced. Feeding for mutasynthesis 
experiments: A preculture of M. fulvus Mx f50 (ΔmxnK), M. fulvus Mx f50ΔCP-1W, or M. 
fulvus Mx f50ΔCP-4W was grown in CY medium at 30 C until OD600=0.3–0.6. The pre-
culture inoculated into CY medium (20 mL; 7.2x106 cells mL-1). Culturing was carried out 
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for a further 12–24 h before feeding with substrate mimics. N-acetyl-cysteamine (SNAC)-
esters (20–100 µM) mimicking western chain 1–12 were fed to M. fulvus Mx f50ΔmxnK 
cultures, 13–15 were fed to M. fulvus Mx f50ΔCP-1W, and 16–18 were fed to M. fulvus Mx 
f50ΔCP-4W. Cultures were grown for a further 48 h, and the cells were harvested. The 
supernatant was extracted twice with an equal volume of ethyl acetate. After evaporation of 
the organic phase, the residue was dissolved in methanol (100 mL). Analysis by LC-MS of 
the crude extract from the cultures showed formation of the novel myxopyronin analogues. 
High-resolution MS confirmed incorporation of the precursors (showing the same 
fragmentation pattern).  
 
HPLC-MS/MS analysis  
All measurements were performed on a Dionex Ultimate 3000 RSLC system (Thermo 
Scientific) with a BEH C18 column (50 x 2.1 mm, 1.7 mm; Waters) by injection of 
methanolic samples (5 mL). Separation was achieved by a linear gradient of A (FA (0.1%) in 
H2O) to B (FA (0.1%) in CAN) at 45 C with a flow rate of 600 µL min-1: 0.33 min isocratic 
step at 5% B: increase to 95% B (9 min); flush step at 95% B (1 min); re-equilibration with 
initial conditions. UV and MS detections were performed simultaneously. Coupling HPLC to 
MS was achieved with a TriVersa Nano-Mate nano-ESI system (Advion, Ithaca, NY) 
attached to an Orbitrap LC-MS (Thermo Scientific). Mass spectra were acquired in centroid 
mode (200–2000 m/z, resolution R = 30000).  
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4.6 Supporting Information 
Full supporting information is available online: 
http://onlinelibrary.wiley.com/store/10.1002/cbic.201402666/asset/supinfo/cbic_2014026
66_sm_miscellaneous_information.pdf 
 
Table S1. List of strains and plasmids used in this study 
Strain/Plasmid Description Reference 
E.coli strains 
HS996 Host for general cloning experiments Invitrogen 
SCS110 Host for cloning experiments to prepare plasmid 
DNA free of Dam or Dcm methylation 
Stratagene 
Myxococcus fulvus strains 
Mx f50 Myxopyronin producing wild-type strain Irschik et al.[1] 
Mx f50ΔpHSU-mxn18 
(ΔmxnK) 
mxnK in-frame deletion mutant;  
no myxopyronin production 
this study 
Mx f50ΔpHSU-mxn48 
(ΔCP-1W, point mutation 
at CP-1W, S1686A) 
CP-1W point mutation;  
myxopyronin production (trace amount) 
this study 
Mx f50ΔpHSU-mxn49 
(ΔCP-4W, point mutation 
at CP-4W, S5168A) 
CP-3W point mutation;  
myxopyronin production (trace amount) 
this study 
Plasmids 
  
pSWU41 
 
Vector contains a neomycin phosphotransferase 
(nptII) gene for selection and a levansucrose (sacB) 
gene for counter selection 
Wu et al.[2] 
pHSU-mxn18 mxnK gene deletion construct, in which a 5624 bp 
fragment of mxnC-mxnH was deleted in-frame 
 
pHSU-mxn48 CP-1
W
 point mutation construct in which the active 
site serine residue is exchanged with alanine 
residue (S1668A) 
this study 
pHSU-mxn49 CP-3
W
 point mutation construct in which the active 
site serine residue is exchanged with alanine 
residue (S5168A) 
this study 
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Table S2. List of primers used in this study 
Primer 
name 
Sequence (5’3’) 
Restriction   
sites  
(in bold) 
mxn54 GCGTTGATGGATCCACAGCA BamHI 
mxn55 TGTATCGCGGCCGCTCAGTGCCGCTGAACCCGAAC NotI 
mxn56 GATACAGCGGCCGCCTTTCCGAGTCCAGCAGC NotI 
mxn57 GTATCGAGCTCATCTGCTGTCCTCTGCCT SacI 
mxn70  CTTGCGCCCTGAGTGCTT  
mxn71  AACACCTCACGGTCCGAC  
mxn72 CCCATCGTCCACAGCTTC  
mxn73 GCACTACAAGCGGCTCTG  
mxn169 GATACACGATCGCACGAGTTCCGAGTCCTC PvuI 
mxn170 CTGCAGGATGAGGGCGTC  
mxn171 TCGACGCCCTCATCCTGCAGGAGTTGATGGCGGAGCTG  
mxn172 TCTATGGCGGCCGCGAGCGCGACCTTGATGAC NotI 
mxn174 GATACACGATCGGACACACACCGGAAGCTG PvuI 
mxn175 ATTCACCAGCGCGTCGAC  
mxn176 CGGCGTCGACGCGCTGGTGAATCTGAGAATCGTCC  
mxn177 TCTATGGAGCTCTTGAGCTGCAGGATGACC NotI 
mxn185 TCGCTCATCCTGCAGGA  
mxn187 CGAGTCGAGTCCCATGG  
mxn189 CAACAGCTTCCTCGACG  
mxn191 TCCCTGGTGAATCTGAGA  
mxn193 GGAGTCGACGCCGAAC  
mxn195 TCGGACTGATGAAGGGGT  
mxn205 CCTTCGGGGAGATGTTGA  
mxn206 GAAGGCCTCCACGTTCTC  
pJET1.2For CGACTCACTATAGGGAGAGCGGC  
pJET1.2Rev AAGAACATCGATTTTCCATGGCAG  
pSWU41-F GTGCAAAAAAGCGGTTAG  
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Figure S1. Schematic representation of in-frame deletion of 5.6 kb mxnK by construct pHSU-mxn18, (a), confirmation 
by Southern blot (b) and the expected fragment size after hydrolysis of wild type and mutant genomic DNA with a set 
of three restriction enzymes and a DIG-labelled 602 bp probe amplified from Mx f50 genomic DNA using the primers 
mxn79 and mxn80. M: Marker III (Roche), 1: hydrolysis with AfeI, 2: hydrolysis with BspHI, 3: hydrolysis with BglII.            
a 
b c 
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Figure S2. Schematic illustration of mutasynthesis using M. fulvus Mx X50 mutants with partially functional western 
chain assembly line. a) A culture of a CP-1W mutant was supplemented with the appropriate precursor which is 
incorporated in the subsequent biosynthesis pathway. b) A culture of a CP-4W mutant was supplemented with the 
appropriate precursor which is incorporated in the subsequent biosynthesis pathway. 
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5 Heterologous Production of Myxopyronin 
5.1 Introduction 
Myxobacteria continue to be a prolific source of anti-infectives with novel scaffolds possessing 
novel modes of action or binding sites.1–3 Myxopyronins, antibiotics belonging to the -pyrone 
class of compounds, are produced by Myxococcus fulvus Mx f50.4 They are active against several 
Gram-negative and Gram-positive bacteria as RNA polymerase (RNAP) inhibitors. In recent 
structural studies, myxopyronin was shown to interact with the RNAP switch region - the hinge 
that mediates opening and closing of the RNAP active center cleft - to prevent interaction of 
RNAP with promoter DNA.5,6 Other myxobacterial compounds, the structurally related -pyrone 
corallopyronin and the macrolactone ripostatin, are also functioning analogously to 
myxopyronin.5 Importantly, the target site at the RNAP switch region has a significant distance 
to the rifampicin binding site. Rifampicin has been used as a first-line anti-tuberculosis (anti-TB) 
drug for a few decades and the resistance to it has caused the rapid emergence of multiple drug 
resistant (MDR) and extensive drug resistant (XDR) Mycobacterium tuberculosis. Antibiotics 
like myxopyronin which target a different site on RNAP will be an alternative to combat 
rifampicin resistant bacteria and it will open up opportunities to develop broad spectrum 
antibiotics. However, myxopyronin cannot be used directly as clinical drugs for various reasons 
such as inadequate physicochemical profile. Thus, it is desirable to bioengineer myxopyronin 
biosynthetic gene cluster to achieve structural modifications with an eye towards better 
bioactivity and properties. 
 The myxopyronin gene cluster has been identified and revealed that the biosynthesis of 
myxopyronin is catalyzed by a hybrid of multimodular polyketide synthase (PKS) and 
nonribosomal peptide synthetase (NRPS). The coding region responsible for the biosynthesis of 
myxopyronin spans approximately 53 kb.7 In agreement with the previously performed 
myxopyronin feeding studies,8 the characterization of the key enzyme MxnB proved that 
myxopyronin is formed from two polyketide chains (named western and eastern chain).9 The role 
of the biosynthetic genes involved in myxopyronin formation was also investigated by directed 
mutagenesis after establishing suitable mutagenesis procedures for the native producer strain 
including a markerless in-frame deletion method based on sacB counterselection.7 However, the 
established mutagenesis procedure is a rather time-consuming process because it usually takes 
around 68 weeks to generate and verify the double crossover mutants.  
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 The increasing number of genome sequences has improved the efficiency of finding the 
responsible gene cluster for a compound of interest. However, further targeted modifications of 
the natural product or attempts to increase the production are not always feasible in the native 
producer. In order to engineer natural product biosynthesis more efficiently, heterologous 
expression of the corresponding biosynthetic gene cluster has been widely applied, especially for 
genetically limited, difficult to handle, or slow growing microorganisms such as myxobacteria, 
cyanobacteria or marine microorganisms.10–12 Various strategies have been used for heterologous 
expression, which aim to improve the yield and the structure of the natural products.13–15 Some 
examples from myxobacterial gene clusters are epothilone,16–20 soraphen,21 myxochromide S,22,23 
myxothiazol,24 and tubulysin,25 where the biosynthetic pathways have been successfully 
subcloned with innovative cloning strategies, reconstituted, engineered and expressed in 
heterologous hosts with different effect on the production yields compared to the natural 
producer.  
In the present study, we aimed to establish a heterologous production and engineering 
platform for α-pyrone antibiotics. By using a combination of directed mutagenesis, Red/ET 
recombineering, and conventional cloning strategies we managed to reconstitute the entire 53 kb 
myxopyronin biosynthetic gene cluster on one expression construct. The reconstituted gene 
cluster was then introduced into the chromosome of the related myxobacterial strain M. xanthus 
DK1622 to achieve a production level comparable to that of the natural producer. After achieving 
reconstitution of the complete set of the gene cluster as one construct; any further modification 
could be efficiently performed in E. coli by Red/ET and transformed into the heterologous host 
strain in one step. The whole process would require a shorter time than performing the 
markerless mutagenesis strategy in the native host. The obtained myxopyronin heterologous 
expression plasmid was also exploited for mutasynthesis experiments to generate myxopyronin 
analogues. 
5.2 Result and Discussion 
5.2.1 Reconstitution of the complete myxopyronin gene cluster 
Heterologous expression of complete secondary metabolite pathways in amenable host strains 
has become an important tool in natural product research and drug discovery.14 When the 
products are from relatively small biosynthetic gene clusters (<30 kb), it was often possible to 
retrieve the entire gene set from a single cosmid within a genomic library of the natural product 
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strain.13 On the other hand, many natural product biosynthetic gene clusters are larger than the 
regular insert size of common cosmid vectors. One of the strategies to overcome this size 
limitation is to use bacterial artificial chromosome (BAC) shuttle vectors for library construction 
which can accommodate inserts in excess of 100 kb. This approach has been successfully applied 
in the expression of 128 kb daptomycin biosynthetic gene cluster from Streptomyces roseosporus 
in a related streptomyces strain.26 Another strategy is termed multi plasmid approach where a 
subset of the biosynthetic gene cluster is cloned into compatible expression plasmids followed by 
their stepwise introduction and coexpression in suitable host strains.18,27 However, these 
approaches usually rely on several rounds of cloning and heterologous host modification, which 
is tedious and time-consuming.  
In the last decade, an alternative to these classical, time-consuming cloning and 
mutagenesis approaches is the reassembly of large natural product pathways on a single 
transferable vector system, by using Red/ET technology. In principle, Red/ET is an in vivo 
homologous recombination-based genetic engineering method utilized mainly in E. coli by using 
short homology arms, catalyzed by two equivalent phage protein pairs, Red/Red from  phage 
and RecE/RecT from Rac prophage, which are integrated in the E. coli K12 chromosome.28–30 
Red/ET recombination technology has greatly facilitated genetic manipulation of complex 
biosynthetic pathways by skipping many steps needed in the standard restriction/ligation genetic 
modification.29,31,32  
In most of the cases, complete biosynthetic pathways from myxobacteria or other 
microorganisms have been reconstructed and engineered by construction and screening of BAC 
or cosmid libraries, followed by Red/ET recombination for stitching and modification for the 
purpose of heterologous expression.24,25,33–35 Here we applied another strategy to reconstitute the 
complete set of mxn gene cluster without cosmid or BAC library generation. We aimed to 
subclone the entire pathway from chromosomal DNA of the producer strain via plasmid recovery 
by introducing two unique restriction sites (PacI) upstream and downstream of the gene cluster 
by two consecutive directed mutagenesis steps using previously established procedures.7 For this 
purpose, two suicide vectors pHSU-mxn16 for integration at the beginning of the cluster and 
pHSU-mxn19 for integration at the end of the cluster were constructed (Fig. 1).  
Suicide vector pHSU-mxn16 containing a ~1.2 kb homologous fragment, p15A 
replication origin (p15A ori), PacI restriction site, and a tetracycline resistance gene (tetR), was 
introduced to the upstream of the mxn gene cluster using the established directed mutagenesis7 
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procedure to obtain M. fulvus Mx f50::pHSU-mxn16 (Fig. 1A). The tetracycline resistance gene 
was introduced as the homologous fragment to transfer the expression construct into M. xanthus 
later on. The p15A ori was used in order to generate the complete biosynthetic gene cluster 
propagated at a lower copy number and to allow greater stability of DNA sequences.  
Another round of directed mutagenesis was performed to introduce the PacI restriction 
site by integrating suicide vector pHSU-mxn19 into M. fulvus Mx f50::pHSU-mxn16 through 
homologous fragment downstream of the mxn gene cluster to obtain M. fulvus Mx f50::pHSU-
mxn16::pHSU-mxn19 (Fig. 1B). The initial strategy was to digest the genomic DNA of this 
resulting mutant through PacI restriction digest and subsequently re-ligate it to achieve cloning 
of the complete mxn gene cluster in one step. Despite several attempts, this one-step subcloning 
approach was not successful, presumably due to the large size of the gene cluster. 
 
 
 
Figure 1. Strategy for subcloning myxopyronin biosynthetic pathway fragments. A) and B) Successive single cross over to 
introduce pHSU-mxn16 and pHSU-mxn19, respectively, resulting in Mx f50::pHSU-mxn16::pHSU-mxn19. The order of 
step A) and B) is not restricted; it can also be performed vice versa. Subsequent plasmid recovery to obtain C) pHSU-mxn27 
containing the first fragment and D) pHSU-mxn26 containing the third fragment. 
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 An alternative strategy was then applied to overcome the gene cluster size problem. The 
mxn gene cluster was isolated in three fragments. The first fragment, covering mxnA and 
downstream genes until half of mxnI, was achieved by restriction digest with PacI/PvuI 
(compatible cohesive ends) of chromosomal DNA from the mutant M. fulvus Mx f50::pHSU-
mxn16::pHSU-mxn19 and subsequent re-ligation to obtain pHSU-mxn27 (17.1 kb) (Fig. 1C).  
The second fragment covering the 3’-end of mxnI until and including a part of mxnJ was isolated 
using the following steps. A directed mutagenesis was performed using pHSU-mxn32 to 
introduce several restriction sites and a zeocin resistance gene (zeoR) yielding M. fulvus Mx 
f50::pHSU-mxn32 (Fig. 2). A plasmid recovery from the resulting mutant genomic DNA using 
PvuI yielded pHSU-mxn35. The zeoR was exchanged with ampR to form pHSU-mxn40 (21 kb).   
 
 
Figure 2. Subcloning strategy for the second fragment of the myxopyronin biosynthetic pathway to generate pHSU-mxn40. 
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Subsequently, the first fragment (in pHSU-mxn27) and the second fragment (in pHSU-
mxn40) were combined by Red/ET recombination (Fig. 3). pHSU-mxn40 was linearized via 
AvrII restriction digest, and the generated linear fragment was used in Red/ET recombination 
with pHSU-mxn27 to achieve pHSU-mxn41 covering mxnA-mxnJ (35.6 kb) (Fig. 3).  
  
 
Figure 3. Cloning strategy to reconstitute the complete myxopyronin biosynthetic pathway on one expression construct.  
 
To complete the mxn gene cluster reconstitution, the third fragment, covering a part of 
mxnJ and downstream genes until mxnM was isolated from the mutant M. fulvus Mx f50::pHSU-
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mxn16::pHSU-mxn19 DNA through EcoRV restriction digest and re-ligation to obtain pHSU-
mxn26 (31.6 kb) (Fig. 1D). In order to enable complete cluster stitching via conventional cloning 
strategy, a unique restriction site SpeI was introduced at the 5’-end of mxnK (pHSU-mxn26) by 
Red/ET recombination to form pHSU-mxn31 (26.3 kb) (Fig. 3).   
Finally, the complete mxn gene cluster was stitched together by digesting pHSU-mxn41 
(mxnA-mxnJ) and pHSU-mxn31 (mxnK-mxnM) with SpeI/PacI restriction enzymes and ligating 
the linear fragments to achieve pHSU-mxn42. The resulting construct, pHSU-mxn42, contains 
the complete mxn biosynthetic pathway on a plasmid backbone harboring a p15A ori and tetR 
resistance gene. In order to enable selection in a modified M. xanthus DK1622 host strain that 
already contains a tetR marker, kanR was lastly introduced to pHSU-mxn42 to form pHSU-mxn43 
(Fig. 3). To confirm the individual cloning steps, each of the constructs that were obtained by 
recombination experiments including conventional cloning experiments were digested with a set 
of restriction enzymes or confirmed by sequencing, e.g. to exclude mutations within the 
homologous gene cluster fragments used for recombination. 
 
5.2.2 Heterologous Expression of the Myxopyronin Gene Cluster in M. xanthus 
 In the last 15 years, several myxobacterial gene clusters have been heterologously expressed in 
different host strains, such as myxochromide, myxothiazol, and tubulysin in Pseudomonas putida 
and myxobacterium M. xanthus,22,25,36 epothilones in Streptomyces coelicolor, M. xanthus, and E. 
coli,16,18,19,34 and soraphen in Streptomyces lividans (S. lividans).21 Generally, the heterologous 
host is selected based on its characteristic compatibility in producing the compound of interest.13 
In particular, PKS and NRPS must be post-translationally modified for their activity, 37 therefore 
the heterologous host must carry a phosphopantetheinyl transferase needed for the modification 
of carrier proteins. In addition the heterologous host must provide activated short-chain 
carboxylic acids and/or amino acids for secondary metabolite production and must be essentially 
resistant/not sensitive to the produced compound. Streptomycetes and related actinomycetes are 
so far the most extensively used systems for heterologous expression in general38 because they 
provide necessary machinery for polyketide synthesis.  
E. coli is another host strain option because it is easy to handle and genetically accessible. 
The disadvantages of E. coli are the need of strain engineering before being utilized in the 
polyketide biosynthesis (lacking postranslational activation of the carrier protein) and the 
different GC content compared with that of most biosynthetic gene clusters. In addition to GC 
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content factor, codon usage of the genes of interest, precursor production, functionality of native 
promoter in the heterologous host strain, and the size of the introduced gene clusters are crucial 
for successful production of secondary metabolites in the heterologous host.13,39  
 In addition to streptomycetes and E. coli, pseudomonads have also been used as 
heterologous hosts. Pseudomonads possess the combination of favorable properties from 
streptomycetes and E. coli. However, pseudomonads similarly to E. coli are unable to produce 
methylmalonyl-CoA which is often used as extender unit in polyketides.40,41 While 
pseudomonads require additional metabolic engineering of the host strain,36 the myxobacterium 
M. xanthus has been successfully utilized for heterologous expression of several myxobacterial 
compounds such as epothilone,16 myxothiazol,24 and tubulysin25 without additional modification.  
Since M. xanthus contains the necessary properties for polyketide synthesis and is 
phylogenetically close to the native producer of myxopyronin M. fulvus, it was chosen as a model 
for a myxopyronin heterologous expression system. In particular, a mutant of M. xanthus 
DK1622 in which the myxochromide A gene cluster has been deleted (M. xanthus DK1622 
ΔmchA::tet, Wenzel, unpublished result) was employed. Myxochromide A is one of the major 
compounds produced by M. xanthus DK1622, and its gene cluster deletion was expected to 
provide a greater precursor pool for production of other secondary metabolites. In brief, the 
myxochromide A gene cluster was completely deleted from M. xanthus DK1622 and replaced by 
a tetracycline resistance gene which will serve as the target site for the chromosomal integration 
for the myxopyronin gene cluster.   
The generated expression construct (pHSU-mxn43, approximately 57 kb), containing the 
complete mxn gene cluster, was transferred to M. xanthus DK1622 ΔmchA::tet by 
electroporation (Fig. 4A). After 6 days, the colonies obtained on soft agar plates containing the 
kanamycin resistance gene were transferred into liquid medium to isolate the genomic DNA. The 
correct integration of the cluster was then verified by PCR using a set of primers (Fig. 4B). As 
expected, the amplification products could be detected only in the mutant clones containing the 
mxn biosynthetic genes when compared to the control reaction (M. xanthus DK1622ΔmchA::tet). 
The correct clone was grown in culture medium and the culture extract was analyzed by LC-MS. 
Myxopyronin A and B heterologous production was confirmed in comparison to the production 
of myxopyronins in the native producer M. fulvus (Fig. 4C). Under the applied culture conditions 
at 30C, myxopyronin production reached around 5 mg/L in 3 days which is in the comparable 
range of the native producer, at 5-10 mg/L in the same cultivation time.4  
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Figure 4. Transformation of the myxopyronin biosynthesis gene cluster into M. xanthus, PCR analysis and HPLC analysis. 
A) Illustration of the transfer of pHSU-mxn43 into M. xanthus DK1622ΔmchA::tet; B) PCR analysis using primer sets 
P4/P2, P3/P1, and P4/P1. Number 1 is the resulting mutant M. xanthus DK1622ΔmchA::tet::pHSU-mxn43 and number 2 is 
the control M. xanthus DK1622ΔmchA::tet; C) HPLC analysis at UV=310 nm for the control M. xanthus 
DK1622ΔmchA::tet, the resulting mutant and the native producer M. fulvus Mx f50. The peaks at 6.7 min and 7 min, are 
myxopyronin A and its isomer, respectively. The peaks between 7.3-7.4 min are keto-enol tautomers of myxopyronin A,  
myxopyronin B, and myxovirescin (from M. xanthus DK1622).  
 
Other myxobacterial biosynthetic pathways that have been expressed in M. xanthus show 
different effects on the production yields: epothilone ( 1 fold, 23 mg/L ),16,42 myxochromide S 
C) 
A) 
B) 
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( 125 fold, 1 g/L),34 myxothiazol ( 6 fold, 60 mg/L),24 and pretubulysin (↓ 5-8 fold, 0.19 
mg/L).25 The tubulysin heterologous expression system showed ~20-fold decrease in production 
yields which might be caused by the interruption of coupled translation within the gene cluster.25 
The other myxobacterial biosynthetic gene clusters responsible for production of epothilone, 
myxochromide S, and myxothiazol showed comparable or significant increase in production 
yields when heterologously expressed in M. xanthus. The successful myxopyronin heterologous 
expression in M. xanthus further demonstrates the suitability of this host for the production of 
myxobacterial secondary metabolites.  
5.2.3 Genetic Modification of the Myxopyronin Heterologous Expression System 
In order to generate myxopyronin analogues, we recently established a mutasynthesis 
system in the native producer M. fulvus. In this system, the production of myxopyronin’s western 
part of the molecule was blocked by in-frame deletion of 5.6 kb mxnK gene and subsequently 
various mutasynthons were fed to the mutant cultures (see details in Chapter 3). However, fast 
degradation of the -keto N-acetylcysteamine (NAC) in the culture and possible difficulties 
regarding cell penetration of the substrates have made the attempts to isolate analogues 
unsuccessful so far.  
The heterologous expression system described here provides the basis for engineering the 
mxn biosynthetic pathway to generate novel analogues. Based on the Red/ET recombineering 
technology,29 in-frame deletions at any desired position within the expression construct are 
feasible. As a proof of concept, we aimed to perform mutasynthesis in the heterologous system 
by deleting an identical mxnK fragment as deleted in the native producer. For this, an ampicillin 
resistance gene (ampR) with 42 bp homology arms to enable homologous recombination was 
amplified by PCR. After replacement of the target fragment at mxnK against the selection marker 
ampR in pHSU-mxn43 by Red/ET recombination, the ampR gene was removed by AflII restriction 
digest and re-ligated to generate pHSU-mxn46 (Fig. 5).  
The resulting construct was subsequently transformed into M. xanthus 
DK1622ΔmchA::tet, and deletion of the fragment was confirmed by PCR analysis. As expected, 
M. xanthus DK1622ΔmchA::tet::pHSU-mxn46 was not able to produce myxopyronin. This 
mutant was then used for mutasynthesis experiments revealing similar results compared to the 
mutasynthesis studies in the native producer strain. Although in principle the mutasynthesis 
system also works in the heterologous host, further work to improve the yield and to enable 
isolation of analogues remains to be performed. 
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Figure 5. Cloning strategy to modify the myxopyronin heterologous expression system  
 
5.3 Conclusions and Perspectives 
Myxobacterial -pyrone antibiotics were recently characterized as RNAP inhibitors with 
a new target site, representing promising candidates for the development of broad-spectrum 
antibiotics. In order to further exploit these natural products, sufficient compound material and 
novel structural derivatives have to be generated. Here we aimed to establish an efficient and 
flexible biotechnological production platform for -pyrone antibiotics by combining directed 
mutagenesis, Red/ET and conventional cloning techniques to reconstitute the complete 
myxopyronin gene cluster without cosmid or BAC library generation. The assembled gene 
cluster was then transferred to M. xanthus, resulting in the heterologous production of 
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myxopyronins. As a further proof of principle, the heterologous expression system was then 
engineered to perform the mutasynthesis studies as already conducted in the native producer. 
The current results presented in this chapter have set up the basis for pathway engineering 
to generate not only myxopyronin derivatives but also other -pyrones such as corallopyronin 
derivatives. To date, the corallopyronin producer is not yet amenable for genetic manipulation. 
Therefore, utilizing the presented heterologous expression platform, corallopyronin can be 
produced in a heterologous host by constructing a “hybrid” of myxopyronin (mxnA-mxnI) and 
corallopyronin (corJ-corO) genes (Fig. 6). Altogether, this study has opened up opportunities to 
facilitate -pyrone analogue generation in order to improve the pharmacokinetic properties and 
to gain more information about the structure-activity relationship (SAR) with RNAP for 
developing broad spectrum therapeutic agents. 
               
 
Figure 6. A) Myxopyronin gene cluster, B) Illustration of the “hybrid” cluster of myxopyronin and corallopyronin which is 
expected to result in corallopyronin A production in heterologous host, and C) Corallopyronin gene cluster 
A) 
B) 
C) 
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5.4 Experimental Section 
 
Bacterial strains and culture conditions 
Bacterial strains and plasmids used during this study are listed in Table S1. Myxococcus fulvus 
Mx f50 wild type and mutants were grown in Casitone Yeast (CY) medium (0.3 % casitone, 0.1 
% yeast extract, 0.1 % CaCl2 x 2 H2O) supplemented with 5 x 10
-4  g L-1 vitamin B12 after 
autoclaving. For liquid cultures, the strains were grown at 30 C and 105 rpm on an orbital 
shaker and harvested after 3 days. E. coli strains were cultured in lysogeny broth (LB) medium (1 
% tryptone, 0.5 % yeast extract, 0.5 % NaCl) at 37 C. Appropriate antibiotic at a final 
concentration of 100 g ml-1 ampicillin, 50 g ml-1 kanamycin, 5 g ml-1 tetracycline or 6.25 g 
ml-1 oxytetracycline was added whenever necessary. 
 
DNA Isolation and PCR  
M. fulvus Mx f50 genomic DNA was prepared either via the Phenol Chloroform Isoamyl alcohol 
extraction method43 or by using the Gentra Puregene Genomic DNA Purification Kit (Qiagen) 
according to the manufacturer’s protocol. Plasmid DNA was either purified by standard alkaline 
lysis43 or by using the GeneJet Plasmid Miniprep Kit (Thermo Fisher Scientific). The PCR 
reactions were carried out in a peqSTAR 96 Universal Gradient thermocycler (Peqlab) or 
Mastercycler® pro (Eppendorf) using Phusion polymerase or Taq DNA polymerase (Thermo 
Fisher Scientific): initial denaturation (3 min, 95 C); 30 cycles of denaturation (30 s, 95 C), 
annealing (30 s, 53 or 57 C) and elongation (varied based on PCR product length 1 kb/min, 72 
C); and final extension (10 min, 72 C). DNA fragments were separated by agarose gel 
electrophoresis and isolated using the peqGold Gel Extraction (Peqlab). The PCR products were 
cloned into pJET1.2 blunt vector (Thermo Fisher Scientific) or pCRII-TOPO vector (Invitrogen) 
and sequenced using the primers pJET1.2For/pJET1.2Rev or M13For/M13Rev, respectively. 
Generated primer sequences are listed in Table S2. 
 
Reconstitution of the Myxopyronin Biosynthetic Gene Cluster 
To establish a heterologous expression system for the myxopyronin biosynthetic pathway (1) the 
pathway genes were first subcloned in fragments and (2) then the expression construct was 
generated, which was later transferred into suitable host strain.  
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(1) Subcloning of pathway fragments 
Three different suicide plasmids were constructed for integration at different sites of the 
myxopyronin pathway region: (1) Tn5 promoter was amplified by PCR using primers mxn33/ 
mxn41 with pCRII-TOPO vector as a template to obtain fragment 1.  A 1191 bp fragment of 
mxnA was amplified from M. fulvus Mxf50 genomic DNA by PCR using primers 
mxn42/mxn30 to obtain fragment 2. Fragment 1 and fragment 2 were linked together using 
overlap PCR with primers mxn33/mxn30. The joined fragments were then subcloned into 
pJET1.2 vector to obtain plasmid pTn5-mxnA/pJET. In parallel, a minimal linear cloning 
vector p15A-Tet was obtained by PCR using primers mxn52/mxn53 with pACYC184 as a 
template. pTn5-mxnA/pJET plasmid was  hydrolyzed with PacI/EcoRV and ligated to the 
PacI/PvuII hydrolyzed cloning vector p15A-Tet to generate pHSU-mxn16; (2) A 1491 bp 
fragment right after the 3’-end of myxopyronin A gene cluster was amplified from M. fulvus 
Mxf50 genomic DNA using primers mxn64/mxn65. The amplified fragment was cloned into 
pCRII-TOPO vector to create pHSU-mxn19; (3) A 1380 bp fragment of mxnJ was amplified 
from M. fulvus Mxf50 genomic DNA using primers mxn124 and mxn125. A zeocin 
resistance cassette was amplified using primers mxn128/mxn129 with pCDNA-Zeo as a 
template and it was subcloned into a minimal linear cloning vector p15A-Tet obtained by 
PCR using primers mxn126/mxn127 with pACYC184 as a template to construct p15A-Tet-
Zeo plasmid. The 1380 bp fragment of mxnJ was then hydrolyzed with PvuI and 
subsequently cloned into p15A-Tet-Zeo hydrolyzed with the same restriction enzyme to 
create pHSU-mxn32. 
First, pHSU-mxn16 was transformed into M. fulvus Mx f50 to obtain mutant Mx 
f50::pHSU-mxn16. For genotypic analysis of the single cross-over, a set of different PCRs 
using the primer combinations mxn60/p15A-Tet1 and mxn61/p15A-Tet2 was carried out to 
verify the correct integration of the inactivation plasmid resulting at the expected PCR 
product size 1342 bp and 1473 bp, respectively. Subsequently, the next single crossover was 
performed by transforming pHSU-mxn19 into Mx f50::pHSU-mxn16 to obtain Mx 
f50::pHSU-mxn16::pHSU-mxn19. The mutant was confirmed by PCR using the primer 
combinations mxn94/pTOPO-out and mxn95/pTOPO-in resulting at the expected PCR 
product size 1720 bp and 1594 bp, respectively. Further confirmation of this mutant was also 
performed by Southern Blot analysis (Fig. S1). Second, pHSU-mxn32 was transformed into 
M. fulvus Mxf50 to obtain mutant Mx f50::pHSU-mxn32. For genotypic analysis of the single 
crossover, a set of different PCRs using the primer combinations mxn136/p15A-Tet1 and 
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p15A-Tet2/mxn137 was carried out to verify the correct integration of the inactivation 
plasmid resulting at the expected PCR product size 1992 bp and 1527 bp, respectively. 
The recovery of pathway fragments was performed as followed: genomic DNA of mutant 
Mx f50::pHSU-mxn16::pHSU-mxn19 was hydrolyzed with EcoRV and subsequently re-
ligated to generate pHSU-mxn26. Independently, it was also hydrolyzed with PacI/PvuI and 
subsequently re-ligated to generate pHSU-mxn27. The genomic DNA of mutant 
Mx f50::pHSU-mxn32 was hydrolyzed with PvuI and then re-ligated to generate pHSU-
mxn35. An ampicillin cassette was amplified by PCR using primers mxn147/mxn148 with 
pJET1.2 vector as a template. pHSU-mxn35 was hydrolyzed with AflII/PacI to replace the 
zeocin cassette with the amplified ampicillin cassette hydrolyzed with the same set of 
restriction enzymes to generate pHSU-mxn40. 
 
(2) Generation of an expression construct harbouring the complete mxn pathway  
The cloning strategy for the generation of an expression construct harbouring the complete 
pathway is shown in Figure 3. First, the western chain biosynthesis pathway was completed 
by integration of the 18.5 kb AvrII fragment from pHSU-mxn40 into pHSU-mxn27 via 
Red/ET recombination. The plasmid pHSU-mxn27 was first transformed to E. coli GB05-
Red and subsequently the cells were electroporated with pHSU-mxn40 linearized fragment. 
The colonies were selected on ampicillin and tetracycline. The expected Red/ET 
recombination product (pHSU-mxn 41) was verified by restriction analysis with a set of 
enzymes. 
Another round of Red/ET recombineering was performed to exchange the 6.2 kb 3’-end of 
mxnI in pHSU-mxn26 with a chloramphenicol resistance (cmR) cassette to generate pHSU-
mxn31. The ~1 kb chloroamphenicol resistance cassette flanked by homologous fragments 
was amplified with primers mxn122/mxn123. The plasmid pHSU-mxn26 was first 
transformed to E. coli HS996-Tet and subsequently the cells were electroporated with linear 
fragment (mxn122/mxn123 PCR product). The colonies were selected on kanamycin and 
chloroamphenicol. The expected Red/ET recombination product (pHSU-mxn 31) was 
verified by restriction analysis with a set of enzymes. 
Both, pHSU-mxn31 and pHSU-mxn41, were then hydrolyzed with SpeI/PacI to ligate the 
mxnK-M fragment into pHSU-mxn41 to generate pHSU-mxn42. A kanamycin resistance 
cassette was amplified from pCRII-TOPO vector as a template using primers 
mxn144/mxn145. The ~1 kb amplified cassette was then subcloned into pJET1.2 vector to 
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obtain pHSU-mxn37. Both, pHSU-mxn37 and pHSU-mxn42 were hydrolyzed with PacI to 
ligate the kanamycin resistance cassette into pHSU-mxn42 to generate pHSU-mxn43. 
 
(3) Transformation of the Expression Construct into Myxococcus xanthus 
The expression construct pHSU-mxn43 described in the section above and shown in Figure 
4a was transformed into the expression host M. xanthus DK1622ΔmchA-tet by 
electroporation. M. xanthus DK1622ΔmchA-tet was grown in a flask with CTT medium (1 % 
casitone, 10 mM Tris buffer pH 7.6, 1 mM KH2PO4 pH 7.6, 8 mM MgSO4 with final pH 7.6) 
at 30 C until an OD600 between 0.60.9 was reached. Cells were then harvested from 2-4 ml 
culture by centrifugation at 12.500 rpm for 1 min at room temperature. After two washing 
steps with 1 ml of H2O at room temperature, cells were resuspended in 65 µl of H2O. Plasmid 
DNA (1-2 µg) was mixed with the cell suspension, and electroporation was carried out under 
the following conditions: 25 µF, 400 Ω, 650 V using 0.1 cm electroporation cuvettes and a 
GenePulser XCell device (Bio-Rad). 1 ml of CTT medium was directly added to the cell 
suspension immediately after electroporation and the cells were transferred into a 2 ml 
centrifuge tube. After 5-6 h cultivation at 30 C and 800 rpm on a thermomixer, the cells 
were mixed with 2 ml of CTT soft agar (CTT medium with 0.7 % agar) and plated on CTT 
agar plates (CTT medium with 1.7 % agar) supplemented with 50 µg ml-1 kanamycin. The 
plates were incubated at 30 C for 5-10 days until colonies became visible. Obtained clones 
were cultured in 1 mL of CTT containing 50 µg ml-1 kanamycin for 23 days. The genomic 
DNA was prepared in the same manner as M. fulvus Mx50 genomic DNA preparation. The 
genomic DNA was then used for PCR verification using primers with the expected size in the 
brackets: InMchP4/P2 (1635 bp), P3/InMchP1 (1609 bp), and InMchP4/InMchP1(1461 bp) 
(Fig. 4B). 
 
Genetic Modification of the mxn Gene Cluster in E. coli for Mutasynthesis Purpose in M. 
xanthus  
The reconstituted mxn gene cluster pHSU-mxn43 was initially transformed into E. coli GB05-
Red. A linear fragment (1171 bp) containing ampicillin resistance cassette (ampR) and 
homologous fragment was amplified from pJET1.2 vector with primers mxn153/mxn154. 
Red/ET recombineering was performed to exchange the 5.6 kb of mxnK in pHSU-mxn43 with an 
ampR cassette to generate pHSU-mxn45. pHSU-mxn45 was then hydrolyzed with AflII to remove 
ampR cassette and was subsequently re-ligated to generate pHSU-mxn46. pHSU-mxn46 was 
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transformed into M. xanthus DK1622ΔmchA-tet as described above to achieve M. xanthus 
DK1622ΔmchA-tet::pHSU-mxn46. The mutant was verified with PCR using primers 
mxn68/mxn72 and mxn68/mxn71 with the expected size of 1478 bp and 2326 bp, respectively.  
 
Phenotypic analysis of the mutant strains 
Well-grown pre-cultures of M. fulvus Mx f50 and the generated expression strain M. xanthus 
DK1622ΔmchA-tet::pHSU-mxn43 were used to inoculate 50 ml of CY and CTT production 
medium (1 % inoculum), respectively, in 300 ml baffled flasks. After cultivation for 2 days at 30 
C and 105 rpm, the cultures were harvested by centrifugation. Myxopyronin A is almost 
exclusively present in the supernatant, which was extracted twice with an equal volume of ethyl 
acetate. After evaporation of the organic phase, the residue was dissolved in 1 ml of methanol. A 
5 µl aliquot of the extract was analyzed by HPLC-MS (Thermo Ultimate 3000 RSLC, coupled to 
a Bruker Daltonics Amazon ESI-MS ion trap instrument) operating in positive ionization mode. 
Compounds were separated on Waters Acquity BEH C18 (50 x 2.1 mm; 1.7 µm particle 
diameter; flow rate 600 µl/min and 45 C)  with a mobile phase of water/acetonitrile each 
containing 0.1 % formic acid, using a gradient from 5 % - 95 % acetonitrile over 9 min. 
Detection was performed by both diode array and ESI-MS. For high resolution mass 
spectrometry analysis, measurements were performed on a Dionex Ultimate 3000 RSLC system 
using a Waters BEH C18 column (50 x 2.1 mm, 1.7 µm dp) by injecting 5 µl of the methanolic 
extract. Separation was achieved by the same gradient as above with 0.33 min isocratic step at 5 
% B. UV and MS detection were performed simultaneously. Coupling the HPLC to 
the MS was supported by an Advion Triversa Nanomate nano-ESI system attached to a Thermo 
Fisher Orbitrap. Mass spectra were acquired in centroid mode ranging from 200-2000 m/z at a 
resolution of R = 30000. 
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5.5 Supporting Information 
 
Table S1. List of strains and plasmids used in this study 
Strain/Plasmid Characteristics Reference 
E.coli strains 
HS996 Host for general cloning Invitrogen 
SCS110 Host for cloning to prepare plasmid DNA, 
free of Dam or Dcm methylation 
Stratagene 
GB05Red Host for Red/ET cloning 44 
Myxococcus strains 
M. fulvus Mx f50 Myxopyronin producing wild-type strain 4 
M. fulvus Mxf50::pHSU-
mxn16:: pHSU-mxn19 
 
Mxf50 with integrated constructs 
containing 1191 bp mxnA under the control 
of Tn5 promoter upstream of mxn gene 
cluster and 1591 bp homologous fragment 
downstream of the mxn gene cluster. Both 
constructs contain several restriction sites 
for the purpose of recovering the mxn gene 
cluster 
 
this study 
M. fulvus Mxf50::pHSU-
mxn32 
 
Mxf50 with integrated construct containing 
1378 bp homologous  fragment of mxnJ 
with zeoR and p15A origin for the purpose 
of recovering part of mxn gene cluster 
this study 
M. xanthus 
DK1622ΔmchA::tet 
M. xanthus DK1622 with deleted 
myxochromide A (mchA) gene cluster and 
integrated tetracycline resistance gene 
Wenzel 
(unpublished 
result) 
Plasmids  
 
pSWU41 
 
Vector contains a neomycin 
phosphotransferase (nptII) gene for 
selection and a levansucrose (sacB) gene 
for counter selection 
45 
pKC1132 Vector contains an apramycin gene for 
selection 
46 
pACYC184 Vector contains p15A origin of replication, 
tetracycline gene, and chloroamphenicol 
for selection 
47 
pCRII-TOPO Vector contains pUC origin of replication, 
kanamycin and ampicillin genes for 
selection 
Invitrogen 
pHSU-mxn16 Vector for the introduction of restriction 
sites into the 5’region of mxn gene cluster 
containing 1214 bp fragment of mxnA 
under p15A ori and tetR 
this study 
pHSU-mxn19 pCRII-TOPO vector containing external 
~1.5 kb downstream mxn gene cluster to 
this study 
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 introduce restriction sites NheI, NdeI, SspI, 
and PacI into the 3’region of mxn gene 
cluster  
pHSU-mxn26 Vector with the 27.6 kb fragment (third 
fragment) recovered from the chromosomal 
DNA of the mutant M. fulvus 
Mxf50::pHSU-mxn16:: pHSU-mxn19 
digested by EcoRV in pCRII-TOPO  
this study 
pHSU-mxn27 Vector with the 17.1 kb fragment (first 
fragment) recovered from the chromosomal 
DNA of the mutant M. fulvus 
Mxf50::pHSU-mxn16:: pHSU-mxn19 gene 
cluster digested by PacI and PvuI in p15A-
TetR  
this study 
pHSU-mxn31 A construct containing mxnK-mxnM with 
cmR in pCRII-TOPO (26.3 kb)  
this study 
pHSU-mxn32 A construct containing 1378 bp 
homologous fragment of mxnJ with zeoR 
and p15A origin  
this study 
pHSU-mxn35 A construct obtained by plasmid recovery 
from M. fulvus Mxf50::pHSU-mxn32 by 
PvuI digestion consisting of fragment of 
mxnI and complete mxnJ (19.9 kb) 
this study 
pHSU-mxn37 A construct containing kanR with flanking 
PacI restriction sites at 5’ and 3’ ends to be 
inserted to the 3’ end of mxn gene cluster 
through PacI restriction site (pHSU-
mxn42).  
this study 
pHSU-mxn40 A construct containing fragment of mxnI 
and complete mxnJ from pHSU-mxn35 
where the zeoR exchanged with ampR. This 
is the second fragment in the mxn gene 
cluster reconstitution. 
this study 
pHSU-mxn41 A construct containing mxnA-mxnJ with 
tetR, ampR under Tn5 promoter and p15A 
ori (35.6 kb) 
this study 
pHSU-mxn42 A construct containing mxnA-mxnM with 
tetR under Tn5 promoter and p15A ori (56 
kb) 
this study 
pHSU-mxn43 A construct containing mxnA-mxnM with 
tetR, kanR, under Tn5 promoter and p15A 
ori (56.9 kb) 
this study 
pHSU-mxn45 A construct containing mxnA-mxnM  (Δ5.6 
kb of mxnK) with tetR, kanR, ampR under 
Tn5 promoter and p15A ori (52.3 kb) 
this study 
pHSU-mxn46 A construct containing mxnA-mxnM  (Δ5.6 this study 
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kb of mxnK) with tetR, kanR under Tn5 
promoter and p15A ori (51.3 kb) 
 
 
Table S2. List of primers used in this study 
Primer 
name 
Sequence (5’3’) 
Restriction   
sites     
(in bold) 
mxn9 GTCAGACATATGAACAACAGCGGT  
mxn10 CGTCGTAAGCTTTCAGTAGGTGAAAACCA  
mxn30 TGCTTAATTAATATT CATATG 
GCTAGCGAGCTCCTGGATGGCCTT 
PacI fused 
with SspI, 
EcoRV, NheI 
mxn33 CAGGTAGATATCTGGACAGCAAGCGAACC EcoRV 
mxn41 AATCTGTACCTCCTTATCCTGTCTCTTGATCAG
AT 
 
mxn42 CAAGATCTGATCAAGAGACAGGATAAGGAGGT
ACAGATTATGACTTTCACCGTCGTT 
 
mxn52 GATACACAGCTGTCCCTCCTGTTCAGCTAC PvuII 
mxn53 ATCTTAATTAAGGACGCGATGGATATGTT PacI 
mxn60 TGCCATGAGCAGACAGTTA  
mxn61 CGGGTGGTTGATATCGTG  
mxn64 GCTGAGACGGTCTTCCTC  
mxn65 TGCTTAATTAATATT CATATG 
GCTAGCACGCGATTCACTGTCTCA 
PacI fused 
with SspI, 
EcoRV, NheI 
mxn68 CAACATCTCGCCGAGTGA  
mxn71 AACACCTCACGGTCCGAC  
mxn72 CCCATCGTCCACAGCTTC  
mxn94 TCACGGCGAAGCACATCC  
mxn95 AGGAGGCAGGGTCCGAAT  
mxn122 CCTCTAGATGCATGCTCGAGCGGCCGCCAGTGT
GATGGATCTTAAGTACCTGTGACGGAAGATCA
C 
AflII 
mxn123 AAGCCACCGCCTCCCGTGAGGACCCAGGCTTC
TCGTGGGCACTAGTGGGCACCAATAACTGCCT
T 
SpeI 
mnx124 CAATACGATCGCTGGACTGGTGAAG  
mxn125 TGCTACTTAAG TTATCA 
ACTAGTCATGGCTTCGCTCCCGCC 
AflII, STOP 
codon, SpeI 
mxn126 GATACACCTAGGTCCCTCCTGTTCAGCTAC AvrII 
mxn127 TCAGGTCCTAGGGGACGCGATGGATATGTT AvrII 
mxn128 ACATCGCCTAGGCGCGCCCTGAGCGCCCTGCG
GAACAAGGAGTGTGATGCGGCGATCGGACAT
ACTTAAGGGATCTGATCAGCACGTG 
AvrII, PvuI, 
AflII 
mxn129 TCTATGCCTAGGTGCGCAAACCAACCCTTGGC AvrII 
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AGAACATATCCATCGCGTCCTTAATTAATCAGT
CCTGCTCCTCGGC 
mxn136 AACATCGGCCACCTGGAG  
mxn137 AGGACCCAGGCTTCTCGT  
mxn147 TATGTCCTTAAGATAATTCGGCTGCAGGGG AflII 
mxn148 TATCTTAATTAATTACCAATGCTTAATCAGTG PacI 
mxn153 CGAGGCGGGCGGCGATCAGCTCGTTCGGGTTC
AGCGGCACCTGACTTAAGATAATTCGGCTGCA
GGGG 
AflII 
mxn154 CGGGAGCACCCACGGCGCGAGCCGCTGCTGGA
CTCGGAAAGGCTTAAGTTACCAATGCTTAATC
AGTG 
AflII 
InMchP1 CGAGCAATCCGCTATTGGC  
InMchP4 CTGTGTCCTTCTGCGACGC  
M13For GTAAAACGACGGCCAG  
M13Rev CAGGAAACAGCTATGAC  
P2 (p15A-
rev-mxnA) 
TCGGTTCAAAGAGTTGGTAGC  
P3 (KanInt5) GAGAACCTGCGTGCAATC  
p15A-Tet1 GGAGAACTGTGAATGCGC  
p15A-Tet2 ACTCCGCTAGCGCTGATG  
pJET1.2For CGACTCACTATAGGGAGAGCGGC  
pJET1.2Rev AAGAACATCGATTTTCCATGGCAG  
pTOPO-in CCTCTAGATGCATGCTCGAG  
pTOPO-out TTGGTACCGAGCTCGGATCC  
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Figure S1. A) Schematic representation of successive single crossover integration of constructs pHSU-mxn16 and pHSU-
mxn19 into M. fulvus Mx f50; B) confirmation of constructs integration by Southern blot; C) the expected fragment size 
after hydrolysis of wild type and mutant genomic DNA with a set of restriction enzymes and hybridization with a DIG-
labelled 1017 bp probe (mxnB marked in black, in panel A) amplified from Mx f50 genomic DNA using the primers mxn9 
and mxn10. M: Marker III (Roche).   
B) 
C) 
A) 
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6 Discussion and Perspectives 
6.1 General Scope of the Present Work 
Natural products, especially microorganism-derived compounds, have been invaluable 
resources in the discovery and development of bioactive anti-infectives. The present thesis 
deals with the identification, elucidation, and engineering of the biosynthetic pathway leading 
to the natural product family of myxopyronins from Myxococcus fulvus Mx f50. Detailed 
biochemical and structural characterizations were carried out for the key enzyme responsible 
for the formation of the -pyrone ring in myxopyronins. Moreover, synthetic biotechnology 
tools were applied to improve the production of myxopyronin and to generate novel 
myxopyronin analogues. 
6.2 Myxopyronin biosynthesis in Myxococcus fulvus Mx f50 
The biosynthetic machineries for secondary metabolites are usually encoded by a set of genes 
organized in so-called ‘biosynthetic gene clusters’ within the bacterial chromosomes. This 
arrangement of the genes facilitates the identification of complete natural product pathways, 
as well as the cloning and analysis of both the pathways and their products.1 The rapid 
advancement in sequencing technologies such as high-throughput next generation sequencing 
have made the identification and analysis of natural product encoding gene clusters in 
sequenced genomes readily accessible.2,3 Nevertheless, myxobacterial genome sequencing is 
still quite challenging due to its large genome size (approximately 9 Mbp or more), GC rich 
sequence and high amount of repetitive sequences.   
 Many microbial natural products are biosynthesized by polyketide synthases (PKS) 
and/or nonribosomal peptide synthetase (NRPS) pathways. In recent years, many 
bioinformatics mining tools have been developed to detect putative genetic blueprints for 
secondary metabolite biosynthesis based on microbial genome sequences. For example, 
antiSMASH,4 ClustScan,5 CLUSEAN,6 SBSPKS,7 and SMURF8 are tools for the 
identification and/or analysis of the enzymatic domains in multi-modular PKS and/or NRPS. 
Myxobacteria have giant chromosomes as exemplified by Myxococcus xanthus (9.1 Mbp),9 
Stigmatella aurantiaca (10.3 Mbp),10 Sorangium cellulosum (13.0 Mbp),11 and Haliangium 
ochraceum (9.4 Mbp).12 More than 8.5% of the M. xanthus genome is dedicated to secondary 
metabolism, a higher percentage than observed in actinomycetal secondary metabolite 
producers such as Streptomyces coelicolor (4.5%) or Streptomyces avermitilis (6.6%).13 For 
instance, M. xanthus chromosome contains 18 secondary metabolite biosynthetic gene 
clusters encoding PKS and/or NRPS megasynthetases. Through studies such as mutagenesis 
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experiments, compound isolation, and proteome studies, 11 out of 18 PKS/NRPS gene 
clusters could be linked to the corresponding gene clusters (e.g. myxovirescin, myxalamid, 
myxochelin, myxochromide, DKxanthenes).13–17 The additional seven pathways might be 
silent clusters or their products might not yet have been detected under laboratory conditions. 
For S. cellulosum So ce56, in silico analysis showed 13 regions of the chromosome encoding 
for proteins containing PKS and/or NRPS domains. However, only four secondary 
metabolites readily identified (etnangien, flaviolin, myxochelin, and chivosazol) in the culture 
extract while the products of the other biosynthetic pathways yet to be determined.11 These 
two examples reveal that the metabolic potential of M. xanthus and S. cellulosum is much 
richer than was observed from traditional fermentation studies. Taken together, the 
established high throughput sequencing technologies and bioinformatics tools have built an 
important basis for genome mining approaches. This platform will facilitate exploitation of 
the biosynthetic capacity of natural product producers not only in identifying new natural 
products but also deciphering the biosynthesis of already known compounds. 
In this study, Illumina HiSeq sequencing system was used to generate the genome 
sequence of M. fulvus Mx f50. To identify the myxopyronin (mxn) gene cluster, the genome 
sequence was screened for gene loci encoding putative polyketide synthase (PKS)/ 
nonribosomal peptide synthetase (NRPS) pathways with high similarity to the corallopyronin 
(cor) biosynthetic pathway.18 Myxopyronin is synthesized from two separate chains (western 
and eastern chains), which are derived from a PKS/NRPS system. The eastern chains of 
myxopyronin and corallopyronin are identical, thus the sequence similarity of mxnI/mxnJ and 
corI/corJ, which are responsible for the biosynthesis of eastern chains is very high. The 
myxopyronin western chain is considerably shorter than that of the corallopyronin structure. 
A detailed comparison of both pathways was performed in silico and the structural 
differences between the two compounds families could be explained (Fig.1).18,19 Although the 
primary sequence information is often available, in silico analysis alone is not sufficient to 
elucidate the role of certain genes in the biosynthetic pathway of natural products. Therefore, 
extensive in vivo and in vitro experiments are often necessary to clarify the function of genes 
in the biosynthetic pathway under study. However, the genetic tools for myxobacteria are 
quite limited and genetic modification methods usually need to be developed individually for 
each strain. Here, M. fulvus Mx f50 becomes one of the few myxobacteria for which a 
markerless in-frame deletion (mutagenesis) procedure could be established. The mutagenesis 
procedure was applied to perform several sets of gene deletions in order to clarify the 
respective gene functions and to generate analogues. Further detailed discussion on the mxn 
gene cluster elucidation is described in Chapter 2. 
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Figure 1. Myxopyronin (~53 kb) and corallopyronin (~65 kb) gene cluster with the corresponding product 
myxopyronin A and corallopyronin A, respectively. In general, red represents the western and blue the eastern chain. 
The coloured boxes in the structures represent the resulting moiety catalyzed by the corresponding genes with the same 
color arrows in the gene clusters. 
6.2.1 An unexpected myxopyronin A derivative from -branching cassette 
deletion 
The myopyronin biosynthetic pathway belongs to the growing number of trans-AT PKS 
systems.20 These systems are known for their ability to introduce unusual chain-branches 
during polyketide assembly, e.g. as observed in the biosynthesis of leinamycin21, mupirocin22, 
bacillaene23 and myxovirescin24. Such so called “-branching events” are directed by a set of 
enzymes usually including a CP, KS, HMG-CoA synthase (HCS), and two enoyl-CoA 
hydratases (ECHs).25 The methyl group at C-21 in myxopyronin is introduced by such a -
branching cassette (MxnC-MxnG) (Fig. 2A). In -branch-incorporation, the CP is loaded 
with a malonyl unit by an acyltransferase (AT) which is often also part of the -branching 
cassette, followed by decarboxylation to generate acetyl-S-CP, catalyzed by KS. The key 
reaction is then performed by HCS, catalyzing the aldol attack of the acetyl enolate onto the 
assembly line-tethered -ketothioester to generate an HMG-S-CP. The HMG-S-CP is then 
sequentially dehydrated and decarboxylated by the ECHs to obtain the -methylated 
intermediate. A few in vivo studies showed that deletion of one of -branching cassette genes 
result in production of novel metabolites. In mupirocin studies, the deletion of mupH (HCS) 
has resulted in derailment of the normal biosynthetic pathway and instead produced a 
truncated polyketide intermediate mupirocin H (Fig. 2B).26 Another effect of HCS deletion 
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was observed during myxovirescin studies. In myxovirescin biosynthetic pathway, TaC and 
TaF are both annotated as HCSs which play role in introducing methyl group at C-12 and 
ethyl group at C-16, respectively. When TaF was deleted, surprisingly TaC rescues 
myxovirescin assembly by installing two acetate building blocks, one at C12 (which is further 
oxygenated and methylated) and another one at the C16 -keto positions of the respective 
intermediates. This results in a novel myxovirescin endowed with two methyl groups (Fig. 
2C).24  
 
 
Figure 2. A) Possible reaction mechanism of MxnC-MxnG in myxopyronin A biosynthesis; B) Illustration of HCS 
deletion effect on mupirocin biosynthesis; C) Illustration of HCS deletion effect on myxovirescin biosynthesis; D) The 
intermediate in western chain assembly line for the wild type, the expected intermediate from the ΔmxnC-G mutant, and 
the postulated intermediate based on the isolated 21-desmethyl-myxopyronin A. The -branches denotes by black 
circles (methylene group derived from the C2 portion of acetate) or boxes (the C2-C3 fragment derived from succinyl-
CoA at carbon C16 for myxovirescin). 
However, the reverse experiment where TaC was deleted did not show a similar 
complementary pattern by the existing TaF. This result might be due to the specificity of their 
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docking interactions with other enzymes comprising the megasynthase complex or 
incorporation of the larger ethyl group early in biosynthesis might result in the rejection of 
the modified intermediate at later biosynthetic steps.24  
Based on the -branching biochemistry illustrated in Fig. 2A, it was initially 
predicted that deletion of the -branching cassette from myxopyronin biosynthetic gene 
cluster would result in the production of novel myxopyronin containing an unmodified C-20 
carbonyl functionality (Fig 2D). Instead, the deletion mutant ΔmxnC-G generated a 
myxopyronin analogue containing a Δ19,20 double bond (21-desmethyl-myxopyronin A) with 
a yield that was fiftyfold lower than that of native myxopyronin in the wild-type strain (Fig. 
2D ). 
The formation of this unexpected double bond can be explained by the downstream 
KR and DH activities at module 4W, which might act on both the C-18 -carbonyl and the C-
20 O-carbonyl functionality of the biosynthetic intermediate (Fig. 2D). There are two 
proposed scenarios to explain this result: (1) the conjugated olefinic system might be essential 
for pyrone ring formation, and C-20 carbonyl intermediates bound to CP-5W are not 
processed, or (2) O-carbonyl reduction on module 4W is highly efficient, but because of the 
lack of the C-21 -branch, the overall productivity of the condensation step is significantly 
decreased. However, the mutasynthesis studies showed that only the -methyl group and -
double bond are necessary for -pyrone ring formation (see Chapter 4).27 These requirements 
would indirectly favour scenario (2) over scenario (1) since the olefinic system is apparently 
not compulsory for myxopyronin production. Future studies to investigate substrate 
specificity for this final condensation reaction can be performed using the established in vitro 
and mutasynthesis system presented in this thesis. 
6.2.2 The importance of MxnH for O-methylation in myxopyronin biosynthesis 
Methylation plays an important role on the functional output of many metabolic pathways 
such as bioavailability, bioactivity, and reactivity of acceptor molecules.28 Natural products 
are often decorated with methyl groups and these methylation reactions are usually catalyzed 
by S-adenosyl-L-methionine (SAM)-dependent methyltransferases (MTs).28 MTs are 
frequently integrated as domains within the PKS machinery, which act on the growing 
intermediate, or encoded by stand-alone genes to introduce methyl groups at different stages 
of the biosynthesis often as post-PKS modifications.29 Myxopyronin and its closely related 
compound corallopyronin possess a unique terminal methyl ester moiety at their eastern chain 
which is also observed in other myxobacterial compounds such as melithiazol A and 
myxothiazol Z. (Fig. 1, Fig. 3). The eastern part of myxopyronin was shown to be important 
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for its bioactivity since initial structure activity relationship (SAR) studies show that slight 
variations in the eastern part of the molecule result in a dramatic loss of inhibitory activity.30 
Thus, investigation on biosynthesis detail of these -pyrone compounds will provide useful 
insights for structural modification via bioengineering.  
 
                
Figure 3. Structures of myxothiazol Z and melithiazol A. Methyl ester moiety is highlighted in grey. 
Feeding studies on myxopyronin and corallopyronin suggested that the methyl ester 
moiety is derived from SAM, possibly carbonic acid which is methylated as free precursor or 
as assembly line intermediate.18,31 In agreement, in silico analysis also proposed that this 
unusual O-methyl functionality is likely to be introduced by putative SAM-dependent-
carboxy-methyltransferases (O-MTs) MxnH and CorH, respectively.18,19 Indeed, Pfam 
analysis32 showed that CorH/MxnH (86 % sequence identity) belong to the family of leucine 
carboxyl methyltransferase (LCMT). These enzymes methylate the carboxyl group of the C-
terminal leucine residue of the protein phosphatase 2A catalytic subunit to form alpha-leucine 
ester residues.33 BLAST search analysis of CorH/MxnH also revealed their sequence identity 
with MelK, putative S-adenosyl methionine (SAM)-dependent MT (identity ~28 %), from 
melithiazol biosynthesis. MelK has been biochemically characterized and is responsible for 
the rare methylation of carboxylic acid during myxothiazol/melithiazol biosynthesis to form a 
methyl ester moiety.34  
As an attempt to elucidate the function of mxnH and to generate myxopyronin 
analogue, an in-frame deletion of mxnH was performed. However, myxopyronin production 
was completely abolished and the expected myxopyronin analogue containing a free 
carbamic acid moiety was not observed. The successful complementation experiment showed 
that the mxn biosynthetic genes are in principle functional in the mxnH deletion mutant, and 
implied that the formation of a methyl carbamate is essential for eastern chain biosynthesis.19 
Accordingly, in vitro assays performed by Schäberle and co-workers using heterologously 
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expressed CorH showed that CorH methylates HCO3- through SAM consumption, indicating 
SAM as the methyl group donor.35 The biochemical studies of CorH also indicated that the O-
methylation reaction seems to precede the attachment of the starter unit to the PKS 
machinery.35 
From the in vivo and in vitro experiments, a carbonic acid or a more stable 
monomethyl ester is likely the first building block loaded onto the PKS-NRPS eastern chain 
assembly line. However, building blocks are usually in the form of coenzyme A (CoA) esters 
before they are loaded by AT. Even though no such enzyme is encoded in the mxn/cor gene 
cluster, the existence of such an enzyme encoded somewhere in the producer genome cannot 
be excluded. The only AT (MxnA/CorA) present in the mxn/cor cluster is a malonyl-CoA-
specific AT domain, which is unlikely to select another substrate to be loaded to the CPs. 
Moreover, the trans-ATs seem to have specific interactions with CPs in the assembly line in 
order to ensure loading of the correct substrate.36 Therefore, MxnA/CorA do not seem to load 
foreign substrate and it is more likely that the substrate is self-loaded onto the CP-1E as 
already described for other CPs.37 
 While PKS substrates are usually activated by attachment of CoA, in NRPS the 
amino acid activation is achieved by reaction with ATP within the adenylation (A) domain to 
enable subsequent loading onto the NRPS CP domains.38,39 Since the free hydrogen carbonate 
(HCO3-) will be in equilibrium with CO2 (which is volatile), a phosphate group from ATP 
might be transferred to HCO3 to form the more stable intermediate carbonyl phosphate. 
HCO3- connected with an activating group will be much more stable than its free form and 
will allow an O-methylation reaction to occur efficiently. In CorH studies, an experiment 
using purified CPL (loading module CP) and cell lysates demonstrated that the concentration 
and stability of the precursor is high enough to enable loading of the CP.35 Whether the 
precursor is methylated hydrogen carbonate itself or its phosphate ester cannot be judged 
from this experiment. However, feeding studies in the myxopyronin producer using 
triethylmethylammonium methyl carbonate did not restore myxopyronin production.19 This 
indicates that the activation through phosphate group attachment is likely to happen before O-
methylation and subsequent transfer of the methoxylcarbonyl moiety to CPL. Indeed, at the 
N-terminus of MxnI (not observed in CorI), there is an unknown domain (X domain) which 
exhibits weak similarity to a truncated phophoglucomutase/phosphomannomutase, alpha, 
beta/alpha domain II (PGM PMM II). This domain might not only be involved in the 
activation of the proposed bicarbonate starter by phosphoryl group transfer but also mediated 
the loading of the methoxylcarbonyl moiety to CPL (Fig. 4).  
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Taken together, the hydrogen carbonate is presumably phosphorylated to form 
carbonyl phosphate (Fig. 4, Route I). Subsequently, the hydroxyl group is methylated by 
CorH/MxnH to form methoxycarbonyl phosphate, which is transferred to the CPL as the first 
building block (Fig. 4, Route I). Further studies need to be conducted to clarify the reaction 
sequence for the proposed phosphorylation and methylation reactions (Fig. 3, Route I or 
Route II). For example, further in vitro studies using methoxycarbonyl phosphate instead of 
methyl carbonate as substrate would shed more light on the loading process of module CPL. 
Figure 4. Proposed methylation step of CPL by MxnH or CorH. In Route I: the hydrogen carbonate is phosphorylated 
before methylation while in Route II the hydrogen carbonate is methylated before phosphorylation. Route I or Route II 
is then continued by the transfer of a methoxylcarbonyl moiety to the CPL. CPL: CP loading, X : PGM PMM II. 
 
In summary, the targeted knock-outs have provided insights into the function of the 
genes involved in myxopyronin biosynthesis. A thorough understanding of the mechanisms 
and specificity regarding all steps involved in natural product assembly will facilitate efforts 
to engineer and modify existing natural product biosynthetic pathways with a goal toward 
optimizing pharmacological properties or using natural products as a starting point for further 
synthetic modifications. 
6.3 -Pyrone ring formation during polyketide biosynthesis – in depth 
studies on myxopyronin 
-pyrones are found in a number of natural products isolated from plants, animals, bacteria, 
fungi, and insects that exhibit a broad range of biological activities, such as antifungal, 
antibiotic, cytotoxic, neurotoxic and phytotoxic.40 However, there is not much information 
available regarding the biosynthetic strategies for -pyrone formation. Up to date, these -
pyrone containing natural products are typically synthesized by type II and type III PKSs 
such as described for wailupemycin41 and csypyrone,42–44 respectively. Type II PKS 
multienzyme complexes carry a single set of iteratively acting activities and usually use CP to 
Discussion and Perspectives | 173 
 
activate the acyl CoA substrates and to channel the growing polyketide intermediates (Fig. 
5).38 Type III PKSs, also known as chalcone synthase (CHS) like PKSs, consist of 
homodimeric enzymes that basically are iteratively acting condensing enzymes using acyl 
CoA substrates (Fig. 4).38 Nevertheless, type II and type III PKSs are essentially different 
systems compared to a type I PKS where multifunctional enzymes organized in modules 
responsible for non-iterative catalytic steps of one cycle of polyketide chain elongation.  
 
Figure 5. Biosynthesis of natural products biosynthesized by type II (wailupemycin)41 and III (csypyrone)43 containing 
-pyrone rings. The protein marked in bold is the responsible ketosynthase catalyzing the ring formation. 
 
Myxopyronin and corallopyronin, synthesized by NRPS/PKS (type I PKS) hybrid, are 
myxobacterial compounds that contain such a structural motif in their structures. In order to 
address the question how this -pyrone ring moiety is generated, a comprehensive in vitro 
study was performed. The key reaction in myxopyronin biosynthesis is the formation of the 
-pyrone ring from two PKS/NRPS derived chains, western and eastern chain (Fig. 6A). This 
reaction is catalyzed by a putative stand-alone ketosynthase (KS), MxnB. In the myxopyronin 
biosynthetic assembly line, the chains are presumably bound to the corresponding CPs - the 
western chain is tethered to the CP-5W and the eastern chain to CP-6E (hereafter referred to as 
CP-W and CP-E, respectively). In order to prove this hypothesis, a series of in vitro assays  
were performed and they showed that MxnB catalyzes this essential reaction step utilizing 
thioester substrates coupled to either N-acetylcysteamine (NAC) or a CP.45 The reaction 
sequence of myxopronin was determined by in-depth biochemical experiments including 
MxnB structural studies and detailed analysis of the identified novel myxopyronin congeners 
in the extract of the producer strain. Based on the crystal structure, MxnB possesses two 
binding tunnels (one for each substrate) namely red (for western chain) and blue (for eastern 
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chain) tunnels (Fig. 6B). By combining all of the data, we proposed that the western chain 
binds to the KS first, before the eastern chain. Further biochemical studies and discussion are 
described in Chapter 3. 
 
     
Figure 6. A) Proposed final step for myxopyronin formation. Red and blue define the western and eastern part 
of the molecule, respectively. B) Side view of the two proposed substrate-binding tunnels in MxnB, canonical 
tunnel (red) and additional tunnel (blue). The active site cysteines (C121) are shown as sticks. Tunnels were 
predicted using Mole 2.0.46  
 
During the MxnB biochemical studies, the reaction involving CP-bound substrates 
had a 12-fold higher turnover rate than SNAC substrates. This finding indicates the 
importance of protein-protein interactions between KS and CP in multimodular PKSs.47,48 
The ability of CPs to conduct self-acylation has been previously reported.37,49 In this study, 
CP-W and CP-E also show such capacities even though differences in the priming efficiency 
between the western and eastern SNAC substrates are observed. The differences in loading 
efficiency are expected to arise from the structural difference between the two chains. 
In the present study, several KS mutations were conducted to investigate the residues 
responsible for accommodating the substrate in the tunnel. However, the performed KS 
mutations were not able to block the tunnels completely. Therefore, further mutation studies 
could be performed in the future to pinpoint residues that make contact with the substrate. 
Understanding the key residues responsible for substrate interaction within the tunnel will be 
an important milestone to modify substrate specificity and further the generation of 
myxopyronin analogues. Initial studies have indeed shown that several unnatural western 
substrates are accepted by MxnB to yield myxopyronin analogues. However, the product 
formation efficiency between different substrates has not yet been determined.  
Furthermore, in order to gain further insights into the molecular basis of interactions 
between KS and CP-W or CP-E in myxopyronin biosynthesis, protein docking and 
A) B) 
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subsequent experimental studies remained to be conducted. Understanding the fundamental 
catalytic mechanisms and protein-protein interactions necessary for myxopyronin 
biosynthesis are necessary for further myxopyronin pathway engineering. The presented in 
vitro approach to form myxopyronin might be one of the routes to produce myxopyonin 
analogues with improved bioactivities. Although total synthesis of myxopyronin has been 
achieved,50 the process is time-consuming and the yield is low. In addition to the isolation of 
main myxopyronin analogues (MxnWE), isolation of the other types (MxnEW, MxnEE and 
MxnWW) is also of interest. The bioactivity assays for all of the myxopyronin analogues 
would help us to better understand the structure-activity relationship (SAR) between 
myxopyronin and RNAP. 
Before MxnB was characterized, there was only one example of 5-membered ring 
formation by a type I PKSs reported; the stand-alone KS (RkD) which condenses a CP-bound 
substrate, forming the tetronate ring during the biosynthesis of the phosphatase inhibitor RK-
682 (Fig. 7).51 MxnB becomes the first stand-alone KS described as catalyzing a 6-membered 
ring formation in a type I PKS pathway. Thus it is an important addition to the thiolase 
enzyme family (Fig. 7).  
 
Figure 7. Biosynthesis of natural products biosynthesized by type I PKS (myxopyronin)19 containing -pyrone ring 
and  RK-682
51
 which contains a tetronate ring. The protein marked in bold is the responsible ketosynthase 
catalyzing the ring formation. 
This enzyme will not only provide novel opportunities to rationally engineer the 
structural diversity of natural products but also to generate antibiotics that are not easily 
accessible by synthetic methods. The established platform will allow us to fine- tune the 
structure of the analogues to achieve optimal balance of good drug parameters, e.g., 
physicochemical, ADME, and low toxicity properties. 
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6.4 Expanding the chemical space of α-pyrone antibiotics – 
Mutasynthesis approach towards novel myxopyronin analogues 
Genetic engineering has become a powerful tool for the generation of new structural variants 
of natural products. More chemical diversity can even be achieved when the genetic tools are 
combined with synthetic chemistry.52 One implementation of these tool combinations is 
named mutasynthesis: the biosynthesis of a natural product precursor is blocked by a relevant 
gene inactivation experiment. Subsequently synthetic analogues of this precursor 
(mutasynthons) are added to the culture medium, giving rise to an incorporation of the 
foreign moiety into the natural product and thereby yielding new derivatives.52–54 A 
prominent example for such a mutasynthesis experiment is exemplified by the production of 
doramectin by the genetically modified avermectin producer Streptomyces avermitilis M1.55–
57 Doramectin was produced by feeding cyclohexane carbocylic acid (CHC) to a mutant of S. 
avermitilis lacking a branched-chain ketoacid dehydrogenase (bkd)  (Fig. 8).56  
 
 
Figure 8. The role of precursors in the biosynthesis of avermectin and doramectin in S. avermitilis. Avermectin B1a 
and B1b are generated using the starter units 2-methylbutyryl-CoA and isobutyrly-CoA, respectively. In the bkd mutant, 
the formation of these starter units from branched-chain amino acid degradation is blocked. Doramectin is generated by 
feeding CHC to the S. avermectilis Δbkd mutant where the CHC is presumably activated by a non-selective acyl CoA 
ligase and loaded onto the avermectin biosynthetic pathway (Figure is adapted from Reference 58)  
In the Δbkd mutant, the biosynthesis of isobutyryl-CoA or 2-methylbutyryl-CoA is disrupted, 
which diminishes the supply of the original substrate of AT domain in the loading module for 
avermectin biosynthesis.56 The generated avermectin analogue, doramectin, was found to 
possess a better bioactivity compared to avermectin.56 
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Despite its importance in drug discovery and lead optimization, mutasynthesis has 
three principal limitations59: (1) the range of the precursors that can be introduced into the 
final molecule is not only limited by the substrate specificity of the downstream biosynthetic 
enzymes but also the toxicity effect from the supplied mutasynthons and/or the generated 
natural product derivatives to the cells; (2) usually only structural features generated in early 
steps of the biosynthesis are addressed due to difficult or even unworkable experimental 
requirements for modifications at later stages; and (3) the range of precursors that can be 
taken up into the producing cells is limited. Nonetheless, even minor modifications can result 
in a significant impact on the bioactivity as exemplified by doramectin, a mutasynthesis 
product of the avermectin pathway (Fig. 8).56  
  In the present work, a mutasynthesis approach towards novel myxopyronin analogues 
was established resulting in 12 new derivatives (Chapter 4).27 Our studies focused on the 
modifications in the myxopyronin western chain as it offers wider scope for structural 
variations according to the results from previous SAR studies.30,60,61 Complete western chain 
biosynthesis was blocked by inactivation of the corresponding PKS MxnK resulting in a 
mutant (ΔmxnK; in-frame deletion of 5.6 kb internal fragment of mxnK) that is not able to 
produce myxopyronin. A series of -keto SNACs were then introduced to ΔmxnK and based 
on this experiment the essential part of the western chain required for pyrone ring formation 
was defined as the -methyl group and the -double bond (Fig. 9). Despite numerous 
attempts, the isolation of new derivatives was not successful due to the limited uptake of the 
-keto SNAC and/or its fast degradation in the culture. In order to circumvent the fast 
degraded and unstable -keto SNAC, simplified and more stable SNAC substrates were 
synthesized, which should be incorporated at earlier stages of the biosynthesis (Fig. 9). For 
this, two additional mutants were generated by site-directed mutagenesis to inactivate the 
carrier protein domains from module CP-1W and CP-4W resulting in ΔCP-1W and ΔCP-4W, 
respectively (Fig. 9).  
The successful incorporation of the simplified SNAC substrates after feeding to the 
ΔCP mutants indicates that all of the corresponding downstream KS domains possess a 
certain range of substrate flexibility. It has been proposed that the KS domains from trans-
ATs developed through horizontal gene transfer, by assembly of substrate-specific KS 
domains.62 In contrast, cis-AT KS domains evolved through duplication of entire modules in 
which KS domains are embedded.63,64 Examination of the X-Cys active site motif in KS 
domains from cis- and trans-AT PKSs revealed interesting differences between the two types. 
This X residue appeared to affect the size of the KS binding pocket. For trans-AT PKSs, 
which accept - and -carbon branched substrates, X is always a less sterically demanding 
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residue such as Ala, Gly, or Asn (exclusively for KSs that use amide-containing substrates). 
On the other hand, cis-AT PKSs might not go through the evolving process to create any 
variety of amino acids at this X position in order to develop a mechanism of specificity. This 
is supported by the data from all the fully assigned cis-PKSs in the literature that X is always 
Ala.65  
 
Figure 9. Illustration of the mutasynthesis experiment on (1) ΔCP-1W, (2) ΔCP-4W, (3) ΔmxnK with the corresponding 
SNAC substrates. The essential structural parts for condensation reaction are marked in bold. R=alkyl chain or other 
functional groups.  
In the myxopyronin PKS/NRPS assembly line, all of the KSs have X = Ala, except 
for KS-3E (X = Leu) (Fig. 10). These data may explain the incorporation of various SNAC 
substrates to the ΔCP-1W and ΔCP-4W and suggest future potential to introduce structurally 
more diverse substrates into the CP-engineered mutasynthesis system. Despite the successful 
CP-engineered mutasynthesis experiment, the yield of final products was still too low for 
product isolation (1-10 g/L) to allow for bioactivity testing. Detection of unconsumed 
substrates in the culture supernatant suggested that insufficient uptake into the cells is a 
limiting factor. Various trials to increase the yield were conducted but still not able to 
improve the yield so far. 
As discussed above, during the initial mutasynthesis studies, the essential part of the 
native western chain to enable pyrone ring formation was determined as the -methyl group 
and the -double bond (Fig. 11, W1-W3). Interestingly, this requirement did not apply to the 
in vitro studies (see Chapter 3), which indicate that MxnB including the involved CPs are 
promiscuous enzymes able to utilize a broader range of substrates for pyrone ring formation 
(Fig. 11, W1-W5). 
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Figure 10. Alignment of the KS involved in myxopyronin biosynthetic pathway. X is the residue right before the active 
site Cys that confers substrate specificity for the KS. 
However, the correlation between the enzymatic in vitro conversion and the subsequent 
yields of myxopyronin analogues from feeding experiments in vivo remain to be investigated. 
Different outcomes for in vitro and in vivo (mutasynthesis) approaches have been reported for 
other natural product biosynthetic pathways as well. In the studies of aminocoumarin 
biosynthesis, the in vitro experiments were used to determine the substrates used in the in 
vivo feeding experiments.66 Aminocoumarin antibiotics contain amide bonds formed between 
an aminocoumarin ring and an aromatic acyl component (3-dimethylallyl-4-hydroxybenzoate 
= ring A). This amide bond formation is catalyzed by amide synthetases (CloL, NovL or 
CouL). In vitro assays using these amide synthetases were performed in order to identify 
which synthetic analogs of the prenylated 4-hydroxybenzoate moiety would be accepted in 
the in vivo feeding experiments using ring A defective mutants of the aminocoumarin 
antibiotic producers.66  
 
 
Figure 11. A few examples of synthetic western side-chain mimics that have been used in both of mutasynthesis and in 
vitro experiments. W1-W3 are accepted in the mutasynthesis experiments while W1-W5 are accepted in in vitro 
experiments. 
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Comparing both approaches established for characterizing and engineering 
myxopyronin biosynthesis, in vitro pyrone ring formation and in vivo mutasynthesis, reveals 
pros and cons relating to the generation of novel myxopyronin analogues (Table 1).  
Regarding the effort for substrate preparation, in vitro experiments need two substrates 
instead of only one substrate required for in vivo mutasynthesis experiments. Hereby, 
however, the in vitro approach in principle also allows for conversion of modified eastern 
chain substrates to access a larger chemical space, which is additionally favoured by a 
broader substrate tolerance observed in the performed enzyme assays. Moreover, the isolation 
process is probably less complicated from in vitro biotransformation compared to the 
complex medium and metabolite mixtures harvested from in vivo experiments. Despite all of 
the mentioned advantages and disadvantages of these two systems, both offer valuable 
insights into the biochemistry and architecture of key enzymes for myxopyronin biosynthesis 
and will enable more directed myxopyronin pathway engineering in the future. 
In addition, parallel in vitro studies on MxnB homolog CorB from the highly related 
corallopyronin pathway (Schäberle and co-workers, unpublished results) have revealed that 
CorB fulfils the same function as MxnB in catalyzing the formation of -pyrone ring 
structures. However, a mutasynthesis system in the native corallopyronin producer 
Corallococcus coralloides could not be established due to limitations in the genetic 
accesibility, which to our knowledge does not allow pathway engineering so far. Therefore, 
the established myxopyronin western chain mutasynthesis system in principle should also 
enable generation of corallopyronin-like analogues in the future. 
Table 1. Comparison between in vitro and in vivo approaches in producing myxopyronin 
analogues 
Parameter In Vitro In Vivo 
Range of substrates Broad Narrow 
Needed substrates 
Eastern chain and western chain 
substrate 
Only western chain substrate 
Resulting analogues 
Four different analogues can be 
obtained (MxnWE, EW, EE, WW) 
Only one analogue 
(MxnWE) 
Isolation process 
Simpler process due to the less 
complex reaction mixture 
More challenging process 
due to complex 
medium/metabolite mixture 
from bacterial culture 
Cell permeability N/A A limiting factor 
N/A: Not Applicable 
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6.5 Heterologous expression of complex natural product biosynthetic 
pathways –myxopyronin production in the myxobacterial model 
strain M. xanthus  
The advances in cloning and characterization of natural product biosynthetic machineries 
have contributed to numerous opportunities for improving the production and diversification 
of natural products.46 However, many natural products are still produced in low yields, which 
limit the downstream experiments such as pharmacokinetics/pharmacodynamics analysis and 
lead optimization. To overcome this limitation, heterologous expression of the engineered 
biosynthetic gene clusters in non-native host strains has been widely and effectively used.47,48 
Moreover, heterologous expression also represents a valuable tool to explore genome mining 
information, e.g. to exploit the biosynthetic potential of a certain strain by awakening its 
silent gene clusters, which are normally not expressed in the native producer under standard 
laboratory conditions.48 Complete gene clusters for the natural products of interest can be 
transferred into a more suitable organism that grows faster, is genetically characterized and 
stable, and is amenable to manipulation. Achieving heterologous expression of natural 
products or their derivatives allows circumventing laborious strain optimization approaches 
and the development of fermentation procedures for the native producers. Especially for slow 
growing or difficult to grow microorganisms such as myxobacteria, symbionts, or sponge 
related bacteria, heterologous expression is a huge advantage. Myxobacteria are not only 
difficult to cultivate but also complicated to be genetically modified. In fact, it was so far 
necessary to establish mutagenesis procedure for each strain independently.67 Genetic 
modification attempts are also hampered by the multi-resistance of myxobacteria to most 
antibiotics commonly used as selection markers, their unfavourable growth characteristics 
(e.g. strains grow in clumps), their overall susceptibility to various stress factors, and the lack 
of basic genetic tools (e.g. suicide vectors).  Thus, these drawbacks have pointed out the 
importance of establishing heterologous expression systems for myxobacterial biosynthetic 
pathways. 
Introduction of large biosynthetic gene clusters into heterologous hosts is still a 
challenging effort, which is limited not only by the biochemistry and genetics of the host 
organisms but also by the size of the DNA that is introduced. Up to date, only a few examples 
for successful expression of complete biosynthetic machineries for myxobacterial compounds 
in either phylogenetically related or distant hosts are known (Fig. 12 and Table 2). These 
examples are the production of epothilone in M. xanthus and in Streptomyces coelicolor 
(initial yields ~0.2 mg/L),68,69 soraphen in S. lividans (yield 0.3 mg/L),70 flaviolin in 
Pseudomonas putida  (yield 6 mg/L),71 myxochromide in P. putida  (yield 40 mg/L),72,72 
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myxothiazol in M. xanthus (yield 20-60 mg/L),73 pretubulysin in P. putida or M. xanthus 
(yield 0.0176 mg/L or 0.176 mg/L, respectively),74 dawenol in M. xanthus (yield 0.05 
mg/L),75 polyunsaturated fatty acid (PUFA) in M. xanthus (yield 0.2-0.8 mg/g cell dry 
weight) (see more examples in Table 2).76 In a few cases, time-consuming cloning procedures 
were used, and the biosynthetic gene clusters were transferred in several fragments such as 
epothilone68,77 and soraphen70. In other cases, the biosynthetic genes are “stitched” together 
mainly from cosmid libraries via Red/ET recombineering to obtain the final construct for the 
gene cluster.72–74 
 
Figure 12. Heterologously expressed myxobacterial gene clusters in either phylogenetically related or distant hosts. 
In order to improve the productivity of myxopyronin and facilitate its pathway 
engineering, a heterologous expression system for the entire biosynthetic pathway was 
established in the course of the present work (see Chapter 5). The myxopyronin biosynthetic 
Discussion and Perspectives | 183 
 
gene cluster was assembled into one entity through several rounds of directed mutagenesis, 
Red/ET recombineering, and conventional cloning technology under control of the Tn5 
promoter employing the low copy number vector p15A ori with tetR. The plasmid was then 
used to integrate the gene cluster into the heterologous host chromosome, M. xanthus 
DK1622ΔmchA::tet (Wenzel, unpublished result). The obtained expression strain indeed 
started to produce myxopyronins with an initial yield of around 5 mg/L. 
There are essentially two ways of introducing the foreign biosynthetic gene cluster to 
heterologous host: (1) plasmid-based expression and (2) chromosomal integration.78 In 
plasmid-based expression, the biosynthetic gene clusters can be expressed from self-
replicating plasmids, either from a single plasmid, containing the entire biosynthetic pathway, 
or from multiple plasmid individually expressing modules in cis. This system relies on the 
availability of plasmid replicons capable of functioning in the host. Although plasmid-based 
expression would be a convenient method, unfortunately there is no replicative expression 
plasmid yet available for introducing gene cluster to myxobacterial host, unless 
choromosomal modifications are performed to facilitate this purpose. Therefore, the 
introduction of the described myxobacterial biosynthetic pathways to the myxobacterial host 
usually depends on chromosomal integration which allows stable heterologous expression in 
the host. 
 Chromosomal integration is further classified to three main methods: (1) homologous 
recombination, (2) transposition, and (3) phage-derived systems.78 In phage-derived systems, 
the recombination event is catalyzed by a phage integrase (int) that promotes recombination 
between two short DNA recognition sequences, the phage attachment site (attP) and a 
corresponding attachment site within the bacterial chromosome (attB) resulting in the 
integration of the entire plasmid at the bacterial attachment locus.79 This method was almost 
exclusively applied to heterologous expression in Streptomyces, until recently it was applied 
to heterologously produce epothilone in M. xanthus using mx8 and mx9 as specific integration 
site in the host.77,80,81 
 For the integration of myxobacterial gene cluster into the heterologous host, 
homologous recombination and transposition have been widely utilized. Homologous 
recombination is a process of exchanging DNA between two regions of identical sequence. 
Endogenous recombinases from the heterologous host can promote integration through large 
regions of DNA sequence homology (normally 1 kb). The length of the homology region has 
shown positive influence in the recombination efficiency.82 For chromosomal integration, a 
“suicide vector” that lacks the ability to replicate in the host, carries a sequence of DNA to be 
integrated along with a region of homology to the intended integration site. This results in the 
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gene of interest being integrated at the selected site. In the present study, homologous 
recombination has been effectively used in the gene knockouts, promoter and restriction sites 
insertion, and importantly in the integration of the complete myxopyronin biosynthetic gene 
cluster.  
The complete myxopyronin biosynthetic pathway was introduced using tetR as 
homologous region. This integration site tetR is located at the locus of the deleted endogenous 
myxochromide A gene cluster (Wenzel, unpublished results). The deletion of the cluster is 
predicted to reduce the number of co-produced compounds as also observed in myxothiazol 
heterologous production. When the myxothiazol gene cluster was introduced to the 
inactivated endogenous myxovirescin gene cluster in M. xanthus, the production yield was 
found significantly higher (20 mg/L) compared to the yield from the native producer S. 
aurantiaca (10 mg/L). The questions whether integration site and method will have any 
significant effect on myxopyronin yield in M. xanthus remains to be investigated in the 
future. Previous studies have indeed shown that integration site for heterologous expression 
of a gene cluster also influences its expression and the production levels of the compound as 
seen in pretubulysin (20-fold lower compared to native producer),74 epothilone (100-fold 
lower) and myxochromide S (75-125 fold higher) in M. xanthus.83 In these cases, the gene 
clusters were introduced to M. xanthus by transposition method which proved to give high 
integration efficiency. In this method, transposable element or transposon itself is flanked by 
inverted terminal repeats that are recognized by a corresponding transposase, which facilitates 
the insertion of the transposon into a target site. They are usually used in genetics to create 
non-specific gene knock-outs for gene function analysis.84,85 Since the integration site by 
transposon insertion is random, it is necessary to assess the compound titres from numerous 
clones, even though in pretubulysin74 and epothilone83 production in M. xanthus the 
difference between each clone was small. 
As we have already learned from the previous examples (Table 1), M. xanthus 
appears to be a suitable and convenient expression host for myxobacterial pathways. M. 
xanthus is the best-characterized model organism in myxobacteria that has been extensively 
studied by many research groups providing comprehensive information such as its complete 
genome sequence,9 transcriptional regulator of secondary metabolite clusters,86 and 
predation.87 The genetics and molecular techniques to engineer this organism has also been 
established since 20 years ago.88 Importantly, M. xanthus offers similarly high GC content, 
preferential codon usage, presence of a broad-spectrum P-pant transferase required for the 
activity of PKS/NRPS megasynthetases, no additional metabolic engineering steps were 
required, growth in suspension, significantly shorter doubling time compared to other 
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myxobacteria. Thus, M. xanthus has become an alternative host for production of polyketides, 
especially those from other myxobacterial pathways. 
On the other hand, P. putida eventually provides similar characteristics to M. xanthus 
regarding its ability to heterologously produce secondary metabolites such as 
myxochromides,72,83 flaviolin,71 and PUFAs (Gemperlein, unpublished result). However, 
additional metabolic engineering in P. putida is sometimes necessary when the introduced 
biosynthetic pathways require certain precursor supply for their biosynthesis, for example 
methylmalonyl-CoA (mm-CoA) which is not naturally produced by P. putida. This was 
exemplified in the production of myxothiazol where an mm-CoA biosynthetic pathway from 
S. cellulosum So ce56 was introduced to P. putida prior to the introduction of myxothiazol 
gene cluster.89 Another well-established system is Streptomyces expression system which also 
has been developed for production of myxobacterial polyketides. However, the yields can be 
low as shown in epothilone, which was attributed to a bacteriostatic effect of these 
compounds to the host. 
After considering the above-mentioned factors, especially the fact that myxopyronin 
producer M. fulvus is closely related to M. xanthus, it was chosen as the first host to 
heterologously express myxopyronin gene cluster. The initial myxopyronin yield was very 
promising (5-10 mg/L, as also in native producer) and comparable, although not to all, to 
other myxobacterial pathways that have also been expressed in M. xanthus (see Table 2). In 
addition to all of the other factors, another important factor for successful heterologous 
expression is transcription of the foreign genes by the host’s RNA polymerase (RNAP). 
Transcription is an essential cellular process which plays important role in controlling 
bacterial gene expression and depends on the efficient interaction of the RNAP with the 
respective promoter DNA. As the recognition specificity for promoters seems to correlate 
with the genomic GC content of a species, the heterologous host might not recognize the 
native promoters present in a specific biosynthetic gene cluster. If closely related 
heterologous hosts are chosen, retaining the native promoters will likely circumvent this 
problem as readily observed in myxopyronin and other myxobacterial compounds production. 
However, there are examples in which the native promoters were replaced by other promoters 
compatible with the respective host (e.g., act promoters68,90,91, ermE promoter92 or with 
certain characteristics such as inducibility (thiostrepton-inducible tipA promoter for 
Streptomycetes93 and the toluic-acid inducible Pm promoter for Pseudomonas strains
72). 
Inducible expression is usually required in gene clusters whose encoded metabolites may be 
toxic to the hosts. Promoter exchange has proved to be crucial in the heterologous expression 
of myxochromide. When the promoter and the host are exchanged from Pm to PaphII and from 
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P. putida to Corallococcus coralloides GT-2, the yield significantly increases from 40 mg/L 
to 600 mg/L.94 Moreover, promoter exchange from Pm to Tn5 and host exchange to M. 
xanthus even increase the yield to 1 g/L.83 These results illustrated that the compatibility 
between a promoter and a heterologous host needs to be considered before introducing a 
certain promoter to the biosynthetic gene cluster. 
Once the heterologous expression is achieved and stably maintained within the 
chosen heterologous host, further optimization of production can be achieved by classical 
strain improvement and improving growth conditions. The production of myxothiazol was 
increased from 20 mg/L to 60 mg/L through classical strain improvement and a careful 
bioprocess optimization enabling also production of epothilone up to 23 mg/L. Fermentation 
conditions are usually optimized by different media trials that can provide all the nutrients 
needed not only to ensure sufficient growth of the respective recombinant microorganism but 
also to enable the efficient biosynthesis of the expected natural product. In the current study, 
growth media improvement has resulted in the increase of myxopyronin production from 5 
mg/L to 100 mg/L (in collaboration with Acies Bio, Slovenia). Further studies to improve the 
heterologous strain for example by random mutagenesis are currently on going. This 
improved productivity will open up many opportunities for further pathway engineering to 
generate novel myxopyronin analogues, e.g. via mutasynthesis which was not efficient in the 
natural producer strain. In summary, there is no exact formulation so far to guarantee 
successful heterologous expression of biosynthetic gene clusters. There are many factors that 
need to be considered such as the host, size of the gene cluster, integration method, promoter 
selection, growth optimization, and so forth. One of these factors might work perfectly for 
one case but it might not give the same effect for another case. Nevertheless, the heterologous 
expression technique is continuously being researched and developed, thus in the future there 
might be a better design to produce a good heterologous expression system.     
6.6 Concluding Remarks and Future Directions 
This thesis focused on the RNAP inhibitor myxopyronin produced by M. fulvus Mx f50. The 
genetically accessible bacterium M. fulvus Mx f50 has greatly facilitated the identification of 
myxopyronin gene cluster including clarification of several gene functions in myxopyronin 
biosynthesis. The knowledge obtained from this part of the study has then become the basis 
of in vitro, mutasynthesis, and heterologous expression studies. The significant improvement 
of the heterologous expression production yields achieved here is now intended to be 
employed to overcome the production issues in mutasynthesis experiments. Mutasynthesis 
and in vitro systems with their advantages and disadvantages offer various ways to generate 
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novel myxopyronin analogues. These approaches will hopefully lead to the successful 
production of biologically more active myxopyronin derivatives in the future. This project 
has contributed to establishing a platform to produce myxopyronin analogues, which could 
also be applied for engineering other anti-infectives from myxobacteria and other organisms. 
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Table 2. Myxobacterial compounds produced in heterologous hosts 
Compound Class Producing 
organism 
Size 
of 
cluster 
Vector 
used 
Strategy to 
ensure 
production 
(i.e., promoters, 
regulator, etc). 
Host 
strain 
Production 
medium 
(host) 
Yield WT 
(Yield Host) 
Ref. cluster/ 
Ref. het. 
exp. 
Epothilone PKS/ 
NRPS 
Sorangium 
cellulosum 
SMP44 
 
 
S. cellulosum  
So ce90 
 
 
 
S. cellulosum  
So ce90 
 
 
S. cellulosum  
 
 
 
S. cellulosum  
So ce90 
56 kb 
 
 
 
 
56 kb 
 
 
 
 
56 kb 
 
 
 
54 kb 
Synthetic 
genes 
 
58 kb 
Artificial 
cluster 
SCP2* based  plasmid 
(replicative) and 
pSET152 based 
plasmid (integrative) 
 
Cloning vectors (2x 
integrated by 
homologous 
recombination) 
 
2x E. coli–
Streptomyces shuttle 
vector  
 
pBR322 ori, RSF1030 
ori, CloDF13 ori 
 
 
pUC ori 
actI promoter  
(in both plasmids) 
 
 
 
- 
 
 
 
 
pikAI  promoter  
(in both plasmids) 
 
 
PBAD promoter 
 
 
 
Tn5 promoter 
S. coelicolor  
CH999 
 
 
 
M. xanthus  
 
 
 
 
S. venezuelae 
DHS2001 
 
 
E. coli 
 
 
 
M. xanthus 
DK1622 
 
 
R2YE 
 
 
 
 
CMM 
 
 
 
 
R2YE  
 
 
 
2xYT 
 
 
 
CTT 
20 mg/L 
(50-100 g/L) 
 
 
 
(1-23 mg/L) 
 
 
 
 
(0.1  µg/L EpoB) 
(0.4 µg/L EpoD) 
 
 
(1 µg/L) 
 
 
 
(100 µg/L) 
68/68 
 
 
 
 
68/69,95 
 
 
 
 
68/96 
 
 
 
68/97 
 
 
 
68/77 
Soraphen A PKS  S. cellulosum  
So ce26 
67.5 kb pTBK (integrative) 
pTBBH (integrative) 
pTUE (replicative) 
tipA promoter, 
addition of 
precursor 
cinnamic acid 
enriched the titer 
Streptomyces 
lividans ZX7   
YEME 150-1000 mg/L 
(0.3 mg/L) 
98/70 
Flaviolin PKS S. cellulosum  
So ce56 
1.1 kb pJB861 (replicative) Pm promoter 
 
P.putida 
KT2440 
 
P. syringae pv. 
tomato 
 
LB - 
(6 mg/L) 
 
trace amount 
71/71 
 
 
71/71 
Myxochromide S PKS/ Stigmatella 30 kb SuperCos 1 derivative  Pm promoter P.putida LB 8 mg/L 
99/72 
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   Het. Exp:: Heterologous expression; CMM: Citrate minimal medium; CTT: Casitone Tris medium LB: Lysogeny Broth; NRPS: Nonribosomal peptide synthetase; PKS: Polyketide synthase; WT: Wild type; *: cell  
dry weight; p15 ori: a vector containing minimal backbone with p15 ori as origin or replication
NRPS aurantiaca 
DW4/3-1 
 
 
 
 
 
Tn5 promoter 
 
 
PaphII promoter 
 
 
Tn5 promoter 
KT2440 
 
P.putida 
KT2440 
 
C.macrosporus 
GT-2 
 
M. xanthus 
DK1622 
 
 
LB 
 
 
M medium 
based 
 
CTT 
 
(40 mg/L) 
 
(0.1 mg/L) 
 
 
(600 mg/L) 
 
 
(1 g/L) 
 
 
99/83  
 
 
99/94 
 
 
99/83 
Myxothiazol PKS/ 
NRPS 
S.aurantiaca 
DW4/3-1 
 
S.aurantiaca 
DW4/3-1 
 
57 kb 
 
 
57 kb 
p15A ori 
 
 
p15A ori 
 
Pm promoter 
 
 
Pm promoter 
 
M. xanthus DZF1 
 
 
P. putida FG2005 
 
 
CTT 
 
 
LB 
10 mg/L 
(20-60 mg/L) 
 
10 mg/L 
(0.005-0.6 mg/L) 
100/73 
 
 
100/89 
 
Pretubulysin PKS/ 
NRPS 
Cystobacter 
sp. BCb004 
40 kb p15A ori 
 
Ptet promoter P. putida 
 
 
M. xanthus 
DK1622 
LB 
 
 
CTT 
1-4 mg/L 
(1.76 g/L)  
 
(0.19 mg/L) 
 
101,102/74 
Dawenol PKS S.aurantiaca 
DW4/3-1 
21 kb ColE1 ori 
 
- M. xanthus 
DK1622 
CTT N/A 
(0.05 mg/L) 
75/75 
PUFA 
DHA/EPA 
 
 
 
 
PKS 
 
 
 
PKS 
Aetherobacter 
rufus SBSr002 
 
 
Aetherobacter 
sp. SBSr008 
 
16.2 kb 
 
 
 
16.2 kb 
p15A ori 
 
 
 
p15A ori 
 
Tn5 promoter 
 
 
 
Tn5 promoter 
M. xanthus 
DK1622 
 
 
M. xanthus 
DK1622 
CTT 
 
 
 
CTT 
Both native 
strains producing 
DHA and EPA 
 
DHA: 
3.8 mg/g  
(0.2 mg/g)* 
 
EPA: 
4.7-6.2 mg/g 
(0.8 mg/g)* 
Gemperlein 
et.al. 
Unpublished 
results 
Myxopyronin PKS/ 
NRPS 
Myxococcus  
fulvus  
Mx f50 
53 kb p15A ori-tetR  
 
Tn5 promoter M.xanthus  
DK1622ΔmchA 
::tet 
CTT 
 
M7s/6a 
5-10 mg/L 
 
(5-100 mg/L) 
19/  
Sucipto, 
et.al.  
unpublished 
results 
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